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The melanocortin (MC) receptors form a subgroup within the G-protein- 
coupled receptor superfamily. To date five receptor subtypes have been 
characterised, differing in their melanocortin peptide specificities and main sites of 
expression.
The work presented in this thesis involved an investigation into the structure- 
activity relationships of the interaction of a-MSH with two of the human 
melanocortin receptor subtypes: MC1-R and MC4-R which have been shown 
previously to exhibit similar ligand binding profiles. Transient and stable receptor 
expression took place in COS7 and HEK 293 cells, respectively, to overcome 
problems associated with relatively low level native expression. Attention was 
focused on the tryptophan-9 residue within the central core and the C-terminal of 
a-MSH, both regions being regarded as important for receptor binding and 
activation. Appropriate a-MSH analogues were synthesised by solid-phase 
techniques and assayed for both receptor binding and stimulation as determined by 
cAMP quantification.
Aromaticity of the tryptophan-9 residue was found to be of prime importance, 
and the requirement for the presence of the C-terminal for full activity confirmed. 
Partial delineation of the structural requirements for high affinity binding to and 
stimulation of the two receptor subtypes was achieved with the discovery that [Pro12] 
and [Gly10] of a-MSH appear critical for conferring peptide selectivity on the human 
MC1-R and MC4-R, respectively.
A preliminary attempt was made at site-directed mutagenesis of the human 
MC1-R with the aim of validating a model for hormone-receptor interaction as 
proposed by this laboratory using molecular modelling techniques.
Taken together, this two-pronged approach aims to yield further information 
about melanocortin receptor subtype specificities. Such a fundamental understanding 
is a prerequisite for the development of both subtype specific agonists and 
antagonists. Given the pleiotropic nature of these peptides, such compounds may 
have important therapeutic implications.
CHAPTER 1: INTRODUCTION
Interest in the melanotropic peptides, or melanocortins, was first stimulated 
early this century when Fuchs (1912) demonstrated that pituitary extracts darken the 
skin of frogs. Shortly afterwards it was shown that amphibian pituitary gland 
removal leads to a loss of pigmentation, thus illustrating how control of amphibian 
skin colour is dependent on an intact pituitary gland. This led to extensive 
investigation into the pigmentation effects of these peptides in lower vertebrates. 
Further research into these peptides disclosed the functional relationship between the 
melanocortins, adrenocorticotropin, lipotropin and endorphin, which culminated in 
the isolation of their common precursor, pro-opiomelanocortin, POMC.
More recent discoveries of peripheral sites of melanocortin synthesis together 
with their apparent multiple roles in the central nervous system and the cloning of 
their receptor subtypes have established the importance of these peptides in 
mammals, including man.
1.1. Production of POMC
Active peptides produced by eukaryotic cells are usually synthesised as 
fragments of large precursor proteins. The prohormone, pro-opiomelanocortin, was 
the first polypeptide to be discovered as a precursor for several functionally distinct 
peptides. Biologically active POMC cleavage products include the a-, p- and y- 
melanocyte-stimulating hormones (MSHs), adrenocorticotropic hormone (ACTH), 









y- l p h P-endorphin
a-M SH  CLIP P-M SH
Figure 1.1. Diagrammatic representation of POMC cleavage giving rise to 
melanocortin, lipotropin and p-endorphin fragments.
Nakanishi et al. (1979) determined the 1091 base pair nucleotide sequence of 
cloned cDNA of the mRNA encoding for bovine POMC and by 1980, the gene 
structure for POMC in several mammalian species, including man (Chang, 1980), 
had been determined. The POMC gene probably evolved by duplication of ancestral 
genes as suggested by the three MSH sequences contained within it. This evolution 
by duplication may have been directed by the pleiotropic function of POMC as a 
prohormone for a number of actions. As all vertebrates investigated to date have a 
POMC gene containing all three sequences, this duplication must have occurred at an 
early stage in evolution (Eberle, 1988).
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As with other precursor proteins, biosynthesis begins on the rough endoplasmic 
reticulum (RER). Cleavage of the signal peptide occurs within the RER with 
subsequent passage to the Golgi apparatus. Further post-translational modifications 
take place within the Golgi, including glycosylation and phosphorylation, 
(Zimmerman et al., 1980). From the Golgi complex the protein passes to storage 
secretory vesicles where upon concomitant vesicle maturation and acidification, the 
processing proteolytic enzymes are activated (Orci, 1986). These specific trypsin-like 
endopeptidases cleave at sites of paired basic amino acids, namely -Lys-Lys-, -Arg- 
Arg-, -Lys-Arg-, and -Arg-Lys-, and, together with further enzymes that modify the 
initial cleavage products generate the various POMC fragments.
Tissue-specific post-translational processing mechanisms for POMC observed 
in the pituitary of adult mammals result in the production of ACTH(l-39) by 
corticotropes and a-MSH, (N-acetyl-ACTH(l-13)amide), by melanotropes as major 
end-products.
1.2. The Melanocyte-Stimulating Hormone Family
1.2.1. OrMelanocyte-Stimulating Hormone
Figure 1.1. illustrates the cleavage pattern of POMC and the formation of a- 
MSH from ACTH. In 1957, Harris and Lemer determined the amino acid sequence 
of porcine a-MSH and described it as having a blocked N-terminal and amidated C- 
terminal. The amino acid sequence of a-MSH corresponds to ACTH(1-13), the final 
composition (Figure 1.2.) of which was elaborated by Harris (1959) and led to the 
characterisation of a-MSH as a tridecapeptide with an isoelectric point of 10.5-11. It
3
Ct |
is now known that the N -amino group of [Ser ] is either free (desacetyl-a-MSH) or 
blocked with one or two acetyl groups, depending on the tissue of synthesis .
It would be predicted that a minimum of three enzymes would be required for 
the conversion of ACTH(l-39) to ACTH(l-13)amide and ACTH( 18-39), the latter 
fragment being known as CLIP. An endopeptidase would first be required to cleave 
the -Arg-Arg- residues at positions 17 and 18 in ACTH(l-39). A carboxypeptidase- 
like enzyme would then be required to remove sequentially the -Lys-Lys-Arg- 
residues at positions 15, 16 and 17. Finally, an alpha-amidating enzyme is needed to 
convert ACTH(1-14) into ACTH(l-13)amide (Dores, 1990). A fourth enzyme, N- 
acetyltransferase, is required to convert ACTH(l-13)amide into a-MSH. This 
enzyme is localised in secretory granules in mammals and the reaction occurs prior 
to secretion (Glembotski, 1982).
Isolation and structural analysis of this peptide from a number of mammals 
shows a high sequence conservation of this peptide during evolution.
Ac-Ser1 -T yr2-Ser3-Met4-Glu5-His6-Phe7-Arg8-T rp9-Gly1 °-Lys11 -Pro12-V al13-NH2 
Figure 1.2. Amino acid sequence of a-MSH as determined by Harris (1959).
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1.2.2. ft-Melanocyte-Stimulating Hormone
The carboxy-terminal of POMC produces the cleavage fragment (3-lipotropin 
(p-LPH), which undergoes further processing to give y-lipotropin (y-LPH), p- 
endorphin and p-MSH (Figure 1.1.).
p-MSH is an octadecapeptide and corresponds with the sequence y-LPH(41- 
58) (Bertagna et al., 1986). The peptide shows considerably more inter-species 
variation than a-MSH with some species expressing more than one form (Lee et al., 
1963), indicating the expression of two different genes or alternative post- 
translational modifications. In common with a-MSH, mammalian p-MSH contains 
the heptapeptide sequence: Met-Glu-His-Phe-Arg-Trp-Gly.
1.2.3. J-Melanocyte-Stimulating Hormone
Analysis of the POMC sequence showed the presence of the tetrapeptide His- 
Phe-Arg-Trp within its N-terminal region. Three possible cleavage sites are present 
which would give rise to three fragments corresponding to the sequences (51-61), 
(51-62), and (51-77) of bovine N-POMC (Ling et al., 1979). These potential 
fragments were named yi-, y r  and y3-MSH respectively (Figure 1.3.). The search for 
the naturally occurring fragments first resulted in the isolation of N-POMC( 1-76/77) 
or pro-y-MSH, from the human pituitary which is the precursor for the smaller 
peptides, (Estivariz et al., 1980). The presence of these peptide products in 
mammalian pituitary extracts has since been determined (Bohlen et al., 1981; Tanaka 
et al., 1980), and all were found to have an additional lysine residue at the N- 






Figure 1.3. Structure of mammalian y-MSH peptides as proposed from analysis of 
the POMC gene (Eberle, 1988).
1.3. Distribution of a-MSH and other POMC Products
1.3.1. Pituitary
POMC is synthesised in the corticotropic cells of the pars distalis and in the 
melanotropic cells of the intermediate lobe, or pars intermedia, of the pituitary gland 
(Eipper and Mains, 1980). The pars intermedia of the pituitary gland is therefore the 
major biosynthetic source of a-MSH in most species, including the rat (Vaudry et 
al., 1978). Adult humans, however, lack an anatomically distinct pars intermedia. 
The pars intermedia present in the foetal human pituitary undergoes regressive 
development after birth and intermingles with the pars distalis (Daniel and Pritchard, 
1975). This modified region along the neural tube is termed the zona intermedia.
Only low concentrations of a-MSH can be detected in the human pituitary 
gland, most of which is in the desacetylated form (Tilders et al., 1981). However, the 
human foetus contains high a-MSH bioactivity which decreases dramatically after
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birth. This may be a consequence of the human foetus, unlike the adult, having a 
well-developed intermediate lobe. p-MSH is not normally produced by the human 
pituitary gland as adult melanotrophs lack the enzyme required for cleavage of y- 
LPH into p-MSH (Scott and Lowry, 1974).
1.3.2. Brain
It has been known for many years that MSH bioactivity exists in the brain 
(Rudman et al., 1973). It was postulated that these peptides are synthesised in the 
CNS rather than being transported from the pituitary gland as a-MSH and p- 
endorphin in the brain are not depleted by hypophysectomy (Vaudry et al., 1978). 
Distribution of a-MSH in both its acetylated and desacetylated forms within the 
human brain is uneven with the highest concentration found in the hypothalamus. P- 
MSH has also been identified in the hypothalamus, suggesting that the human 
pituitary is an exception in its inability to cleave y-LPH into p-MSH (Bertagna et al., 
1986).
1.3.3. Placenta
Opiomelanogenic peptides, including ACTH and a-MSH have been identified 
in human placental extracts (Clark et al., 1978). The foetal pituitary may be the 
source although it is improbable that a-MSH can cross the placental barrier. The 
maternal pituitary may produce a-MSH during pregnancy, but the placenta cannot be 
ruled out as a site of production. Indeed, biosynthesis of opiomelanotropinergic 
peptides similar to that described in the pituitary has been demonstrated in cultured
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human placental trophoblastic cells (Liotta and Krieger, 1980). This suggests a 
trophic function during foetal development, although Chen et al. (1986) found 
placental POMC mRNA content to remain unchanged during pregnancy. In addition, 
the close interrelationship of the foetal brain and pituitary with the placenta together 
with the synthesis of a wide range of hormones and growth factors, makes it difficult 
to assess the relative importance of MSH and other POMC peptides for foetal 
development.
1.3.4. Gastrointestinal Tract
POMC products have been found by immunoreactive detection studies in 
endocrine cells of the human gastrointestinal tract and pancreas and were not 
eliminated by hypophysectomy (Feurle et al., 1980). Their presence suggests local 
synthesis and processing but a precise physiological role is still uncertain.
1.3.5. Skin
POMC mRNA and its melanocortin products have been detected in the skin 
(Slominski et al., 1993; Thody et al., 1983), including constitutive expression in 
keratinocytes (Wintzen et al., 1996). Keratinocyte-derived factors have been shown 
to affect human melanocyte growth and melanogenesis in vitro (Gordon et al., 1989), 
emphasising the importance of these cells as regulators of melanocyte behaviour and 
suggesting a paracrine role for the melanocortins in pigmentation.
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1,3.6. Ectopic Tumours
MSH bioactivity has been found in various tumour tissues. For example, 
a-MSH and p-MSH largely account for melanocortin bioactivity detected in patients 
with ectopic ACTH syndrome (Abe et al., 1967; McLoughlin et al., 1980).
Elevated plasma levels of a-MSH have also been detected in melanoma 
patients with Ghanem et al. (1986) reporting increased values for about one third of 
their patient sample as compared to controls.
As can be seen from the above summary, MSH peptides occur widely 
throughout the body. This suggests that the melanocortins have multiple endocrine 
regulatory functions mediated by various responsive tissues expressing receptors for 
these hormones.
1.4. Functions of a-MSH
1.4.1. Amphibians
MSH was so-termed after discovery of its pigmentation role in lower 
vertebrates (Lemer et al., 1954). It causes rapid dispersion of melanin granules stored 
within the melanosomes of melanophores thereby causing the colour changes 
commonly seen in these animals. This observation led to the development of assay 
methods involving visual detection of changes in amphibian skin pigmentation 
(Tilders et al., 1975; Carter and Shuster, 1978), most commonly in the lizard 
(Anolis) and frog (Rana).
This research has been reviewed by Eberle (1988) and is only considered 




Melanin pigmentation is recognised as being the most important factor in 
determining hair and skin colour and is formed from specialised pigment-producing 
cells known as melanocytes. Melanocytes originate from neural crest cells which in 
turn are derived from the embryonic ectodermal germ layer. Most melanocytes 
migrate during embryogenesis to the epidermis, where they differentiate towards 
epidermal or follicular melanocytes. Each melanocyte is associated with 
approximately 36 keratinocytes. The established function of epidermal melanocytes 
is the production and transfer of melanin granules to surrounding keratinocytes with 
subsequent degradation. Follicular melanocytes, however, undergo cyclical 
proliferative and melanogenic activity which is coupled to the growing phase of the 
hair follicles and determines the colour of the mature hair shaft (Fitzpatrick et al., 
1979).
Although administration of a-MSH causes skin darkening in man (Lemer and 
McGuire, 1961) and specific a-MSH binding sites have been demonstrated on 
human melanocyte cell surfaces (Donatien et al., 1992; De Luca et al., 1993), early 
data suggested that MSH peptides fail to stimulate tyrosinase activity and hence 
melanin production in cultured human melanocytes (Halaban et al., 1983). However, 
Hunt et al. (1994) proposed that these results were a consequence of mitogens such 
as TPA and cholera toxin routinely included in the culture media, which were found 
to affect basal melanogenesis levels. Exclusion of these agents produced significant, 
although variable increases in tyrosinase activity and melanin content on a-MSH 
stimulation (Hunt, 1995).
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1.4.2.1.1. Mechanism of action
The complex formed on interaction of MSH with its receptor appears to be 
rapidly internalised (Garcia-Borron et al., 1992), with lysosomal degradation 













C Y STEIN YLDOP A
TRP-2
TRP-l
DHI oligomers DHICA oligomers
\  /
EUMELANIN MIXED MELANIN PHAEOMELANIN
Figure 1.4. Schematic representation of the metabolic pathway of tyrosine to 
melanin (adapted from Thody, 1995).
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The mechanism of action of a-MSH on pigment production in mammalian 
melanocytes and melanoma cells is thought to be via receptor-mediated induction of 
the second messenger, cAMP, since both dibutyryl cAMP and theophylline, a 
phosphodiesterase inhibitor, mimic MSH action (Bitensky and Demopoulos, 1970; 
Wong, and Pawelek, 1973; Fuller and Lebowitz, 1980). MSH stimulation of the 
enzyme adenylate cyclase via G-protein activation (Kreiner et al., 1973) is 
responsible for this increase in cAMP which in turn induces protein phosphorylation 
via protein kinase A (PKA) stimulation (de Graan et al., 1987). However, Buffey et 
al. (1991) proposed the involvement of a second system. They found that whereas 
the melanogenic response to MSH is dependent on cell density, cAMP production is 
not. Further work established a role for protein kinase C, whose effect appears to be 
at least partially mediated by PKA-induced phosphorylation of the receptor itself 
(Buffey et al., 1992).
Although these molecular events are still unclear, they culminate in tyrosinase 
activation and melanin production. Tyrosinase is the rate-limiting enzyme in the 
melanin biosynthetic pathway depicted in Figure 1.4. and is a multifunctional 
copper-containing glycoprotein which exists as a single chain. Synthesis occurs on 
ribosomes, followed by transfer through the endoplasmic reticulum to the Golgi 
complex, where glycosylation takes place. It is then packaged into vesicles which 
fuse with the pre-melanosomes where the enzyme becomes functionally active and 
where melanogenesis occurs (reviewed Hearing and Tsukamoto, 1991). The human 
tyrosinase gene has been cloned and mapped to the albino locus on the long arm of 
chromosome 11 (Kwon etal., 1987).
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Tyrosinase catalyses three reactions in this pathway: (1) the hydroxylation of 
L-tyrosine to L-dopa, generally considered to be the most critical reaction as the 
subsequent stages can proceed spontaneously at physiological pH; (2) the oxidation 
of dopa to dopaquinone, an extremely reactive compound that rapidly enters the 
eumelanin or phaeomelanin pathway; (3) the hydroxylation of 3,6-dihydroxyindole 
(DHI) to indole-quinone leading to eumelanin production (Komer and Pawelek, 
1982). This last enzymatic role may explain why eumelanogenesis is more dependent 
on tyrosinase than is phaeomelanin production, as discussed below. The first and 
third reactions require dopa as a co-factor whereas in the second, dopa is a substrate.
Tyrosinase activity is regulated by a-MSH, which induces a 2-5 fold increase 
in the transcription of its gene (Kwon et al., 1988; Hoganson et al., 1989) and a 5-50 
fold increase in tyrosinase activity (Wong and Pawelek, 1975; Halaban et al., 1984). 
However, the precise molecular mechanisms underlying tyrosinase induction were 
debated for some time. Wong and Pawelek (1975) proposed that MSH acts on 
Cloudman S91 mouse melanoma cells by converting pre-existing tyrosinase 
molecules from an inactive to an active state. Jimenez et al. (1988) found a large 
increase in tyrosinase activity which preceded the necessary time lag for de novo 
tyrosinase synthesis, thereby lending weight to this proposal. However, Halaban et 
al. (1983, 1984) found an approximately linear correlation between tyrosinase 
mRNA abundance and tyrosinase activity produced by MSH stimulation in both 
mouse melanoma cells and cultured human melanocytes. They therefore suggested 
that the increase in tyrosinase activity can be attributed solely to increased enzyme 
synthesis. Other studies by Fuller et al. (1987) provided evidence that melanogenesis 
absolutely requires both continued transcription and translation. However, in contrast
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to the above results, the increase in tyrosinase mRNA which they detected was 
insufficient to account for the large increase in enzyme activity.
Valverde et al. (1992) attempted to reconcile these apparent contradictions 
with their discovery of tyrosinase isoenzymes with different catalytic properties. 
They proposed that the isoenzyme preferentially induced by meianotropic agents 
displays a larger ratio of tyrosine hydroxylase to dopa oxidase activity, and would 
therefore primarily affect the first, rate-limiting step of the melanogenic pathway.
These tyrosinase-related proteins (TRPs) are structurally related to tyrosinase, 
showing 45% sequence homology with conserved copper-binding sites. Together 
with tyrosinase, they constitute the “tyrosinase gene family” and the expression of 
their protein products is increased by a-MSH stimulation (Abdel-Malek et al., 1995). 
TRP-1 has been shown to have dihydroxyindole carboxylic (DHICA) oxidase 
activity and may therefore have an enzymatic role in the eumelanin pathway 
(Jimenez-Cervantes et al., 1994). It is present in both human epidermis (Tobin et a l,
1994) and cultured melanocytes (Abdel-Malek et al., 1993). Orlow et al. (1993) 
found TRP-1 to be associated with pre-melanosomes unlike tyrosinase which is 
primarily found in mature melanosomes. This raises the possibility of TRP-1 having 
a melanosomal development role. TRP-2 is detectable in human melanocytes in vivo 
(Tobin et al., 1994) and, in mice, has been shown to act as a dopachrome 
tautomerase, an enzyme involved in eumelanogenesis (Tsukamoto e ta l,  1992).
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1.4.2.1.2. Melanin production
There are two main types of mammalian melanin produced which share the 
same biosynthetic pathway: eumelanin, which gives rise to brown-black coloration, 
and phaeomelanin, which produces yellow-red coloration (Prota, 1980). As discussed 
above, tyrosinase acts on its L-tyrosine substrate, converting it first to dopa and then 
to dopaquinone. At low tyrosinase activity, the levels of dopa are low and the default 
pathway is the synthesis of cysteinyl-dopa which is incorporated into melanin to give 
phaeomelanin. On excess production of dopa, as results after maximal stimulation by 
MSH, dopa is converted to dopachrome which gives black eumelanin when 
incorporated into melanin.
The relative amounts of eumelanin and phaeomelanin are controlled primarily 
by two loci in mammals: extension and agouti (Jackson, 1993).
Extension
It has been shown that the murine extension locus encodes the melanocortin-1 
receptor, or MC1-R (section 1.6.). The locus increases brown / black pigment when 
dominant (E), and blocks eumelanin synthesis, thereby extending the range of red / 
yellow pigment, when recessive (e).
The absence of functional MC1-R in the recessive yellow mouse demonstrates 
its dispensability for normal melanocyte growth and development. However, MSH 
receptor activity is absolutely required for most eumelanin pigmentation of hair 
(Robbins et al., 1993). Eumelanin synthesis in dermal melanocytes is less dependent 
on MSH receptor stimulation than it is in hair follicular melanocytes since eumelanin
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is still found in the skin of homozygous recessive (e/e) animals (Hauschka et al., 
1968). Several dominant mutant murine alleles have been isolated. The tobacco
tnhallele, E  , results from a serine-to-leucine change at position 69 in the first 
intracellular loop of the receptor. The expressed receptor exhibits a slightly elevated 
basal activity and is a greater stimulant of adenylate cyclase as compared to the wild- 
type. The mutant sombre alleles, E?° and E?°~3J, in contrast, create constitutively 
active receptors which are a result of leucine-to-proline changes at position 98 and 
glutamic acid-to-lysine at position 92, respectively (Robbins et al., 1993). High 
concentrations of a-MSH were found to have no additional stimulatory effect, 
although the a-MSH analogue, [Nle4,DPhe7]-a-MSH, further activated these sombre 
mutants to maximal level (Cone et al., 1996).
Agouti
Cloning and characterisation of the agouti locus have found the murine gene to 
encode for a 131 amino acid polypeptide with a central lysine-rich domain, a C- 
terminal tail containing ten cysteine residues capable of forming five disulphide 
bonds and a signal sequence (Bultman et al., 1992). This latter property suggests a 
paracrine role for agouti protein. In vitro site-directed mutagenesis studies have 
established the importance of the signal peptide and the C-terminal cysteine residues 
for full biological activity. However, at least a portion of the lysine-rich basic domain 
appears to be dispensable for normal function (Perry et al., 1996).
Protein database scans have indicated that agouti is a novel protein with no 
strong identity or sequence homology to other known families. However, its overall 
structure is similar to several short venomous peptide toxins which disrupt the
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function of cellular receptors and ion channels in a similar manner to the mechanism 
proposed for agouti protein in coat-colour determination (Olivera et al., 1994).
Agouti functions to regulate the differential production of melanin pigments by 
melanocytes. In animal hair follicles, it opposes the a-MSH-induced synthesis of 
eumelanin resulting in a band of yellow phaeomelanin (Jackson, 1993).
Recent research showed the competitive inhibition of both agonist binding and 
activation at the murine melanoma MC1-R over a range of agouti protein and MSH 
concentrations (Lu et al., 1994; Blanchard et al., 1995). This supports the view that 
agouti acts to inhibit melanocortin binding and action at the receptor level. However, 
this action appears to be specific to certain melanocortin receptor subtypes as 
antagonism also occurs at the MC4 receptor but not the MC3 or MC5 receptors 
(section 1.6) (Lu et al., 1994). There is also evidence that agouti protein may increase 
intracellular Ca2+ concentrations, perhaps by the binding to, and stimulation of, Ca2+ 
channels, (Zemel et al., 1995) - an observation supported by Hunt and Thody’s 
finding (1995) that agouti antagonises the effect of verapamil on melanogenesis. 
Hunt and Thody (1995) also demonstrated the inhibitory effect of agouti protein on 
basal melanogenesis together with an absence of inhibition of a-MSH-induced 
melanogenesis except at high agouti protein concentrations. Siegrist et al. (1996) 
observed an anti-proliferative effect by agouti protein on B16 murine melanoma cells 
in vitro, with concomitant MC1-R down-regulation. They hypothesised that down- 
regulation of the MC1-R produces lower levels of intracellular second messengers 
such as cAMP which are necessary for normal cell growth and function.
Taken together, these data suggest that the antagonism hypothesis is an 
oversimplification and support a multi-functional role for agouti protein in the
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regulation of melanogenesis, perhaps via a specific agouti receptor as proposed by 
Conklin and Bourne (1993) and Yen et al. (1994).
Dominant mutations at this locus in the mouse lead to phenotypic changes, 
including obesity, hyperinsulinaemia and a predominantly yellow coat colour (Wolff 
et al., 1986; Wolff, 1987; Klebig et al., 1994; Yen et al., 1994). Agouti has been 
found to antagonise the MC4 receptor which is largely expressed in the 
hypothalamus (Lu et al., 1994). This is an area recognised to be important in the 
regulation of feeding behaviour, and has led to the hypothesis of aberrant ectopic 
agouti expression producing obesity as a result of pathogenic antagonism of one or 
more melanocortin receptors.
As no agouti pigmentation phenotype is known in man, it was for a long time 
uncertain as to whether humans expressed the agouti protein. Kwon et al. (1994) 
resolved the debate with their cloning and characterisation of the human homologue. 
It was found to be 85% identical to the mouse gene, encoding a 132 amino acid 
protein. The group mapped it to a region of chromosome 20, close to a locus which 
has been implicated in the development of non-insulin-dependent diabetes.
Human agouti mRNA has been identified in testis, ovary and heart, and at 
lower levels in adipose tissue, liver and foreskin (Willard et al., 1995; Wilson et al,
1995). This discovery together with demonstrated inhibition of melanogenesis by 
agouti protein in human melanocytes (Hunt and Thody, 1995) provides further 
evidence of a possible correlation with disease states in man similar to those seen in 
mice as described above.
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1.4.2.1.3. UV radiation
The physiological response to ultraviolet radiation includes an increase in 
melanocyte number, melanin synthesis, and the transfer of pigment granules to 
surrounding keratinocytes (Goldsmith, 1991).
Exposure of Cloudman melanoma cells in culture to UVB was found to 
increase MSH binding capacity and cellular responsiveness to MSH (Bolognia et al., 
1989), leading to the proposal that the effects of UV radiation on melanogenesis may 
be mediated through the MSH receptor system. Support for this hypothesis came 
from a demonstration that exposure to UVB radiation stimulates the production of 
mRNA for both POMC and the melanocortin-1 receptor in the murine melanoma 
cells and keratinocytes (Chakraborty et al., 1995). The superoxide anion, O2 ', was 
found to be a preferable substrate to molecular oxygen for tyrosinase (Wood and 
Schallreuter, 1991) thereby providing melanocytes with a specific anti-oxidant 
mechanism. Cytotoxicity induced by the superoxide anion was found to be lower on 
melanocortin stimulation of a murine melanoma cell line expressing high tyrosinase 
levels. This protective effect correlated with tyrosinase, rather than melanin 
biosynthesis (Valverde et al., 1996). These findings suggest that it is not melanin 
production per se that provides protection against UV-induced damage, rather the 




Ferrari (1958) first demonstrated the behavioural changes induced by 
intracisternal injection of MSH peptides into mammals and early data have been 
reviewed in detail by de Wied and Jolles (1982), and O’Donohue and Dorsa (1982).
The manifestations included excessive grooming, a habit characteristic of 
rodents exposed to novel or conflicting environmental stimuli. The minimum 
sequence necessary to induce this phenomenon was found to be ACTH(4-7) (Gispen 
et al., 1975), and was blocked by opiate (Gispen and Wiegant, 1976), muscarinic 
(Ferrari et al., 1963), and dopaminergic antagonists (Wiegant et al., 1977), indicating 
the involvement of multiple neurotransmitter systems.
Other effects include heightened sexual arousal (Everard et al., 1977; Thody et 
al., 1979), and improved avoidance learning together with retention of avoidance- 
induced behaviour in hypophysectomised rats, (de Wied, 1964, 1965, 1966).
1.4.2.2.2. Peripheral nerve regeneration
Exogenous administration of melanotropic peptides, including the a-MSH(4-9) 
analogue, [Met(0 2 )4,DLys8,Phe9]a-MSH, (Org2766), has a trophic action on nerves, 
an effect which is most apparent during development and nerve regeneration, i.e. in 
instances of nerve plasticity. It has been proposed that this phenomenon is an 
amplification of the stimulatory action of endogenous melanocortins (Plantinga et 
a l, 1995). Indeed, melanocortin immunoreactivity has been demonstrated in 
degenerating, but not intact, nerves (Edwards et al., 1984), further suggesting that 
local production by traumatised nerves helps mediate neurite outgrowth.
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Schwann cells are known to play a significant role in facilitating regeneration 
and a melanocortin receptor has been isolated from such cells (Dyer et al., 1993). 
Although originally proposed to be of the MC1-R subtype, further work apparently 
contradicts this hypothesis as the Org2766 pentapeptide melanocortin sequence was 
found to be needed for full binding capacity, (Dyer et al., 1995). An explanation 
could be the expression of multiple melanocortin receptor subtypes on the Schwann 
cell surface. These results are supported by the observation of Tatro et al. (1994) that 
Org2766 showed no ability to compete with [Nle4,DPhe7]a-MSH for binding 
throughout the CNS, implying the existence of further melanocortin receptors to 
mediate the effects of this peptide.
1.4.2.2.3. Anti-inflammatory effects
Cannon et al. (1986) found that a-MSH directly interferes with the 
inflammatory action of interleukin-1 (IL-1) on target cells. They postulated that IL-1 
and a-MSH are involved in a negative feedback loop whereby stimulated 
mononuclear cells induce IL-1 to increase pituitary peptide release, which in turn 
suppresses the production and cellular actions of IL-1. a-MSH appears to have no 
effect in the absence of IL-1, suggesting that it acts as an endogenous antagonist. 
However, its superpotent analogue, [Nle4,DPhe7]a-MSH, does not effectively block 
IL-1 action on thymocytes implying that a-MSH action may not be mediated by the 
receptors cloned to date (section 1.6 .).
The C-terminal tripeptide, a-M SH(ll-13), exhibits antipyretic and anti­
inflammatory action but has lower potency than the parent peptide (Deeter et al.,
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1988; Richards and Lipton, 1984). However, Hiltz et a l (1991) found that alterations 
of amino acid chirality within the tripeptide can markedly alter potency. D-isomer 
substitution at position 13, and di-substitution to give [DLys11, DVal13]a-M SH (ll- 
13) confers four-fold greater potency than that exhibited by the L-tripeptide. [DLys11] 
substitution into the tripeptide results in approximate equipotency with a-M SH (ll- 
13) whereas [DPro12]a-MSH has no significant anti-inflammatory activity. This 
supports the concept of a-MSH as a natural modulator of the host response and 
suggests that the anti-inflammatory sequence lies within the carboxy-terminal 
fragments.
Ceriani et al. (1994) found that peripheral inflammation induced by a number 
of cytokines viz. IL-lp, IL-8 , platelet activating factor (PAF), and leukotriene-B4 
(LTB4) was inhibited by central administration of both a-MSH and a-M SH(ll-13). 
Spinal transection of these mice completely abolished this effect, indicating the need 
for intact descending pathways for the anti-inflammatory influence of the central 
peptide. These findings contradict current theory that mediation and modulation of 
inflammation is controlled solely by local events and substances produced by 
peripheral cells and tissues.
Interestingly, intraperitoneal injection of a-MSH( 11-13) into spinal transected 
mice had a strong anti-inflammatory effect, suggesting that the tripeptide can also act 
directly as an anti-inflammatory in the periphery without induction of central anti­
inflammatory signals. The parent peptide produced a small and delayed anti­
inflammatory effect, perhaps indicating metabolism of the injected a-MSH and 
subsequent action of the more active tripeptide (Macaluso et al., 1994).
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a-MSH has been identified in the synovial fluid of rheumatoid arthritic 
patients, suggesting local production (Catania et a l , 1994). Star et al. (1995) showed 
the inhibition of the inflammatory mediator nitric oxide (NO) by a-MSH in cultured 
murine macrophages via inhibition of NO synthase II mRNA and protein production. 
They also detected low level MC1-R expression on cultured macrophages and found 
a-MSH to be released by macrophages in response to cytokine treatment. These data 
suggest that a-MSH is an autocrine factor in macrophages which modulates 
inflammation by counteracting the effects of pro-inflammatory cytokines. Human 
neutrophils have also been shown to express MCI receptors, but unlike 
macrophages, do not produce melanocortins. a-MSH was found to reduce neutrophil 
migration, this effect being attributed to alterations in signal transduction induced by 
cAMP (Catania et al., 1996).
The combined evidence therefore shows that a-MSH has both central and 
peripheral sites of action and its wide spectrum of activity suggests it inhibits an 
agent or event common to multiple forms of inflammation.
1.5. Structure - Activity Relationships of the Melanocortins
Early investigations were carried out by measuring and comparing the pigment- 
dispersing properties of the naturally occurring melanotropic peptides, their 
analogues, and fragments thereof on reptilian skin. Extrapolation of these results to 
the various melanocortin receptor subtypes which have since been cloned must be 
undertaken with caution, although useful insights can be gained from such work.
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These data have been extensively reviewed by Eberle (1988), and the following 
points summarise the general conclusions drawn.
2.5.2. N-terminal Sequence
Acetylation of the N-terminal has been shown to have variable effects 
depending on the assay used. For example, a-MSH shows almost ten-fold greater 
potency as compared to desacetyl-a-MSH in Rana melanophores but approximately 
equivalent activity in Xenopus melanocytes (Eberle et al., 1984). If the size or 
lipophilicity of this functional group is increased, peptide activity is greatly reduced 
in these systems (Eberle, 1988). Acetylation decreases N-terminal hydrophilicity, 
which may increase receptor affinity or protect the peptide from degradation.
The N-terminal tetrapeptide, Ac-Ser-Tyr-Ser-Met-OH, is biologically inactive 
but when covalently linked to a-MSH(5-13), activity is increased by 50 to 100 fold 
(Eberle, 1988). Decreased hydrophilicity of residues 1-3, or decreased lipophilicity of 
[Met4], results in lower potency. However, replacement of [Met4] by the isosteric 
norleucine produces increased activity (Sawyer et al., 1980) as discussed in section
1.5.4. Introduction of an iodine atom at [Tyr ] slightly decreases potency in several 
assays whereas insertion of two atoms greatly reduces activity in all assay systems 
studied (Eberle and Hiibscher, 1979).
These data suggest that the primary role of the N-terminal residues is to form a 




These residues are known to be critical for full activity of the melanotropic 
peptides (Eberle, 1988) and would therefore be expected to be particularly sensitive 
to alteration. The retro-inverse analogue of the a-MSH(5-9) sequence is inactive, 
suggesting that the peptide backbone as well as the spatial arrangement of the side 
chains is important for receptor binding and stimulation (Chung and Li, 1967).
Yajima et al. (1965, 1966, 1967) investigated in detail the effect of a change in 
configuration of these core residues and found that substitution of the D-stereoisomer 
at positions [Phe7]+[Trp9] and [Phe7] alone produced ten-fold greater activity than 
that seen with the all L-analogue. Single substitution to give [DTrp9]a-MSH or di­
substitution to give [DHis6,DPhe7]a-MSH and [DPhe7,DArg8]a-MSH gives similar 
activity to a-MSH, with all other diastereoisomeric substitutions being detrimental.
Other alterations at positions 7 and 8 greatly reduce melanotropic potency, 
except for replacement of [Arg8] by norleucine which produces a full agonist (Al- 
Obeidi et al., 1990), suggesting that [Phe7] and [Arg8] play a key role in eliciting the 
response after hormone-receptor interaction.
[Glu5] appears to be the most dispensable residue in this sequence although the 
attachment of large groups to the side chain reduces affinity (Eberle, 1988).
1.5.3. C-terminal Sequence
[Gly10] was described as having a spacer function as substitution with alanine 
was found to have minimal effect and the addition of one or two further amino acids 
only moderately affected activity (Medzihradszky, 1976). Omission of this residue,
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however, decreases pigment-dispersion in the frog skin assay to 1% of the parent 
peptide (Medzihradszky 1976; Medzihradszky et al., 1979).
The C-terminal tripeptide, Lysn -Pro12-Val13, is generally regarded to be more 
important for biological activity than the N-terminal tripeptide. It exhibits weak but 
distinct activity in the Rana and Anolis assays, resulting in the claim of Eberle and 
Schwyzer (1975) that it contains a “secondary message sequence”. However, other 
studies show that the tripeptide does not significantly increase the activity of certain 
a-MSH fragments (Hruby et al., 1987) which, together with data from Sawyer et al. 
(1990), dispute its importance. Loss of the basic side chain of [Lys11] or an increase 
in lipophilicity decreases activation whereas its D-stereoisomer analogue retains 
some activity. [DPro12] substitution abolishes activity and [Val13] alterations were 
found to have minimal effect on potency provided that the side chain remains 
lipophilic (Eberle, 1988).
ACTH has approximately 1% of the activity of a-MSH in the classical frog 
skin assay and it is thought that the extension of the C-terminal as found in ACTH 
hinders contact between the active site of the hormone and its receptor. However, 
ACTH and a-MSH have been found to have similar activity in human melanocytes 
and melanoma cells, (Chhajlani and Wikberg, 1992; Gantz et al., 1993a). This raises 
the possibility of a gradual evolution of the human MSH receptor into an MSH / 
ACTH receptor.
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1.5.4. [Nle4, DPh e 7] Or MSH: A Superpotent Melanocortin Agonist
Radioiodination of the [Tyr2] residue of a-MSH for binding assay purposes is 
difficult as concomitant oxidation of [Met4] produces a hundred-fold loss of activity 
(Siegrist et al., 1992). This can be overcome by the use of the analogue [Nle4]a- 
MSH in which the sulphur atom of methionine has been replaced by a methylene 
group. This analogue has been shown to be more potent than a-MSH at stimulating 
adenylate cyclase activity (Medzihradszky, 1976), as well as being resistant to 
inactivation by chloramine-T, the oxidant used in peptide iodination for assay 
purposes.
It has long been recognised that heat-alkali treatment of a-MSH results in its 
prolonged biological activity (Lee and Buettner-Janusch, 1963). Analysis of the 
treated peptide revealed partial racemisation, most notably at the [Met4] and [Phe7] 
positions (Sawyer et al., 1980). Heat-alkali treated [Nle4]a-MSH was also found to 
exhibit this prolongation despite position 4 being no longer prone to significant
n
racemisation. This suggested that [DPhe ] is responsible for the observed effect and 
was confirmed by the chemical synthesis and biological analysis of [Nle4,DPhe7] a- 
MSH (Hadley et al., 1981). The high potency and post-iodination stability of [125I- 
Tyr2, Nle4,DPhe7]a-MSH as compared to a-MSH has led to its routine use as the 
standard for melanotropic peptide assays.
The observed prolongation of action may be due to slow dissociation kinetics 
from the receptor resulting from favourable conformational properties of the 
diastereoisomer for “irreversible” peptide-receptor interaction (Haskell-Luevano et 
al., 1996). [Nle4,DPhe7]a-MSH was also found to be resistant to degradation by
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serum enzymes, suggesting that enzymatic stability is partly responsible for enhanced 
peptide action in vivo (Hruby et a l, 1987).
1.5.5. Cyclic Peptides
Potent agonists with rigid structures can provide valuable information 
regarding the spatial organisation of receptor sites on which they act.
The MSH peptides are linear and therefore extremely flexible. They would be 
expected to have a random conformation in solution with the preferred conformation 
only being induced by contact of the hormone with cell surface lipids and receptor 
proteins, thus ensuring both kinetically and thermodynamically optimal hormone- 
receptor interaction.
Restriction of this conformational flexibility is a prerequisite for studying the 
receptor-specific conformations of the peptide. This is carried out in practice by 
cyclisation of suitable linear derivatives. Specific topological features can be 
deduced from such compounds as their conformational properties in solution are 
likely to be very similar to those at the receptor.
It has been suggested that a-MSH analogues adopt a |3-tum in the active 
tetrapeptide, His-Phe-Arg-Trp, and molecular modelling work has shown that it is 
indeed possible for such a turn to exist. However, the lowest energy conformers were 
found to lack this structure (Chan et al., 1995). Several approaches have sought to 
stabilise this postulated reverse turn, including the synthesis of monocyclic a-MSH 
derivatives. One such analogue, cyclic[Cys4,Cys10]a-MSH, was described as 
“superpotent” in reptilian bioassays (Sawyer et al., 1982), but was later shown to 
have a slightly lower binding affinity than the natural ligand in the B16 murine
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melanoma cell line (Sahm et al., 1996). It showed a significantly higher binding 
affinity than its linear counterpart although the activities of the linear and cyclic 
analogues were similar. This was proposed to be a consequence of the reduction of 
the disulphide bridge under the activity conditions used (Sahm et al., 1996). Haskell- 
Luevano et al. (1995b) synthesised bicyclic derivatives with the aim of further 
limiting the number of available conformations around this “message” sequence. 
However, the further constraints introduced, resulted in these analogues being less 
potent than their monocyclic parents, although appropriate modifications may lead to 
antagonists.
1.5.6. Antagonists
Receptor-specific and potent antagonists would be valuable tools to aid 
understanding of MSH interaction with its receptors and to help determine 
physiological roles. This is especially so in the brain where melanocortin receptor 
expression is complex and associated with numerous CNS functions. Melanocortin 
receptor antagonist development has been slow as there appears to be little 
distinction between binding and trigger elements. This suggests that those residues 
responsible for strong binding are also responsible for receptor activation. Early 
research resulted in peptides that exhibited low potencies or mixed action, i.e. the 
display of agonist properties at high concentration and weak antagonistic or 
potentiating properties at low concentrations.
Al-Obeidi et al. (1990), reported the linear a-MSH(4-10) analogue Ac-Nle- 
Asp-Trp-DPhe-Nle-Trp-Lys-NH2 to be an antagonist in the frog skin assay but an 
agonist in the lizard skin assay. Jayawickreme et al. (1994) employed a multi-use
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peptide library, enabling large-scale screening of potential antagonists of which the 
most potent was found to be Met-Pro-DPhe-Arg-DTrp-Phe-Lys-Pro-Val-NH2. This 
compound competitively inhibited [125I-Tyr2,Nle4,DPhe7]a-MSH binding from each 
cloned melanocortin receptor subtype, albeit with different potencies (Chhajlani,
1996). Larger combinatorial libraries identified a shorter peptide with antagonistic 
properties. DTrp-Arg-Leu-NFL antagonised the MCI receptor but exhibited a higher 
IC50 value, within the micromolar range, than that determined for the fuller length 
peptide cited above (Quillan et al., 1995). Adan et al. (1994b) investigated the 
antagonist properties of various linear ACTH(4-10) analogues on the rat MC3, 
human MC4 and ovine MC5 receptors with modifications in the (6-10) positions.
n
The paraiodophenylalanine-substituted analogue, [Phe-I ]ACTH(4-10), was one of 
the most potent compounds tested and it antagonised all three receptors, perhaps 
through steric hindrance by the introduced iodine atom. Further substitution at 
position 7 with bulky aromatic amino acids resulted in the first reported potent and 
selective MC receptor antagonists. For example, substitution with [D-2’- 
naphthylalanine7] to give the cyclic lactam peptide Ac-Nle4-c[Asp5DNal(2)7,Lysl0]a- 
MSH(4-10) produced a potent antagonist for the MC4 receptor, a less potent 
antagonist at the MC3 receptor and a full agonist at the MCI and MC5 receptors 
(Hruby et al., 1995).
These data intriguingly point to different structural requirements for antagonist 
activity at different pigmentary receptors in different species and at different 
melanocortin receptors in the same species.
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1.5.7. Further Melanocortin Receptor Characterisation Tools
The physiology of the different melanocortin receptor subtypes can also be 
probed using specific antisera. To date, only two antipeptide antibodies have been 
prepared, both against the human MCI receptor, which specifically immunostained 
MCI receptor expressing cells, including the cells of malignant melanoma tumours 
(Xia et al., 1995a). Composites have been synthesised consisting of multiple copies 
of [Nle4,DPhe7]a-MSH and a fluorophore on a biologically inert macromolecule. The 
multivalency produced stronger binding and the fluorophore increased detection 
sensitivity and was used to demonstrate the presence of specific melanotropin 
receptors on various human melanoma cell lines (Sharma et al., 1994).
Both these types of melanotropin-receptor-expressing-cell-surface markers may 
represent potential tools for identification, localisation and chemotherapy of 
melanoma.
1.6. The Melanocortin Receptor Family
Comparison of the melanocortin receptor sequences with those of other 
receptors has defined them as a subgroup within the G-protein-coupled receptor 
superfamily. G-protein-coupled receptors are characterised by being organised into 
seven putative hydrophobic transmembrane domains, each region consisting of 20-25 
amino acids. They share considerable sequence homology, particularly in these 
transmembrane regions which are thought to form the ligand binding pocket (Lameh 
et al., 1990). It has not been possible to identify consensus amino acid sequences that 
confer G-protein specificity, thus G-protein interactions cannot be predicted from the 
primary amino acid sequence. Studies with other G-protein-coupled receptors have
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shown the third cytoplasmic loop, 3i, to be important in the signalling cascade 
(Lefkowitz and Caron, 1988), although the precise mechanism remains unclear. 
Agonist-bound receptors interact with heterotrimeric G-proteins located on the 
cytoplasmic side of the cell membrane with subsequent stimulation of second 
messenger systems.
The melanocortin receptors are the smallest subgroup of G-protein-coupled 
receptors identified to date, having short amino-terminal extracellular and carboxy- 
terminal intracellular domains as well as a short second extracellular loop (Mountjoy 
et al., 1992). These receptors also lack several amino acid residues common to most 
G-protein-coupled receptors (Probst et al., 1992) including proline residues in the 
fourth and fifth transmembrane domains, which are thought to introduce a bend in 
the a-helical structure and to participate in the formation of the binding pocket 
(Applebury and Hargrave, 1986), and one or both cysteine residues thought to form a 
disulphide bond between the first and second intracellular loops (Dixon et al., 1987; 
Karnik et a l, 1988).
To date, five melanocortin receptors have been cloned which share between 
39% and 61% amino acid homology. The MC3, MC4 and MC5 receptors appear to 
be more closely related to each other (55-61%) than to the MCI and MC2 receptors 
(43-46%).
1.6.1. Melanocortin-1 Receptor
Cloning of the melanocortin receptors began with the isolation by Chhajlani 
and Wikberg (1992) of a human gene whose product is the “classic MSH receptor”,
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but is now more commonly referred to by the recognised nomenclature as the 
melanocortin-1 receptor, or MC1-R. The gene encodes for a 317 amino acid protein 
with a molecular weight of 34.8 kDa which is considerably lower than the value of 
45 kDa reported from photoaffinity labelling studies (Gerst et al., 1988; Solca et al., 
1989) and suggests that the receptor is normally glycosylated.
Mountjoy et al. (1992) concurrently isolated both the human (hMCl) and 
murine (mMCl) receptors and found 76% sequence homology between them. These 
independently determined sequences for the human receptor differed by two amino 
acids although later work by Gantz et al. (1993a) produced a sequence identical to 
that reported by Mountjoy et al. (1992).
Functional MC1-R is expressed on human melanocytes (Donatien et al., 1992), 
most cultured and in vivo murine melanoma cell lines (Tatro et al., 1990) and some 
human melanoma cell lines (Ghanem et al., 1988; Legros et al., 1981; Siegrist et al., 
1989). Low level expression has more recently been detected on neutrophil and 
macrophage cell surfaces (section 1.4.2.2.3.) and in the periaqueductal grey matter of 
the brain (Xia et al., 1995b), suggesting mediation by this receptor of some of the 
physiological actions of the melanocortins in this region.
As described previously, the murine MC1-R gene maps to a single locus at the 
distal tip of chromosome 8 and is identical with the pigmentation locus, extension 
(Robbins et al., 1993). The localisation of the human MC1-R gene to chromosome 
16q24 was determined by Gantz et al. (1994b) and Magenis et al. (1994).
High levels of MC1-R mRNA were found in bovine testis (Vanetti et al., 
1994), and its product shows 80% sequence homology with hMCl-R. This receptor 
may be involved in spermatogenesis although no transcripts for melanocortin
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receptors have been detected in human testis, suggesting a possible species 
difference.
Chhajlani and Wikberg (1992) found a-MSH and ACTH to have equivalent 
binding affinities on this receptor. These data are consistent with the observation of 
Gantz et al. (1993a) of equal potency and efficacy as measured by cAMP production. 
However, these results are at variance with those of Mountjoy et al. (1992) who 
found ACTH to have lower potency and efficacy than a-MSH on the murine 
receptor. It is therefore possible that the ability to differentiate between a-MSH and 
ACTH is a property unique to the murine melanocortin receptors. p-MSH had a ten­
fold lower potency than a-MSH whereas y-MSH and the truncated peptides 
ACTH(4-10) and ACTH(l-lO) were unable to elicit a full cAMP response even at 
maximal concentrations.
These data illustrate the importance of the amino- and carboxy- terminal 
residues for full biological activity and specificity at this receptor subtype.
1.6.2. Melanocortin-2 Receptor
This receptor is recognised as the adrenocorticotropic hormone (ACTH) 
receptor, or MC2-R and has been localised to the adrenal cortex and adipocytes 
(Oelofsen and Ramachandran, 1983). Mountjoy et al. (1992) isolated the human 
gene and found 39% sequence homology to the human MCI receptor. On the basis 
of this low homology there has been some disagreement as to whether it should be 
included in the melanocortin receptor nomenclature (Chhajlani et al., 1993).
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Cammas et al. (1995) cloned the murine homologue which exhibits 84% DNA 
sequence homology and 89% peptide homology to its human counterpart. This group 
reported ready expression of the murine MC2 receptor in HeLa cells whereas 
difficulties in the expression of the human homologue have been reported by a 
number of laboratories.
Despite their close structural relationship to ACTH, a-MSH and other 
melanocortins were found to have no significant stimulatory action (Cammas et al. 
1995, Schioth et al., 1996a) on this receptor subtype. This indicates that the “core” 
tetrapeptide His-Phe-Arg-Trp, is less important for binding to the MC2-R than has 
been reported for other melanocortin receptors. It further suggests that binding to, 
and stimulation of the MC2 receptor is mediated by separate epitopes. Binding 
studies performed on transfected cells confirmed the loss of agonist activity with 
ACTH analogues containing fewer than the first 17 residues and found an antagonist 
role for ACTH(11-24) (Kapas et al., 1996).
This receptor maps to a conserved syntenic region of chromosome 18 in the 
mouse and human (Gantz et al., 1993c; Magenis et al., 1994). Although it does not 
map near any previously characterised phenotypic deviant, the identification of an 
ACTH receptor gene mutation in an individual with ACTH resistance identifies this 
region as a site of familial ACTH resistance (Weber et al., 1993).
1.6.3. Melanocortin-3 Receptor
Gantz et al. (1993a) characterised the 361 amino acid human homologue of the 
third member of the melanocortin receptor family, which has a molecular weight of 
35 kDa after de-glycosylation as determined by photoaffinity labelling (Sahm et al.,
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1994). Surprisingly, this receptor has been shown to couple to both cAMP and 
inositol phosphate / Ca2+-mediated signalling systems with the latter exhibiting an 
unexpected biphasic effect. Both ACTH and a-MSH exhibited a stimulatory effect 
on inositol phospholipid turnover at low concentrations but a dose-dependent 
inhibitory effect at higher doses. The 3i portion of the MC3 receptor appears to be 
responsible for this biphasic response as a chimeric H2-histamine receptor 
substituted with the 3i region of hMC3-R conferred this biphasic property on the 
normally monophasic wildtype H2 receptor (Konda et al., 1994).
Northern blot hybridisation showed receptor expression in the CNS to be 
largely localised to the cortex, hypothalamus, hippocampus and thalamus. This 
distribution corresponds quite well with the distribution of y-MSH immunoreactivity 
(Kawai et al., 1984). It was also found to be highly expressed in the placenta. As 
a-MSH levels are known to rise markedly in the maternal circulation during late 
pregnancy (Clark et al., 1978), it is possible that the MC3 plays a role in these 
changes.
Ligand specificities were found to be quite different from the human MCI 
receptor with [Nle4,DPhe7]a-MSH, a-MSH, p-MSH, y-MSH, and ACTH exhibiting 
equipotency on the hMC3-R with respect to cAMP production. The truncated 
peptides ACTH(l-lO) and ACTH(4-10) demonstrated full efficacy but their observed 
lower potency was attributed to their smaller size (Gantz et al., 1993a). This suggests 
that the common core sequence of these melanotropic peptides forms the specific 
recognition site.
The rat and murine homologues were cloned by Roselli-Rehfuss et al. (1993) 
and Desarnaud et al. (1994), respectively, and consist of 323 amino acids, the latter
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showing 8 8 % identity with the human gene. Both groups reported binding and cAMP 
data that correlate well with the above results for the human homologue. This 
receptor therefore, was cited as the first identified subtype to which y-MSH binds 
with significant affinity although specificity is lacking. Sahm et al. (1994) also 
determined comparable affinities for a-MSH and yj-MSH on the rat MC3-R but 
found [Nle4,DPhe7]a-MSH to have approximately 100-fold higher affinity which is 
at variance with the above reports. Alanine substitution within the a-MSH peptide 
determined the favourable presence of tyrosine at position 2  for binding to the rat 
MC3 receptor (Sahm etal., 1994).
This receptor maps to an area of conserved synteny between mouse 
chromosome 2 and human chromosome 20 (Gantz et al., 1993c; Magenis et al., 
1994). This site overlaps with the location reported for the condition known as 
benign familial human neonatal epilepsy (Leppert et al., 1989), and in the mouse an 
epilepsy susceptibility locus has been mapped near the MC3 receptor locus. These 
data promote the MC3 receptor gene as a candidate gene for epilepsy.
1.6.4. Melanocortin-4 Receptor
Gantz et al. (1993b) subsequently cloned the human MC4 receptor. The 
intronless gene encodes a protein of 333 amino acids and was localised to 
chromosome 18. As with the MC3 receptor, it is expressed in the CNS, 
predominantly in the hypothalamus, but has a more widespread distribution 
throughout each major division of the brain (Mountjoy et al., 1994).
In agreement with their data for the MCI and MC3 receptors, Gantz et al. 
(1993b) found a-MSH and ACTH to have equipotency as measured by cAMP
37
production. y-MSH, ACTH(4-10) and ACTH(l-lO) did not elicit a full response on 
this receptor whereas P-MSH exhibited equipotency with a-MSH and ACTH. This 
latter observation is in contrast to data for the MC1-R. This implies that a portion of 
the p-MSH molecule at the C-terminal extension can determine selectivity between 
these two receptors. The group hypothesised that [Pro12] of ACTH, which is also 
present in a-MSH and p-MSH but not y-MSH, is critical for binding as a full agonist 
to the human MC4 receptor (chapter 5). The presence of MC4 mRNA in regions of 
the brain associated with learning and memory appears to produce a pharmacological 
basis for the CNS effects described above. However, neither the MC4-R nor the 
MC3-R respond well to Org2766 or ACTH(4-10), peptides that are recognised to be 
more active than native melanocortins in the retention of learned behaviour (de Wied 
and Jolles, 1982) and neural regeneration (Biijlsma et al., 1981; Strand et al., 1980). 
This suggests that the behavioural and regenerative effects of the melanocortins are 
mediated by further brain melanocortin receptors.
1.6.5. Melanocortin-5 Receptor
Various species homologues of the MC5 receptor have been isolated: the 
human MC5 (Chhajlani et al., 1993; Fathi et al., 1995), the mouse MC5 (Gantz et 
al., 1994a; Labbe et al., 1994; Fathi et al., 1995), the rat MC5 (Griffon et al., 1994), 
and the ovine MC5 (Barrett et al., 1994).
The human MC5 receptor gene encodes for a 325 amino acid protein and 
together with its murine homologue has been found to have a wide distribution, 
being expressed in skeletal muscle, lung, spleen, brain (Gantz et al., 1994a; Labbe et 
al., 1994), and in adipocytes (Boston and Cone, 1996). The potency order on the
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human receptor was found to be identical to that reported for the human MC1-R, 
with a-MSH exhibiting equipotency with ACTH. However, the overall affinities for 
the melanotropic peptides were determined to be several-fold lower (Chhajlani et al., 
1993). Despite these similarities, the receptor shows greatest homology (53%) to the 
MC3 receptor described by Gantz et al. (1993a).
Once again, a-MSH was found to be significantly more potent than ACTH in 
the stimulation of cAMP production on the murine MC5 receptor (Gantz et al., 
1994a; Labbe et al., 1994). These conflicting human versus murine data lend further 
weight to the hypothesis that the ability to differentiate between a-MSH and ACTH 
is a property unique to murine melanocortin receptors. The fragment ACTH(4-10) 
which is common to all melanocortins was found to have no significant biological 
activity. However, the truncated peptides containing an amino-terminal, namely 
ACTH(l-lO), or carboxy-terminal, namely ACTH(4-13), extension exhibited full 
efficacy albeit with diminished potency relative to a-MSH in stimulating cAMP 
production. These data imply that the heptapeptide core may act as an important 
spacer between the two termini with the specific sequences playing a less important 
role in the binding of the melanocortins to the murine MC5-R (Gantz et al., 1994a).
The overall lower affinities seen for the melanotropic peptides on the MC5-R 
suggest the existence of an, as yet undiscovered, high affinity endogenous ligand.
1.7. Clinical Perspective
Melanoma is notoriously difficult to treat and MSH coupled with an anti­
cancer agent represents a potential chemotherapeutic approach. This theory exploits 
the higher MCI mRNA receptor expression in melanoma cells as compared with
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normal melanocytes and other cells (Ghanem et al., 1988), and relies on conjugate 
entry into the melanoma cells by receptor-mediated endocytosis (Varga et al., 1977). 
Tatro et al. (1992) and Morandini et al. (1994) have demonstrated peptide- and cell- 
type specific uptake via the MCI receptor with cytotoxic diphtheria toxin and 
melphalan coupled to a-MSH, or fragments thereof, respectively. However, this 
concept has major limitations as not all human melanoma cells express detectable 
numbers of the MCI receptor (Libert et al., 1989) and not all of those that do were 
found to respond to [Nle4,DPhe7]a-MSH (Jiang et al., 1995). In addition, the 
correlation between in vivo and in vitro data appears somewhat weak (Siili-Vargha et 
al., 1990).
Similarly, Bard et al. (1990) have investigated the potential use of a chelating 
derivative of a-MSH with radioisotope attachment in malignant melanoma. 
However, they found that the high non-specific uptake observed would preclude the 
therapeutic targeting of their compounds although use as an imaging agent might be 
possible.
Two compounds are currently in trials as potential tanning agents. The 
superpotent a-MSH analogue [Nle4,DPhe7]a-MSH (section 1.5.4.), also known as 
Melanotan-I, has been shown to induce tanning in the absence of sunlight in normal 
males, albeit with minor side effects. A cyclic lactam analogue, Ac-Nle4-c[Asp5- 
His6-DPhe7-Arg8-Trp9-Lys10]-NH2, or Melanotan-II, was found to increase human 
skin pigmentation at cumulative doses much lower than with Melanotan-I, although 
side effects were also more prominent (Dorr et al., 1996). Further studies with these 
peptides are currently taking place.
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1.8. Aims and Objectives
The melanocortins are a peptide family to which a diverse range of functions 
have been attributed. It is most probable that these various effects are associated with 
specific melanocortin receptor subtypes. Subtype-specific agonists and antagonists 
might therefore be exploited therapeutically. However, a prerequisite for such 
development is a detailed understanding of the mechanisms by which the 
melanocortins interact with their receptors to produce these responses.
Previous research has established the importance of the tryptophan-9 residue of 
a-MSH for high affinity binding to the melanocortin receptors, yet a detailed 
knowledge of the necessary features of this tryptophan moiety is lacking. Part of this 
work therefore, involved testing substituted a-MSH analogues to aid further 
understanding of the physicochemical requirements at this position.
The MCI and MC4 receptor subtypes are particularly intriguing given their 
similar ligand binding profiles and that the importance of the melanocortin C- 
terminal for subtype selectivity has been postulated (section 1.6.4.). This hypothesis 
was investigated and the role of the C-terminal more fully defined by determining the 
effect of a-MSH analogues on the binding to and stimulation of the human MCI and 
MC4 receptors. Use of human receptor homologues is more clinically relevant, given 
the proposed existence of a species difference (section 1 .6 .) and also enabled a fuller 
study of this supposition.
Further insight into hormone-receptor interaction can also be gained from a 
study into receptor residues involved in formation of the ligand-binding pocket and 
G-protein stimulation. A model for melanocortin interaction with the MCI receptor 
has been proposed in this laboratory and the work presented here comprised an
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attempt to investigate this hypothesis. Use of site-directed mutagenesis techniques to 
produce point mutations at postulated key receptor residues coupled with biological 
testing of these altered receptors would enable determination of the validity of this 
model.
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Water for the preparation of all cell culture media and solutions was freshly 
double glass distilled using a bi-distillation Fistreem still fitted with a Fistreem pre- 
deioniser (Fisons Ltd., Loughborough, Northants.).
2.1.1.2. Growth medium and additives
All solutions detailed below were routinely obtained from Gibco Life 
Technologies Ltd., Paisley, Scotland.
lOx R PM I1640 (w ithout L-glutamine and sodium  bicarbonate). 
lOOx MEM non-essential am ino acids 
L-glutam ine 200 mM
Penicillin (10,000 IU/ ml) and streptomycin (10,000 mg/ml)
Foetal bovine serum (FBS)
Batches of foetal bovine serum were tested prior to routine use to ensure 
support of cell growth. All cells lines were cultured in lx RPMI 1640 medium 
supplemented with 10% FBS, 2 mM L-glutamine, 100 IU/ml penicillin and 100 
IU/ml streptomycin, lx MEM non-essential amino acids and 0.2% w/v sodium 
bicarbonate. pH was adjusted to 7.4 by the addition of an appropriate volume of IN 
sodium hydroxide. The medium was stored at 4°C and used within two weeks.
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2.1.1.3. Further solutions
Solutions of 7.5% w/v sodium bicarbonate, IN sodium hydroxide and 0.02% 
w/v EDTA in PBS were prepared in freshly de-ionised double distilled water. 
Phosphate buffered saline (PBS) tablets deficient in magnesium and calcium (Oxoid 
Ltd., Basingstoke, Hants.) were each dissolved in 100 ml de-ionised double distilled 
water to a pH of 7.3.
The above solutions were sterilised by autoclaving for 15 minutes at 15 lbs/sq. 
inch (121°C) on a liquid cycle in a Swingclave Type SFT-LAB oven (British Steriliser 
Co. Ltd.).
2.1.1.4. Laboratory apparatus
All aseptic techniques were performed in a laminar flow cabinet (MDH Ltd.) 
with vertical recirculation. Cells were maintained at 37°C in a LEEC PF2 anhydric 
incubator (Laboratory and Engineering Company). An inverted microscope, WILD 
M40 (Wild Heerbrugg Ltd.) was used for monitoring cell growth and determining cell 
numbers together with a standard double grid haemocytometer (Fisons Ltd.).
2.1.1.5. Disposables
Sterile tissue culture flasks were obtained from Falcon (Fahrenheit Labs., 
Bristol) polypropylene ampoules for cell freezing from Coming, (Fahrenheit Labs.) 
96- and 24- well culture plates were supplied by Nunc, Roskilde, Denmark.
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2.1.1.6. Glassware
Used glassware was soaked in a 2% v/v solution of RBS 25 (Fisons) for 30 
minutes with rinsing in three changes of single distilled water. Items were 
subsequently soaked in double distilled water for approximately two hours, dried in a 
hot air oven (Gallenkamp) capped with aluminium foil and oven sterilised 
(Gallenkamp) by dry heat at 160°C for 1 hour.
2.1.2. Methodology
2.1.2.1. Mammalian cell lines
The SV40 transformed monkey kidney cell line COS7, and the human kidney 
embryonic (HEK) 293 cell line were obtained from the European Collection of 
Animal Cell Cultures (ECACC), Porton Down, Salisbury.
HEK 293 cells transfected with the hMCl and hMC4 receptor genes ligated 
into the vector pcDNAl Neo were donated by R.D. Cone, Vollum Institute, Portland, 
Oregon and a B16 murine melanoma cell line was supplied by L.R. Kelland, Institute 
of Cancer Research, Sutton.
2.1.2.2. Cell receipt, recovery and storage
All cell lines were obtained as frozen samples. Cryotube contents were rapidly 
defrosted by brief incubation in a 37°C water bath, diluted with 5 ml pre-warmed 
medium and centrifuged for 10 minutes at 200 g in a Jouan B 3.ll bench-top 
centrifuge. The cell pellet was resuspended and transferred to a tissue culture flask 
containing pre-warmed, fresh medium.
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Further cell stocks were prepared for storage by detachment (section 2.1.2.3.) 
pelleting and resuspension in fresh medium containing 10% v/v DMSO (Aldrich, 
spectrophotometric grade) as a cryoprotectant. Cells underwent gradual freezing to 
-70°C in a Union Carbide BF6  biological freezer unit plug inserted into a Union 
Carbide LR33 liquid nitrogen freezer and were then transferred to a Union Carbide 
LR-40 liquid nitrogen freezer for storage at approximately -148°C.
2.I.2.3. Cell line maintenance and subculture
Cells were grown as monolayers in 175 cm2 tissue culture flasks and examined 
daily for possible microbial contamination. The time taken to reach monolayer 
coverage varied between cell lines but all were subcultured on reaching 70-80% 
confluency. The medium was replaced between passages if necessary, as denoted by 
the yellow colour formed by the phenol red indicator within the RPMI 1640 medium. 
This ensured an adequate nutrient supply and optimum pH for cell growth. 
Subculturing entailed washing the monolayer twice with PBS followed by a 10 
minute incubation at 37°C with 2 ml 0.02% w/v EDTA / PBS. Due to the particularly 
adherent nature of the COS7 cells, a trypsin (0.05% w/v) / EDTA (0.02% w/v) 
solution in modified Puck’s saline A (Gibco BRL) was used as an alternative to the 
above for monolayer removal. Detached cells were diluted with medium and the 
resulting cell suspension centrifuged at 200 g for 10 minutes. The pellet was 
resuspended in 10 ml fresh medium, a sample counted (section 2.1.2.4.) and sterile 
175 cm2 flasks inoculated with approximately 2 x 106 cells.
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2.1.2.4. Determination of cell density
A 0.1% w/v trypan blue (Sigma, Poole, Dorset) solution in PBS was used 
according to the manufacturer’s directions for the determination of cell density. After 
several minutes to allow dye uptake, a sample of the stained suspension was loaded 
onto a grid haemocytometer and viewed under an inverted microscope. Viable cells 
exclude the dye whereas non-viable cells stain a uniform dark blue.
2.1.2.5. Re-selection of 293 transfectants using geneticin (G418)
pcDNAl Neo carries the gene for geneticin resistance which can be used as a 
selection marker for cells transfected with this plasmid.
M TT assay fo r  determination o f  cell number
Assays were based on a modified MTT assay as described by Mosmann (1983) 
and Amould et al. (1990). Cells were seeded into 96-well plates at the desired 
density. Medium was removed when appropriate by inversion, and cells washed 
twice with serum-free RPMI 1640. A 200 pi volume of 1 mg/ml MTT formazan 
(Sigma) in complete medium was added to each well and the plate incubated at 37°C 
for 3 hours. The MTT solution was carefully removed from the plate by gentle 
inversion and the remaining formazan blue crystals solubilised with 200 pi DMSO. 
The plate was gently agitated on an orbital mixer for 5 minutes to allow complete 
solubilisation and optical density measured on a Titretek plate reader at 540 nm with 
a reference wavelength of 690 nm.
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M TT assay calibration
A calibration curve was constructed to establish compliance with the Beer- 
Lambert Law over the employed cell density range. 293 cells were seeded in a 96- 
well plate at various densities to a maximum of 5 x 104 cells/well and allowed to 
adhere overnight. An MTT assay was subsequently performed and analysed as 
described above.
MTT viability assay for optimisation of G4 18 treatment o f cells
293 cells were seeded at a density of 5 x 10 cells per well in a 96-well plate 
and incubated overnight in full medium. Fresh incubation medium containing 0-2 
mg/ml geneticin was added to the cells with culturing under standard conditions for 5 
days. The plate was analysed by an MTT assay to determine cell survival.
From the resulting data (chapter 4) a final concentration of 0.8 mg/ml geneticin 
was added to the culture medium for two passages to re-select for the 293 cells stably 
transfected with the pcDNAl Neo plasmid.
2.2. hMCl-R Expression in COS7 Cells
2.2.1. Plasmid Vectors and Bacterial Strains
Control expression studies were performed using the mammalian expression 
vector pRSVlacZ, obtained from D. Ogllvie, Zeneca Pharmaceuticals, Cheshire and 
electroporated into E. coli XL 1-Blue.
pcDNAl Neo and E. coli M CI061 which expresses the P3 plasmid as required 
for successful bacterial transformation with this vector were obtained from R&D 
Systems Europe Ltd., Abingdon, Oxon. pcDNAl Neo containing the human MCI
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receptor gene (pcDNAl Neo / hMCl-R), was donated by R.D. Cone, Vollum 
Institute, Portland, Oregon.
2.2.2. Preparation o f Electrocompetent E. coli M CI 061 Cells
An overnight culture of E. coli MCI061 was diluted 1:100 and grown to an 
OD600 of 0.5-1.0 in 500 ml LB medium in a shaking incubator at 37°C. After 
chilling on ice the cells were centrifuged at 4000x g for 15 minutes at 4°C. The ionic 
strength of the suspension was gradually reduced by washing the cells sequentially in 
(i) 500 ml ice-cold sterile water (ii) 250 ml ice-cold sterile water (iii) 10 ml sterile 
ice-cold 10% v/v glycerol with final resuspension in 1 ml 10% v/v glycerol. The 
electrocompetent ice-cold cell suspension was dispensed as 40 p.1 aliquots in sterile 
microfuge tubes, snap-frozen in cardice / methanol and stored at -70°C.
2.2.3. Transformation o f  E. coli MC1061 /  P3 Cells by Electroporation
The chosen method was based on that described by Dower et al. (1988). 
Electrocompetent E. coli MCI061 cells were thawed slowly on ice and 2 jig chilled 
pcDNAl Neo / hMCl-R added to each aliquot. The cell suspension was pipetted into 
a sterile pre-chilled 0.2 cm electroporation cuvette (Bio-Rad Laboratories Ltd., 
Herts.). The cuvette was placed into the pre-chilled cuvette holder of a Gene Pulser 
and Pulse Controller (Bio-Rad) set to a capacitance of 25 jiF and a resistance of 
200 Q. The cells were subjected to a single 2.5 kV pulse resulting in a time constant 
for the capacitor discharge of 5 ms. Cell recovery took place in 1 ml SOC medium at 
37°C for one hour with shaking. Transformed cells were selected for by plating onto
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LB agar containing am picillin  (30 |Lig/ml) and tetracycline (7.5 p g/m l) w ith overnight 
incubation at 37°C.
In a control transformation, antibiotic resistance was confirmed as plasmid- 
mediated by electroporating cells in the absence of recombinant DNA.
2.2.4. Small-scale Plasmid Preparations (Minipreps)
Plasmid isolation to confirm successful transformation took place using an 
alkali lysis method based on the procedure described by Birnboim and Doly (1979) 
as modified by Sambrook et al. (1979).
Several random colonies were picked from the plate with a sterile wire and grown 
overnight in 5 ml LB broth containing ampicillin (30 pg/ml) and tetracycline (7.5 
pg/ml). 1 ml of each of these overnight suspensions were centrifuged at 10,000 g for 
one minute. The supernatants were removed and 100 pi of Solution I 
(50 mM glucose / 25 mM Tris / 10 mM EDTA) added to each tube by vigorous 
vortexing. A 200 pi volume of freshly prepared Solution II (0.2N NaOH / 1 % SDS 
from 10N NaOH and 20% SDS stocks, respectively) was added with subsequent 
mixing by gentle inversion followed by a 10 minute incubation on ice. A 150 pi 
volume of ice-cold Solution HI (0.5M potassium acetate / 0.12% glacial acetic acid / 
0.28% water) was added to each tube followed by gentle vortexing and a further 
incubation on ice for 5 minutes. The tubes were centrifuged for 5 minutes at 10,000 g 
with removal of the supernatants to further sterile eppendorfs. The supernatants were 
extracted with an equal volume of phenol : chloroform and chloroform : isoamyl 
alcohol. Eppendorf contents were vortexed, re-centrifuged at 10,000 g for
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2 minutes and the upper aqueous layers removed to clean tubes. Plasmid DNA was 
precipitated by the addition of two volumes 96% v/v ethanol with gentle mixing and 
chilling for 5 minutes on ice before centrifuging at 10,000 g for 5 minutes. The 
supernatant was discarded and the remaining pellet washed with 1 ml 70% v/v 
ethanol. This was carefully decanted with any residual alcohol being evaporated 
under vacuum in a Speedvac SVC 100 at medium drying temperature. The resultant 
dried plasmid was resuspended in 50 pi TE buffer containing RNAase 20 pg/ml and 
the presence of pcDNAl Neo / hMCl-R confirmed by linearisation and gel 
electrophoresis.
2.2.5. Plasmid Digestion
DNA digestion was performed using restriction enzymes and buffers (NEB 
Ltd., Hitchin, Herts.) according to the manufacturer’s directions. Incubation took 
place at 37°C for approximately 60 minutes to allow complete digestion.
2.2.6. Agarose Gel Electrophoresis
Agarose gels were cast and set in Bio-Rad DNA sub-cells. Ultrapure (Gibco 
BRL) agarose, electrophoresis grade was dissolved in 0.5x TBE buffer at 100°C and 
when cooled to approximately 60°C, ethidium bromide was added to a final 
concentration of 0.5 pg/ml. After pouring and positioning of the gel comb the gel 
was allowed to set at room temperature for approximately 30 minutes before being 
submerged in 0.5x TBE buffer in the gel tank. DNA samples were mixed with 0.2 
volumes of 5x DNA loading buffer and gently pipetted into the wells along with a 
M3NA / Hind HI marker (Promega, Southampton). Electrophoresis was carried out
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for approximately one hour at 100 V until the tracking dye neared the end of the gel. 
The resulting DNA bands were visualised on a UV light box.
The remaining primary culture of the successful transformants was centrifuged 
at 10,000 g for 1 minute and the cells resuspended in 1 ml LB broth containing 10% 
v/v glycerol and stored at -70°C.
2.2.7. Large-scale Plasmid Isolation, Purification and Quantification
Large scale plasmid isolation for eukaryotic transfection employed a Plasmid 
Maxi Kit (Qiagen Ltd., Dorking, Surrey) the buffer composite of which is detailed in 
Appendix B.
A sterile loopful of transformed bacterial stock was used to prepare a primary 
culture and subsequently transferred to 500 ml of antibiotic-supplemented LB broth 
for a secondary overnight culture. The bacterial suspension was transferred to four 
50 ml tubes and centrifuged at 2000 g for 15 minutes at 4°C in a Chillspin bench-top 
centrifuge. This step was repeated for the remainder of the culture. Each pellet was 
resuspended in 2.5 ml buffer PI and the contents pooled in an ultra-centrifuge tube. 
10 ml buffer P2 was added and the tube contents mixed by gentle inversion. After 
four minutes, 10 ml buffer P3 was added to the cell lysate. The tube was incubated 
on ice for 30 minutes then centrifuged at 70,000 g at 4°C for 60 minutes 
in a Beckman Ti45 rotor. The supernatant was removed promptly and applied to an 
anion exchange purification column pre-equilibrated with 10 ml buffer QBT. 
Column washing took place with 30 ml buffer QC followed by plasmid elution using 
15 ml buffer QF. Plasmid DNA was precipitated by the addition of 10.5 ml 
isopropanol, gentle mixing of tube contents and centrifugation at 4°C for 45 minutes
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at 70,000 g. The resultant DNA pellet was washed with 15 ml ice-cold 70% v/v 
ethanol and re-pelleted by centrifugation. The isolated plasmid DNA was stored in 
TE buffer (pH 8.0) at -20°C.
Determination o f sample purity and quantification
Triplicate samples of plasmid DNA solution were diluted in TE buffer for 
optical density (OD) measurement using a Milton Roy Spectronic 601 
spectrophotometer. A measure of purity is given by the ratio of absorbance at 260 nm 
and 280 nm with contaminating proteins and phenol absorbing at 280 nm. A value of 
1.8 or greater is considered acceptably pure for transfection purposes and all samples 
met this standard.
An OD of 1.0 at 260 nm corresponds to approximately 50 jig/ml for double­
stranded DNA.
2.2.8. Transfection of COS7 Cells by Electroporation
Transient transfection of the COS7 cells was performed using electroporation 
protocols based on procedures described by Neumann et al. (1982) and Wong and 
Neumann (1982). The procedure was modified by the use of lower voltage and 
higher capacitance settings as described by Chu et al. (1987). For these mammalian 
transfections the Bio-Rad Gene Pulser apparatus was connected to a Bio Rad 
Capacitance Extender and 0.4 cm electroporation cuvettes used (Bio-Rad).
Semi-confluent layers of COS7 cells were pelleted by centrifugation for 10 
minutes at 200 g. Cells were washed in 5 ml ice-cold PBS and re-pelleted. This 
washing process was repeated with pellet resuspension in 0.5 ml PBS to give an
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approximate cell concentration of 5-10 x 106 cells/ml and transferred to pre-chilled 
0.4 cm electroporation cuvettes. A 20 pg sample of supercoiled pcDNAl Neo / 
hMCl-R was added to each cuvette and after a 5 minute incubation on ice, 
electroporation took place at the optimal transfection settings of 300 V and 250 pF as 
determined below. The cuvettes were subsequently incubated on ice for 10 minutes 
before transferral to tissue culture flasks containing fresh medium.
Although electroporation is applicable to most cell types, critical parameters 
vary and must be determined for each cell line used.
Parameter optimisation
2.2.8.I. FITC-dextran uptake during electroporation
Optimisation of electroporation settings was performed with measurement of 
cellular uptake of FTTC-labelled dextran (Sigma, average MW 71,200) in a protocol 
based on that described by Andreason and Evans (1989) and Graziadei (1991).
COS7 cells were prepared for electroporation as described above to a lower 
concentration of 2 x 106 cells/ml. To each 500 pi aliquot was added 50 pi FITC- 
dextran 10 mg/ml with incubation of the cuvettes on ice for 5 minutes. 
Electroporation was performed over 100-400 V at capacitance values of 125 and 
250 pF. A non-electroporated control of COS7 cells and FITC-dextran was left on 
ice for the entirety of the assay for determination of non-electroporation-associated 
cell death. After a further 5 minute incubation on ice, cells were seeded into 100 mm 
tissue culture dishes and incubated at 37°C in 5% CO2 / 95% air for four hours. Cells 
were removed by trypsinisation and together with non-adherent and dead cells were
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washed and resuspended in 50 (xl PBS for fluorescence measurement by FACS 
analysis. Cell death was quantified by labelling cells with 100 ng/ml propidium 
iodide and measuring the fluorescence of the same population of cells in a protocol 
based on that described by Sasaki et al. (1987).
2.2.8.2. In situ cytochemical staining for (3-galactosidase activity
A qualitative determination of electroporation efficiency and an approximation 
of the post-transfection interval required for maximum expression was made using 
the plasmid pRS V/acZ. This vector encodes the E. coli lacZ gene for (3-galactosidase 
under the control of the Rous sarcoma virus long terminal repeat sequence. 
Expression efficiency was determined by histochemical staining using 5-bromo-4- 
chloro-3-indolyl-(3-D-galactopyranoside (X-gal) based on the method described by 
MacGregor et al. (1991).
Transfected cells were seeded onto 100 mm culture dishes (Nunc) and 
incubated at 37°C with fresh culture medium. At post-transfection time intervals of 
24, 48 and 72 hours the growth medium was aspirated from the adherent cell 
monolayers. Cells were washed twice with PBS and overlaid with fixative solution 
(1% glutaraldehyde, 1 mM magnesium chloride, 100 mM sodium phosphate) with 
incubation for 5 minutes at 4°C. Removal of the fixative solution was followed by 
two further PBS washes. A 1:10 dilution of X-gal 2% w/v in DMF was made with 
3.3 mM potassium ferrocyanide, 3.3 mM potassium ferricyanide, 1 mM magnesium 
chloride, 150 mM sodium chloride and this staining solution incubated with the cells 
for a minimum of four hours in a humidified atmosphere at 37°C.
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After staining the cells were washed three times with PBS and examined under 
a light microscope. Cells expressing the lacZ gene hydrolyse the chromogenic 
substrate X-gal to the insoluble dye bromochloroindole. A positive reaction is seen 
as a blue colour against an unstained background.
2.3. Peptide Synthesis
Peptides were prepared in house by Dr. G.W.J. Olivier and Dr. U.G. Sahm 
using solid-phase peptide synthesis methods based on the Fmoc strategy (Atherton 
and Sheppard, 1989) and is therefore not described in detail.
Peptide purification involved semi-preparative HPLC with a gradient elution of 
0.1 % TFA in water and 0.1 % TFA in 70% acetonitrile / 30% water at a flow rate of 3 
ml / minute. UV spectrophotometry at 217 nm was used to monitor the eluate. 
Fraction collection took place every 30 seconds and subjected to analytical scale 
HPLC. Appropriate peptide fractions were then pooled and freeze-dried. 
Confirmation of peptide purity was executed using FAB-MS provided by Swansea 
University Mass Spectrometry Service: a-MSH M+H calculated 1664.8, found 1664; 
[Nle4,DPhe7]a-MSH M+H calculated 1646.8, found 1647; [Nle4,DPhe7,Phe9]a-MSH 
M+H calculated 1607.8, found 1608; [Nle4,DPhe7,Tyr9]a-MSH M+H calculated 
1623.8, found 1624; [Nle4,DPhe7,Thr9]a-MSH M+H calculated 1564.8, found 1565; 
[Nle4,DPhe7,Ala9]a-MSH M+H calculated 1531.8, found 1532; [Asp10]a-MSH M+H 
calculated 1722.8, found 1723; [Phe10]a-MSH M+H calculated 1754.8, found 1755, 
[Phe12]a-MSH M+H calculated 1714.8, found 1715; [Asp10,Phel2]a-MSH M+H 
calculated 1772.8, found 1772; [Alan ,Alal2]a-MSH M+H calculated 1581.7, found
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1582; [Ala11, Ala13]a-MSH M+H calculated 1579.7, found 1581;
[Alan ,Ala12,Ala13]a-MSH M+H calculated 1553.7, found 1554.
2.4. Radioiodination of [Nle4,DPhe7]a-MSH
Radioactive iodine was coupled at the [Tyr2] position of [Nle4,DPhe7]a-MSH 
by the oxidative chloramine-T method described by Eberle and Hubscher (1979).
2.4.1. Column Chromatographic Solutions
* 1 % v/v TFA (Aldrich, analytical grade).
* 50%, 60% and 80% v/v methanol +1% v/v TFA.
0.25M sodium phosphate buffer, pH 7.4 (freshly prepared from stock solutions).
* Stored at 4°C for a maximum of 3 months.
2.4.2. Iodination Reaction Reagents
0.25% w/v BSA in 0.05M sodium phosphate buffer, pH 7.4. *
1 % w/v Polypep (Sigma) in 0.05M sodium phosphate buffer, pH 7.4. *
0.1% w/v chloramine-T (BDH Chemical Ltd.) dissolved in distilled water 
immediately prior to use.
* prepared on day of use.
2.4.3. Pre-conditioning of Purification Columns
A C l8 reverse phase column packed with Spherisorb ODS (Anachem) was 
pre-conditioned by washing according to the following protocol:
57
3x  1 ml 1% v/v TFA.
3 x 1 ml 80% v/v methanol /1%  v/v TFA.
1 x 1 ml 1% w/v Polypep solution.
3 x 1 ml 80% v/v methanol /1%  v/v TFA.
3x  1 ml 1% v/v TFA.
2.4.4. Peptide Iodination
Ten jj.1 Na125I (nominally 37 MBq of activity) was added to 1.5 p.g 
[Nle4,DPhe7]a-MSH diluted to 20 |il in 0.25M sodium phosphate buffer, pH 7.4. 
Reactive oxidation was initiated with the addition of 10 |il 0.1% w/v chloramine-T 
solution. After 30 seconds the reaction was quenched with 0.6 ml 0.25% w/v BSA. 
The reaction mixture was applied to the pre-conditioned ODS column followed by 
two washes with phosphate buffer to remove the unreacted Na125I. The iodinated 
ligand was eluted by washing the column with 4 x 1 ml 50% v/v methanol / 1% v/v 
TFA followed by 2 x 1 ml 60% v/v methanol / I % v/v TFA.
The eluate was retained for further purification by reverse-phase HPLC.
2.4.5. [ 1251-Tyr2,Nle4,DPhe ] a-MSH Purification
Further purification of the eluate was essential to separate the mono- from the 
di-iodinated product. An exponential gradient of 0.1 % TFA in water and 0.1 % TFA 
in 70% acetonitrile / 30% water was used and fractions collected at one minute 
intervals from 25 to 40 minutes after injection. The desired mono-iodinated product 
eluted between 35 and 36 minutes after injection with elution of the di-iodinated 
peptide approximately three minutes later. Radioactivity of the collected fractions
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was quantified on a LKB 1277 Gammamaster gamma counter (Wallac, Milton 
Keynes, UK). A trace for the elution profile is shown in Figure 2.1.
The fractions associated with the mono-iodinated peptide peak were pooled 
and the collective activity measured in counts per minute (cpm). Apparatus 
efficiency was determined by regular standardisation with a sample of Na129I of 
known activity and estimated accuracy of ± 3% (Wallac) and found to be constant at 
70%. The concentration of [125I-Tyr2,Nle4,DPhe7]a-MSH was determined as outlined 
below.
2.4.6. Calculation o f Radiotracer Concentration
By definition, 1 atom of 125I associates with 1 mole [Nle4,DPhe7]a-MSH to give 
1 mole [125I-Tyr2,Nle4,DPhe7]a-MSH.
Carrier-free Na125I has a specific activity of 80.5 x 1015 Bq/atom (Amersham)
/. Activity of 1 mole [125I-Tyr2,Nle4,DPhe7]a-MSH = 80.5 x 1015 Bq
1 Bq = 1 decay per second, or 60 decays per minute and the efficiency of the gamma 
counter = 70%
1 mole [125I-Tyr2,Nle4,DPhe7]a-MSH would register (80.5 x 1015) x 60 x 0.7 cpm











Figure 2.1. Elution profile of: (1) mono-iodinated and (2) di-iodinated 
[Nle4,DPhe7]a-MSH from HPLC purification as measured on the LKB 1277 Wallac 
Gammamaster gamma counter.
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2.5. Radioligand Binding Assays
The method used was adapted from Siegrist et al. (1988) as described by Sahm 
(1994) and followed the general protocol detailed below.
Due to the detachment of COS7 and 293 cells from culture plates during 
incubation at 4°C, 96-well filter plates were routinely used. Cells were detached and 
seeded at a density of 2 x 105 cells / well. After a 4 hour incubation at 37°C to allow 
the cells to settle, the medium was filtered using a vacuum-manifold and the cells 
washed twice with 150 |il PBS. Appropriate dilutions of [125I-Tyr2,Nle4,DPhe7]a- 
MSH and competing ligands were made in a serum-free RPMI 1640 binding buffer 
containing 25 mM HEPES and 0.2% w/v BSA and 100 (il aliquots added to each 
well. Each time / concentration point was assayed in quadruplicate.
After sufficient incubation at 4°C for equilibrium binding (section 2.5.1.), cells 
were washed twice with PBS, filters transferred to LP4 tubes using the Multiscreen 
Assay System (Millipore) and activity measured on the LKB 1277 Gammamaster 
gamma counter.
2.5.1. Determination o f  Equilibrium Binding Time
Seeded cells were stimulated with approximately 0.2 nM [125I-Tyr2,Nle4,DPhe7] 
a-MSH in binding buffer and non-specific binding was determined concurrently by 
the addition of lOOOx of unlabelled [Nle4,DPhe7]a-MSH. The equilibration time for 
radioligand binding at 0-4°C to COS7 and 293 cells was determined by measuring 
cell-associated radioactivity at appropriate time intervals.
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2.5.2. Determination o f Time o f Maximum Expression in C0S7 Cells
The time-course of receptor expression in the transfected COS7 cells was 
investigated by measuring cell-associated radioactivity from 24 to 144 hours post­
electroporation. At each post-electroporation time-point cells were detached from 
culture flasks, seeded and incubated at 4°C with radioligand, nominally 0.2 nM, and 
excess unlabelled peptide as described above.
The results from these assays (chapter 3) led to the routine use of a 72 hour 
post-transfection interval with a 16 hour peptide stimulation time.
2.5.3. Binding Isotherm o f [125I-Tyr2,Nle4,DPhe7 ]a-MSH
An isotherm was generated using a range of radioligand concentrations. Non­
specific binding was determined using a 1000-fold excess of cold ligand. Specific 
binding was calculated by subtraction.
Binding isotherm analysis
Receptor numbers and dissociation constants were determined using MINSQ 
non-linear least squares regression analysis employing the Langmuir Isotherm 
equation:
rHRl = n Ka [H] = n[H]
1 + Ka[H] Kd + [H]
where [H] = concentration of free hormone
[HR] = concentration of hormone-receptor complex
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n = total receptor number
Ka = association constant of ligand- receptor complex
K<i = 1 / Ka = dissociation constant of ligand-receptor complex
The linearising plot of [HR] / [H] against [HR] produces the Scatchard plot 
with a gradient approximating to -Ka and x-axis extrapolation giving an estimation of 
n (Scatchard, 1949).
2,5.4. Competition Binding Assays
Serial dilutions of each peptide were made in binding buffer containing a fixed 
concentration of [125I-Tyr2,Nle4,DPhe7]a-MSH, nominally 0.2 nM. Displacement of 
radioligand by each concentration of competing ligand was monitored by 
measurement of cell-associated radioactivity as described above.
Analysis of competition binding data
MINSQ non-linear least squares regression analysis was used to calculate 
dissociation constants from the competition binding data employing the following 
equation:
(cpm (m ax) - cpm (m in )) X [R] 
Cpm (test) =  Cpm(min) +  — £------------------------------ — ---------
[R] + Kdr X —
Ki
where cpm(test) = cpm associated with a given competitor concentration 
cpm(max) = cpm associated with maximum radioligand binding 
(no competitor)
cpm(min) = cpm associated with minimum radioligand binding 
(excess competitor)
[R] = concentration of radiotracer 
[I] = concentration of competitor 
Kdr = dissociation constant of radiotracer 
K j = dissociation constant of competitor
2.6. cAMP Quantification
Functional coupling of the melanocortin receptors was analysed by quantifying 
cAMP produced by peptide stimulation. The method used was based on the 
procedure detailed by Salomon (1991).
2.6.1. Pre-prepared Solutions
20x BSA (Sigma) 2 mg/ml, stored at -20°C.
20x IBMX (Sigma) 10 mM dissolved in water in a boiling water bath and stored at 
-20°C for a maximum of three months.
lOx PCA (BDH Chemicals, Poole, England) 25% v/v stored in the dark 
lOOOx cAMP (Sigma) 0.1M neutralised with Tris-Cl to pH 7.5
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2.6.2. [  3H]-cAMP Production
Cells were seeded into 24-well plates at a density of 5 x 105 cells / well and 
incubated overnight at 37°C in a humidified atmosphere of 5% CO2 / 95% air. Cells 
were subsequently incubated with pre-warmed culture medium containing 
2.5 |iCi/ml [8-3H]-adenine (Amersham International Pic., Bucks.). The radioactive 
medium was aspirated after a pre-determined incubation period (section 2.6.3.2.) and 
the cells washed with 0.5 ml pre-warmed PBS. Serial dilutions of test peptides were 
made in pre-warmed serum-free culture medium supplemented with 0.1 mg/ml BSA 
and 0.5 mM IBMX. Cells were stimulated with 0.5 ml samples of this medium for a 
fixed time (section 2.6.3.1.) at 37°C. Each concentration was assayed in 
quadruplicate. The medium was aspirated and 1 ml ice-cold 2.5% v/v PC A 
containing 0.1 mM cAMP added to each well. After a 30 minute incubation on ice 
with occasional agitation for efficient [3H]-cAMP extraction, 0.8 ml cell-free PC A 
extract was transferred to clean tubes and neutralised with 80 p,l 4.2N KOH. The 
tubes were vortexed and the potassium perchlorate precipitate allowed to settle. If 
necessary, samples were stored at 4°C overnight or at -20°C for longer periods.
2.6.3. Chromatographic Separation of [  H]-cAMP
Distilled water was added to each tube to a final volume of 1.3 ml. The tubes 
were vortexed and the crystals allowed to resettle. A 0.1 ml sample was removed for 
determination of total [3H]-adenine uptake and the remaining solution subjected to 
double-column chromatography as described by Johnson and Salomon (1991).
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2.6.3.1. Column apparatus and reagents
Two sets of 17 ml polypropylene separation columns (Mitchell Plastics Inc.) 
with plastic filter discs were mounted over each other in a tiered rack set which in 
turn was suspended over 4 ml collection tubes.
Dowex 50 AG50W-X8 resin (Bio-Rad) was washed sequentially with 
approximately 6 volumes each of 0.1N NaOH, water, IN HC1 and water before 
initial use and poured into the first set of columns in an approximately 2:1 slurry. 
When the flow rates decreased the columns were regenerated by repeating the above. 
Approximately 0.6 g neutral alumina activity grade 1, type WN-3 (Sigma) was 
poured dry into the lower column set.
2.6.3.2. Column washing procedure
Before each use the Dowex 50 columns were washed with 3 x 10 ml distilled 
water and the alumina columns with 8 ml 100 mM Tris-Cl, pH 7.4.
The neutralised PCA extract solutions were decanted onto Dowex 50 columns, 
leaving the perchlorate crystals undisturbed. Each column was then washed with 
3 ml water and the eluate discarded. The Dowex 50 columns were then placed 
directly above the alumina columns and washed with 8 ml water. The slightly acidic 
eluate from the Dowex 50 resin caused retention of [3H]-cAMP on the alumina. 
After elution from the alumina, the columns were placed over collection tubes and 
[3H]-cAMP eluted with 4 ml 100 mM Tris-Cl, pH 7.4. A 0.5 ml sample of each 
eluate was added to 4 ml Optiphase scintillation cocktail (Wallac) with vigorous 
vortexing. Radioactivity of the scintillation vial contents was quantified on a LKB 
Wallac 1215 RackBeta liquid scintillation counter.
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The Dowex 50 columns were regenerated after each use with 5 ml IN HC1 and 
the alumina columns with 8 ml Tris-Cl, pH 7.4.
2.6.3.3. Quench curve
A 10 pi volume of [8-3H]-cAMP of known activity (Amersham) was diluted to 
500 jllI in PBS and mixed with Optiphase scintillant in each of 10 scintillation vials. 
0-2000 |il of chloroform was added to each vial with subsequent analysis on the 
scintillation counter. Figure 2.2. shows the quench curve generated by calculation of 
efficiencies and channel ratios. The counting efficiency of an unknown sample is 
read from the quench curve using its R value and used to calculate dpm associated 
with sample cpm. Quench curve generation and storage together with dpm 
determination was performed automatically.
2.6.4. Assay optimisation
A B16 murine melanoma cell line which natively expresses the MCI receptor 
was used for initial assay optimisation negating the need for expensive and time­
intensive plasmid preparation.
2.6.4.I. Determination of optimum stimulation time
After pre-incubation with [ H]-adenine, cells were stimulated with 5 nM 
[Nle4,DPhe7]a-MSH. [3H]-cAMP quantification proceeded according to the above 
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Figure 2.2. Standard quench curve for [3H]-cAMP on the LKB Wallac 1215 
RackBeta liquid scintillation counter showing the relationship between counting 
efficiency and channel ratios, R.
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2.6.4.2. Determination of maximum [3H] -adenine-uptake time
Cells were incubated with [3H]-adenine for 30 to 180 minutes and 
subsequently stimulated with 5 nM [Nle4,DPhe7]a-MSH. After PC A extraction 
0.1 ml samples were taken and counted to give a measure of total [3H]-adenine 
uptake.
Calculation ofECso values
MINSQ non-linear least squares regression analysis was used to calculate EC50 
values for the tested peptides employing the following equation:
(dpm (m in) - d p m  (max)) 
dprn(test) =  d p m  (max) + — £----------------—7;------------
1 + J S -
ECso
where: dpm(test) = dpm associated with a given peptide concentration 
dpm(max) = dpm associated with maximum stimulation 
dpm(min) = background dpm (no stimulant)
[C] = peptide concentration
EC50 = peptide concentration required to produce half maximal stimulation
2.7. Statistical Analysis
Data analysis was performed using MINITAB 9.1. Significant differences were 
determined using a one-way analysis of variance following Fisher’s multiple 
comparison procedure at the 99% confidence interval.
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2.8. Site-directed Mutagenesis of the hMCl-R
2.8.1. Nucleotide Sequence Analysis
Analysis of the human MCI receptor gene sequence (accession number 
x65634) as submitted by Cone et al. (1992) to the Genbank, and restriction enzyme 
choice was determined using the GCG (University of Wisconsin Genetics Computer 
Group) package at the SERC Seqnet computing facility at Daresbury, UK. Genbank 
database searching was performed using the FAST A software.
2.8.2. Ligation o f the hMCl-R Gene into pBluescript (SK+)
The hMCl-R gene was excised from pcDNAl Neo / hMCl-R for insertion into 
the bacterial vector, pBluescript (SK+) (Stratagene). Digestion took place (section
2.2.5.) using the restriction enzymes BamHl and Xbal (NEB). pBluescript was 
similarly restricted in a separate reaction mixture. The digested samples were 
analysed by gel electrophoresis (section 2.2.6.) with excision of appropriate bands 
and purification by DNA adsorption to a silica matrix using the Geneclean II DNA 
purification system (Bio-101, La Jolla, CA, USA). Four and a half volumes of 6M 
Nal and 0.5 volumes of Geneclean-TBE modifier were added to each gel slice with 
incubation at 50°C until the agarose melted. To this DNA mixture was added 5 pi of 
Geneclean glassmilk suspension with a 5 minute incubation on ice to allow DNA 
adsorption onto the glass beads. Glassmilk beads were pelleted at 10,000 g for 5 
seconds and washed 3 times with Geneclean ‘NEW’ wash. DNA was eluted from the 
beads into water at 50°C for 5 minutes.
The restricted products were ligated with a 5-fold excess of insert DNA over 
vector using T4 DNA ligase (NEB) in accordance with the manufacturer’s
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instructions. The ligation mixture was incubated at 16°C overnight and purified 
following the Geneclean protocol using three volumes of Nal and 5 |il Glassmilk. 
The ligated product was transformed into the host cells by electroporation.
2.8.3. E.coli XLl-Blue Transformation with pBluescript (SK+) /  hMCl-R  
Electrocompetent E. coli XLl-Blue (Stratagene) were prepared and
electroporated with pBluescript / hMCl-R (sections 2.2.2., 2.2.3.). Transformed cells 
were selected for by spreading onto LB-agar plates supplemented with 100 |ig/ml 
ampicillin and 12.5 |ig/ml tetracycline and coated with 40 jllI X-gal (Melford 
Laboratories) 20 mg/ml in DMF and 4 pi 0.84M IPTG. After incubation at 37°C for 
approximately 18 hours, cells containing recircularised pBluescript plasmids 
appeared blue whereas recombinants grew as white colonies. Several white colonies 
were picked with a sterile wire and grown overnight in antibiotic- supplemented LB 
broth. Plasmid DNA was recovered using the miniprep procedure (section 2.2.4.) and 
presence of the hMCl-R gene confirmed by restriction endonuclease digestion and 
gel electrophoresis.
2.8.4. Recognition Peptide Synthesis and Purification
A recognition peptide for attachment to the N-terminal of the hMCl-R was 
synthesised based on the octapeptide sequence engineered by Hopp et al. (1988). 
Primer design incorporated EcoRl and BamUl restriction sites for ligation with 
pBluescript / hMCl-R.
Synthesis of the complementary single stranded oligonucleotides DNA took 
place in-house (School of Biochemistry, University of Bath) with DNA elution from
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the resin using ammonia solution (Aldrich). The eluates were incubated at 55°C 
overnight and subsequently dried under medium heat in a Speedvac SVC 100 for 
ammonia evaporation. The pellets were resuspended in water.
2.8.5. Concentration o f DNA by Ethanol Precipitation
DNA was precipitated from aqueous solution by the addition of 3M sodium 
acetate pH 5.2, to a final concentration of 0.3M followed by two volumes of 96% 
ethanol at -20°C. The solution was vortexed thoroughly and precipitated at -70°C for 
15 minutes. The DNA pellet was recovered by centrifugation at 10,000 g at 4°C for 
30 minutes using a Jouan A14 centrifuge. The supernatant was aspirated and the 
pellet washed with 70% ethanol at 4°C. The DNA was subsequently dried at 37°C 
for 10 minutes and resuspended in TE buffer.
The concentration of DNA was quantified and purity determined by optical 
density measurement (section 2.2.7.). For single stranded DNA an OD260 of 1-0 
corresponds to approximately 40 |ig/ml DNA.
2.8.6. Primer Annealing, Restriction and Purification
Approximately 20 jig of each oligonucleotide were mixed together and ethanol 
precipitated as described above. The resulting pellet was resuspended in water,
heated at 70°C for 10 minutes for strand annealing and subsequently cooled to room
temperature. Approximately 5 |ig of this annealed mixture was restricted with 
BamHl and EcoRl (section 2.2.5.). An equal volume of phenol : chloroform was 
added to the digestion mixture with thorough vortexing. The mixture was centrifuged
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for 10 minutes at 10,000 g at 4°C. The supernatant was removed and underwent 
ethanol precipitation as detailed above.
2.8.7. Ligation of the Recognition Peptide with pBluescript (SK+) /  hMCl-R  
pBluescript / hMCl-R was digested with BamUl and EcoRl and run on an
0.8% w/v agarose gel. The desired band was excised from the gel and purified using 
Geneclean. The digested vector was ligated with the annealed and restricted 
oligonucleotide using T4 DNA ligase. The ligation mixture was purified, used to 
transform E. coli XLl-Blue and resultant colonies “mini-prepped” (sections 2.8.2., 
2.8.3., 2.2.4.). Prepared plasmid was re-restricted with BamHl and EcoRl and 
analysed for successful ligation by polyacrylamide gel electrophoresis.
2.8.8. Non-denaturing Polyacrylamide Gel Electrophoresis
Non-denaturing polyacryamide gel electrophoresis was performed using a Bio- 
Rad Miniprotean cell as described by Sambrook et al. (1989). The glass plates were 
thoroughly cleaned to remove all traces of grease and assembled with 0.4 mm 
spacers between them. To 20 ml of a 30% w/v acrylamide solution was added 140 jul 
of 10% w/v ammonium persulphate solution and 7 |il TEMED to catalyse 
polymerisation. A sharktooth comb (Bio-Rad) was inserted and the gel allowed to set 
for 60 minutes at room temperature. The comb was gently removed and the gel 
surface washed with lx TBE.
To determine ligation success, the modified vector was digested with BamH.1 
and EcoRl and gently pipetted into the wells together with a pBR322 / HaeJR 
marker (Sigma). The gel was run for approximately 90 minutes at 50 V and
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subsequently stained by submerging in lx TBE containing 0.5 JLig/ml ethidium 
bromide for approximately 40 minutes with viewing on a UV light box.
2.8.9. Mutagenesis o f the hM Cl-R
Mutagenesis of the human MCI receptor was to be performed according to 
manufacturer’s directions using the Clontech Transformer Site-Directed Mutagenesis 
kit (Cambridge Bioscience).
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CHAPTER 3: RESULTS and DISCUSSION ( Part I )
Binding affinity o f OrMSH derivatives to COS7 /  hMCl-R cells
The tetrapeptide His-Phe-Arg-Trp which is invariant between the isolated 
MSH peptides has been denoted as the smallest active fragment of a-MSH (Otsuka 
and Inouye, 1964). It was later described as the ‘classical’ active site of a-MSH and 
is therefore sensitive to structural change (Eberle, 1988). However, whilst the 
presence of the tryptophan-9 residue of a-MSH is important for full activity, this 
residue has been shown to be more amenable to certain structural changes. Despite 
this finding, no systematic study into the role of tryptophan at this position has been 
carried out.
The aim of this work was to determine the essential features of the tryptophan 
moiety for high affinity binding to the human MCI receptor. To this end modified 
peptides were synthesised, the choice of substituents being made on the basis of the 
physicochemical properties of the particular amino acid residues. Optimisation of 
electroporation parameters for the COS7 cell line took place and using these data the 
human MCI receptor was transiently and regularly expressed in these cells. Binding 
and cAMP assays were optimised and subsequently employed to correlate binding 
affinity with functional activity of the peptide analogues under analysis.
The COS7 cell line is frequently used for transient, high-level receptor 
expression. It is derived from an African green monkey kidney cell line CV-1, by 
transformation with an origin-defective simian virus, SV40, integrated into the 
chromosomal DNA, hence the acronym COS, (CV-1 origin, 5V40) (Gluzman, 1981).
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COS cells express high levels of the SV40 large tumour (T) antigen which is 
required to initiate viral DNA replication at the origin of SV40. Three T-antigen 
positive cell lines were isolated and developed of which two, designated COS 1 and 
COS7, are in common use. Transfection of these cells with any plasmid containing 
an SV40 origin of replication such as pcDNAl Neo, enables the T-antigen to initiate 
runaway replication of the plasmid. This produces high expression levels of any gene 
of interest ligated into the vector. However, the excessive stress placed on the cells 
by the replicating plasmid and the ensuing high levels of protein production result in 
plasmid loss. This loss typically occurs within a week of electroporation, hence the 
transient nature of gene expression and the need for repeated transfection.
The human MCI receptor sequence was obtained using PCR with human 
melanoma as a template and degenerate oligonucleotides from transmembrane 
domains IQ and VI as primers. Screening of a human genomic DNA library and 
hybridisation took place at high stringency. An approximately 1 kb HindlB. and Xbal 
fragment including the human MCI receptor gene was ligated into the polylinker 
sequence of the mammalian expression vector, pcDNAl Neo (Figure 3.1.) 
(Mountjoy etal., 1992).
3.1. Optimisation of hMCl-R Expression in COS7 Cells
Electroporation is generally recognised to produce high efficiency transfection 
of a wide range of mammalian cells. Subjecting the cells to a high-voltage electric 
field results in the temporary disruption of the cell membrane and pore formation 
with subsequent passage by electrophoresis of biological molecules into the cell 







Figure 3.1. Schematic representation of the expression vector pcDNAl Neo 
depicting salient features for replication and selection in mammalian cells together 
with the site of ligation of the human MC1 receptor.
natural decay process and a short post-transfection incubation on ice has been found 
to increase the electroporation efficiency of certain cell lines (Potter, 1988). 
Although linearised DNA has been found to promote the integration into 
chromosomal DNA necessary for stable transfection, supercoiled DNA is preferable
pcDNAl Neo
PCMV+ hM C l-R
hMC1 -R
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for transient expression (Potter, 1988). This is possibly a result of reduced 
degradation of the supercoiled form.
Optimal transfection parameters vary between cell lines and should, therefore, 
be determined for each system used to ensure maximal expression.
3.1.1. Electroporation Parameter Optimisation Using FACS 
Fluorochrome-conjugated dextrans such as FTTC-dextran are high molecular
weight molecules that cannot passively enter cells and are not associated with the 
external cellular surface (Graziadei et al., 1991). These characteristics along with 
their cellular non-toxicity (Oliver et al., 1984), make these compounds suitable 
molecular markers for quantification of cellular uptake.
FITC-labelled dextran was used in conjunction with FACS analysis (section
2.2.8.1.) to optimise uptake into COS7 cells during the electroporation process. 
Measurements were made over a voltage range of 100 to 400 V at capacitance 
settings of 125 |XF and 250 |xF and the data are given in appendix D. Cellular uptake 
of FTTC-dextran was quantified by FACS analysis of cell fluorescence. Cell death 
was quantified by staining with the nucleic acid interchelator, propidium iodide. 
Entry of propidium iodide in isotonic solution into cells is prevented by the cell 
membrane and laser-excited fluorescence is seen only within the nuclei of dead cells 
(Krishnan, 1975).
Figure 3.2a. illustrates the general trend of the greater uptake of FTTC-dextran 
with increasing voltage as evidenced by increased fluorescence. This increase is 




—■— 125ji F 
— 250 \i F
30 -
20 -
150 200 250 300 350 400100
Voltage /  V
(b)
100-
— 125 n F 






300100 150 200 250 350 400
Voltage /  V
Figure 3.2. FACS analysis of COS7 cells electroporated with MTC-labelled 
dextran at capacitance settings of 125 and 250 |xF. (a) Fluorescence intensity as a 
function of electroporation voltage; (b) Cell viability as a function of electroporation 
voltage, determined by the proportion of non-viable cells taking up 100 ng/ml 
propidium iodide.
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values above 300 V apparently producing negligible further increases in uptake. The 
higher uptake observed for the 250 |iF capacitance value at voltages of 300 V or 
more, is also associated with a rapid decrease in cell viability (Figure 3.2b.). 
Selection of electroporation parameters therefore involves a compromise between the 
greater cell death obtained at higher voltage and capacitance values and the 
correspondingly greater uptake of FTTC-dextran by the remaining viable cells.
On the basis of these data electroporation settings of 250 fiF and 300 V were 
used routinely for the transient transfection of COS7 cells.
3.1.2. X-gal Staining of COS7 Cells
The above work illustrates the uptake by electroporated COS7 cells of high 
molecular weight but non-nucleic acid material. A qualitative determination of 
plasmid uptake efficiency and the time required for maximum gene expression was 
made using the 7.8 kb reporter vector pRSVlacZ (section 2.2.8.2.). The E. coli lacZ 
gene encodes the glycoside hydrolase, P-D-galactosidase (p-gal) under the control of 
the Rous sarcoma virus long terminal repeat. 5-bromo-4-chloro-3-indolyl-P-D- 
galactoside (X-gal) acts as a substrate for this enzyme, being broken down to give 
galactose and soluble indoxyl molecules. The potassium ferrocyanide and 
ferricyanide within the staining solution together act as an oxidation catalyst 
converting the soluble indoxyl to insoluble indigo, thus enhancing localisation of the 
stain (MacGregor et al., 1991).
Electroporation was performed using the predetermined parameters of 250 pE 
and 300 V. Results are shown in Figure 3.3. for the cell staining of control COS7 
samples electroporated in the absence of plasmid and COS7 cells transfected with
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Figure 3.3. C0S7 cells fixed and treated with X-gal solution after electroporation, 
{i} electroporation in the absence of plasmid (control); {ii} electroporation with 
20 pg pRSVlacZ. Post-transfection interval: (a) 24 hours; (b) 48 hours; (c) 72 
hours.
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20 jig of pRSWlacZ, at post-electroporation time points of 24, 48 and 72 hours. No 
staining in the control cell samples was observed over the studied time period 
(Figure 3 .3 a { i} ,b { i} ,c { i} ) , indicating the absence of an endogenous p-gal response. 
This validates the assumption that the staining depicted in Figure 3.3a{ii}, b { ii} and 
c { ii} is due solely to lacZ expression as a consequence of pRSYlacZ  uptake via the 
electroporation process. Expression, determined by the number of blue / green 
stained cells, was minimal after 24 hours but significantly greater at both the 48 and 
72 hour time points. Maximum expression equated with approximately 60 to 80% 
staining.
From these data it is clear that electroporation is an efficient method for 
introducing recombinant DNA into COS7 cells and suggests that a post- transfection 
interval of 48 to 72 hours would be required for maximum gene expression.
3.1.3. Optimum Post-Electroporation Interval fo r  MC1-R Expression
A time-course experiment was performed (section 2.5.2.) to confirm the 
optimum interval before assaying the electroporated COS7 cells. A time lag, such as 
that required for lacZ expression (section 3.1.2.) would be expected to be necessary 
to enable plasmid replication and the associated protein synthesis to occur. The 
results are presented graphically in Figure 3.4. Total radioligand binding i.e. both 
specific and non-specific, was determined by incubating cells with radioligand alone. 
Addition of 1000-fold excess unlabelled [Nle4,DPhe7]a-M SH displaces radioligand 
from the expressed receptors and the resulting radioactivity is due solely to non-
] 25specific binding to the cell surface and filter plate. Specific receptor binding of [ I- 
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Figure 3.4. Binding at 0-4°C of [125I-Tyr2,Nle4,DPhe7]a-MSH to the human MCI 
receptor transiently expressed in COS7 cells, as a function of post-electroporation 
incubation time at 37°C.
(■) total binding of 0.28 nM [125I-Tyr2,Nle4,DPhe7]a-MSH; ( • )  non-specific binding 
in the additional presence of lOOOx excess non-iodinated [Nle4,DPhe7]a-MSH; 
(A) specific binding calculated by subtraction.
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shows an approximately linear increase in specific binding, hence hMCl receptor 
expression, between 24 and 72 hours post-transfection with a plateau being reached 
before a rapid loss of expression after five days.
From these data, a 72 hour incubation at 37°C post-electroporation was 
allowed before execution of binding assays.
3.2. Optimisation of Binding Assay Parameters
3.2.1. Confirmation o f  an Absence o f  Endogenous Receptors
The suitability of the COS7 cell line for heterologous expression of the human 
MCI receptor is dependent upon an absence of endogenous melanocortin receptor 
expression. A comparison of ligand binding was made (section 2.5.3.) between 
COS7 cells electroporated with the hMCl-R and non-transfected wild-type COS7 
cells. Figure 3.5. clearly shows that whereas specific binding to the electroporated 
COS7 cells rises exponentially with increasing concentrations of [125I- 
Tyr2,Nle4,DPhe7] a-MSH until receptor saturation is reached, total binding to wild- 
type cells is virtually indistinguishable from non-specific binding. Specific binding 
as determined by subtraction is therefore negligible. These observations are at 
variance with those reported by Weber et al. (1993) who discovered a small response 
of COS7 cells to melanocortin stimulation as determined by cAMP measurement and 
proposed the existence of an endogenous melanocortin receptor. However, the 
negligible specific binding determined in this study confirms the suitability of COS7 












Figure 3.5. Comparison of binding at 0-4°C of [125I-Tyr2,Nle4,DPhe7]a-MSH to the 
hMCl-R transiently expressed in COS7 cells with binding to wild-type COS7 cells.
(■) total binding of [125I-Tyr2,Nle4,DPhe7]a-MSH to wild-type COS7 cells; ( • )  non­
specific binding to wild-type COS7 cells, in the additional presence of lOOOx excess 
non-iodinated [Nle4,DPhe7]a-MSH.
(A) specific binding to COS7 cells electroporated with the hMCl-R.
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3.2.2. Determination o f  Equilibrium Binding Time
Under equilibrium binding conditions the rates of formation and breakdown of 
the hormone-receptor complex are equal. Determination of the time required for 
equilibrium binding of [125I-Tyr2,Nle4,DPhe7]a-MSH to the MCI receptor was 
performed as described in section 2.5.1. Equilibrium binding is attained after 
approximately 12 hours at 0-4°C with negligible decrease of this maximum over the 
studied 24 hour period (Figure 3.6.). Non-specific binding appears to be time- 
independent, remaining approximately constant throughout the time period of the 
assay.
The presence of a competing ligand invariably slows the approach to binding 
equilibrium by reducing the free receptor concentration. This diminishes the effective 
association rate constant of the radioligand. Determination of the time required for 
equilibrium binding in the presence of unlabelled ligand is therefore imperative. 
Binding assays are routinely performed at 0-4°C in this laboratory as association at 
higher temperatures has been found to be more rapid but does not reach steady state 
(Eberle, 1988). This is largely due to the equally rapid and significant hormone- 
receptor internalisation that has been shown to occur at these temperatures (Adams,
1993).
These data together with practical time considerations led to the use of a 16 
hour incubation period at 0-4°C for the electroporated cells with the melanocortin 
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Figure 3.6. Binding at 0-4°C of [l25I-Tyr2,Nle4,DPhe7]a-MSH to the hMCl-R 
transiently expressed in COS7 cells, as a function of incubation time.
(■) total binding in the presence of 0.23 nM [125I-Tyr2,Nle4,DPhe7]a-MSH; 
( • )  non-specific binding in the additional presence of lOOOx excess non-iodinated 
[Nle4,DPhe7]a-MSH; (A) specific binding calculated by subtraction.
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3.3. Binding Isotherm of [125I-Tyr2,Nle4,DPhe7]a-MSH
The dissociation constant, Kd, for the binding of [125I-Tyr2,Nle4,DPhe7]a-MSH
to the human MCI receptor transiently expressed in COS7 cells was determined 
from four replicate binding assays (section 2.5.3.). A representative isotherm is 
shown in Figure 3.7. Non-specific binding shows an approximately linear 
dependence on radioligand concentration and is non-saturable over the working 
concentration range. The form of the specific binding curve is described by the 
Langmuir Isotherm (section 2.5.3.). At low concentrations, formation of the 
hormone-receptor complex, as determined by cpm measurement, shows a linear 
dependence on radioligand concentration. As the tracer concentration increases, the 
gradient decreases until a plateau is reached indicating saturation of receptor binding. 
An average IQ of 0.56 ± 0.07 nM was calculated using MINSQ non-linear least
squares regression. This is comparable to the value of 0.48 nM obtained in our 
laboratory for the murine MCI receptor (Sahm, 1994). The receptor population also 
determined by MINSQ analysis was within the range of 25,000 to 60,000 per cell, 
which is significantly greater than the range of 5000 to 25,000 per cell obtained with 
B16 murine melanoma cells (Sahm, 1994). This high expression is indicative of 
efficient electroporation and is in accordance with expected values for high copy 
number plasmids containing an S V40 origin of replication. The inter-assay difference 
in receptor number is not unexpected given the variation of growth characteristics, 
transfectability and protein expression properties of COS cells over time. Scatchard 











Figure 3.7. Isotherm for the binding at 0-4°C of [125I-Tyr2,Nle4,DPhe7]a-MSH to 
the hMCl-R transiently expressed in COS7 cells.
(■) total binding of [125I-Tyr2,Nle4,DPhe7]a-MSH; ( • )  non-specific binding in the 
additional presence of lOOOx excess non-iodinated [Nle4,DPhe7]a-MSH; (A) 
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Figure 3.8 Scatchard plot for the confirmation of a homogeneous melanocortin 
receptor population in COS7 cells transiently transfected with the hMCl-R.
(Curves show 95% confidence interval.)
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Non-specific binding to the filter plates was high in the absence, but 
significantly lower in the presence of cells. This binding to the empty wells could not 
be reduced by the addition of excess unlabelled [Nle4,DPhe7]a-MSH, thus 
confirming its non-specific nature.
3.4. Binding of [NIe4,DPhe7]a-MSH Analogues Substituted at Position 9
The peptide standard used for all competition binding assays was the 
“superpotent” a-MSH analogue, [Nle4,DPhe7]a-MSH (section 1.5.4.). [DPhe7]a- 
MSH analogues have been shown to exhibit higher receptor binding affinities than 
their [LPhe7]a-MSH counterparts (Peng et a i, 1996). Given the predicted sensitivity 
of position 9 to structural alteration (see below) and to render as measurable any 
detrimental effect on binding affinity, substituted peptides were synthesised as 
[Nle4,DPhe7]a-MSH, rather than a-MSH, derivatives.
Binding experiments were performed as described in section 2.5.4. The results 
obtained conformed to the sigmoidal plot expected for such assays with standard 
deviations associated with the replicates of generally less than 10% (Figure 3.9.). 
Displacement of [125I-Tyr2,Nle4,DPhe7]a-MSH by the substituted peptides resulted in 
the binding curve being shifted to the right, a phenomenon indicative of competition 
by lower affinity analogues. Each peptide with the exception of [Nle4,DPhe7,Ala9]a- 
MSH, was capable of complete inhibition of radioligand binding.
[Nle4,DPhe7,Ala9]a-MSH, however, was unable to displace fully [125I- 
Tyr2,Nle4,DPhe7]a-MSH from the MCI receptor at 0.1 mM, the highest working 
concentration, as dictated by peptide availability.
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Figure 3.9. Competitive binding at 0-4°C of 0.20 nM [125I-Tyr2,Nle4,DPhe7] a-MSH 
and position 9-substituted analogues to the hMCl-R transiently expressed in COS7 
cells.
(■) [Nle4,DPhe7]a-MSH;







Ligand affinities are routinely cited as the reciprocal of their association 
constants, the notation for which throughout this work is K j ,  i.e. the dissociation 
constant as determined by inhibition of radioligand binding. Absolute dissociation 
constants for these substituted analogues were determined by MINSQ analysis and 
are given in Table 3.1 together with Kj values relative to [Nle4,DPhe7]a-MSH. 
Statistical analysis of the binding data (section 2.7.) is given in appendix E.
[Nle4,DPhe7]a-MSH exhibited a dissociation constant of 0.68 nM which is 10- 
fold lower than the value of 6.6 nM assigned to a-MSH (Table 3.1.). A 
diastereoisomeric change at position 9 of [Nle4,DPhe7]a-MSH to D-tryptophan 
produced an insignificant difference in affinity to the L-tryptophan analogue. This 
indicates a lack of preference for specific stereochemistry at this position. 
Substitution with phenylalanine to give [Nle4,DPhe7,Phe9]a-MSH retains the 
aromatic ring and non-polarity at position 9 but considerably increases 
hydrophobicity as measured on the Kyte and Doolittle (1982) and Engelman et al. 
(1986) hydropathy scales (appendix A). However, this peptide exhibited no 
significant reduction in affinity as compared to [Nle4,DPhe7]a-MSH which shows the 
dispensability of the pyrrole moiety. [Nle4,DPhe7,Tyr9]a-MSH exhibited a 
significantly reduced binding affinity of 16-fold and 6-fold as compared to 
[Nle4,DPhe7]a-MSH and [Nle4,DPhe7,Phe9]a-MSH, respectively. Tyrosine-9 
substitution retains aromaticity but the hydroxyl group increases hydrophilicity. and 
suggests that the significant difference in affinity between [Nle4,DPhe7,Phe9]a-MSH 
and [Nle4,DPhe7,Tyr9]a-MSH is a consequence of reduced hydrophobicity at this
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Peptide
K j / M  
(± standard deviation).
Binding relative to 
[Nle4,DPhe7]a-MSH
a-MSH
6.59 x 10'9 




6.82 x Iff10 




1.51 x 10'9 




1.82 x Iff9 




1.14 x Iff8 




2.42 x 10-6 




2.59 x Iff5 
(±7.77 x 10"6) 
n = 4
0.000026
Table 3.1. Dissociation constants (± standard deviation) and relative values
compared to [Nle4,DPhe7]a-MSH for peptide analogues as determined by 
displacement binding at 0-4°C of [125I-Tyr2,Nle4,DPhe7]a-MSH from the hMCl-R 
transiently expressed in COS7 cells, (n = number of replicate experiments)
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position. The linear amino acid substitutions to give [Nle4,DPhe7,Thr9]a-MSH and 
[Nle4,DPhe7,Ala9]a-MSH resulted in the greatest detrimental effect on binding, with 
these analogues exhibiting a greater than 3500 and 35000-fold reduction in affinity, 
respectively. Threonine is a linear amino acid with a polar side-chain and a 
hydrophobicity comparable to that of tryptophan (appendix A). Alanine has a higher 
or comparable hydrophobicity to tryptophan according to the Kyte and Doolittle 
(1982) and Engelman et al. (1986) hydropathy scales, respectively. 
[Nle4,DPhe7,Ala9]a-MSH exhibits the lowest affinity of the tested peptides, with a 
significantly higher dissociation constant than [Nle4,DPhe7,Thr9]a-MSH. This 
suggests that the small alanine side-chain alters peptide backbone conformation 
producing a further detrimental effect on binding to the MC1-R. The greatly reduced 
binding affinity observed with these two analogues as compared to [Nle4,DPhe7]a- 
MSH stresses the importance of aromaticity at position 9.
Many structure-activity studies have been carried out with melanocortin 
analogues over the years although the majority of this work was performed prior to 
receptor subtype cloning and employed amphibian melanin-dispersion assays. Since 
the isolation and characterisation of the melanocortin-1 receptor, however, further 
studies on various mammalian homologues have been reported. The murine receptor 
has been the most widely studied as a consequence of its high levels of endogenous 
expression although significant data have now been reported for the human 
homologue.
The affinities obtained for [Nle4,DPhe7]a-MSH and a-MSH on the human 
MCI receptor in this study were approximately 3-fold higher than those determined
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for the murine analogue in this laboratory (Sahm, 1994) under similar assay 
conditions. However, the two peptides show similar relative values on the receptor 
homologues with [Nle4,DPhe7]a-MSH exhibiting a 10-fold higher potency than a- 
MSH. Replacement of methionine-4 of a-MSH with the isosteric norleucine has 
been found to be possible with no loss of affinity or activity. The term 
“superpotency” was coined for the behaviour of its derivative [Nle4,DPhe7]a-MSH as 
compared to a-MSH (Sawyer et al., 1980; Siegrist et al., 1988). [DPhe7] substitution 
was subsequently found to confer “superpotency” on further linear and some cyclic 
a-MSH derivatives (Cody et al., 1985) and to exhibit higher receptor binding 
affinities than their [LPhe7]a-MSH counterparts (Peng et al., 1996). All other tested 
alterations at position 7 produced a reduction of pigment-dispersing activity (Eberle, 
1988). More recently, substitution with alanine-7 was found to decrease binding 
affinity to 0.2% of that exhibited by a-MSH for the murine MCI receptor (Sahm,
1994).
Yajima et al. (1966, 1967) were the first to investigate the effect of 
stereoisomeric substitutions within the core sequence of a-MSH. They reported a 
greater activity for the pentapeptide His-DPhe-Arg-Trp-Gly as compared to its all L- 
analogue in the frog skin assay and determined that additional D-stereoisomer 
substitution was only possible at the tryptophan-9 residue of a-MSH without loss of 
potency. This is in agreement with later findings by Sawyer et al. (1980). Sugg et al. 
(1986) attempted to correlate biological data with side-chain topology of the central 
residues. They investigated the effect of D-tryptophan substitution within the 
fragment [Nle4]a-M SH(4-ll) and reported a 10-fold higher potency than its parent
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analogue and equipotency with [Nle4,DPhe7]a-MSH(4-l 1) in the lizard skin bioassay 
and 30-fold higher potency than [Nle4]a-M SH(4-ll) in the frog skin assay. The 
anisotropic properties of these central residues were utilised in NMR studies to 
elucidate solution topology and the possible preferred and adopted conformations 
recognised by the receptor. Consistent with their biological data, the resonances of 
the [Trp9] indole protons were found to be less sensitive to stereochemical change 
than other D-substitutions within the central core. However, the backbone 
conformation of these analogues was found to be preserved and the enhanced 
melanotropic potency of these fragments attributed to the chiral topological 
arrangement of the side chains in the core sequence. These data on the 
stereochemistry at this position are in broad agreement with the results reported here 
for the full length peptide [Nle4,DPhe7,DTrp9]a-MSH. However, the variation in data 
obtained from the different biological assays performed by Sugg et al. (1986) 
illustrate the apparent disparity between different amphibian models. This 
emphasises the caution required when attempting to compare data obtained from 
uncloned receptors in different assay systems.
Van Nispen et al. (1977) investigated the effect of replacement of tryptophan-9 
with pentamethylphenylalanine (Pmp) and phenylalanine in a-MSH. Substitution to 
give [Pmp9]a-MSH reduced biological activity in the lizard skin assay to half of that 
observed for a-MSH but it exhibited 4 to 5-fold higher activity than [Phe9]a-MSH. 
These results were attributed to the comparable charge-donor properties between 
tryptophan and pentamethylphenylalanine with the correspondingly poorer donor 
properties of phenylalanine. This hypothesis would suggest that substitution of 
tryptophan with leucine would result in even lower activity than the phenylalanine
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derivative and, indeed, Eberle and Schwyzer (1979) found [Leu9]a-MSH to have 
approximately half the affinity of [Phe9]a-MSH in the lizard skin assay.
Sugg et al. (1986) reported different effects of leucine-9 substitution in 
different assay systems and with different parent fragments. In the lizard skin assay, 
the fragment [Nle4]a-M SH(4-ll) was found to be equipotent with the full length a- 
MSH. Substitution of leucine-9 into [Nle4]a-M SH(4-ll) produced a 1500-fold 
decrease in potency whereas substitution into the [DPhe ] analogue to give 
[Nle4,DPhe7,Leu9]a-M SH(4-ll) further halved activity to approximately 0.03% of 
the parent fragment. However, in the frog skin assay, the fragment [Nle4]a-MSH(4- 
11) was weak as compared to a-MSH. In this system [Nle4,Leu9]a-M SH(4-ll) was 
approximately equipotent with [Nle4]a-M SH(4-ll) whereas [Nle4,DPhe7,Leu9]a- 
MSH(4-11) had 400-fold lower potency than [Nle4,DPhe7]a-MSH(4-l 1). These data 
further highlight that any conclusions drawn from structure-activity investigations 
should be restricted to the species used. The results are unusual as leucine-9 
substitution into the [DPhe7] analogue had a greater detrimental effect than 
substitution into [Nle4]a-MSH. The higher potency normally conferred to [DPhe7] 
analogues might be expected to mask some of the affinity loss observed with further 
amino acid substitution within the peptide.
Topographical modifications were investigated by Haskell-Luevano et al. 
(1995a) who theorised that the introduction of a methyl group at the /2-carbon of 
tryptophan-9 would restrict freedom of rotation. This would decrease the number of 
possible side-chain conformations whereas peptide cyclisation still permits a large 
degree of flexibility of amino acid side chains. They synthesised Ac-[Nle4]-
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c[Asp5,His6,DPhe7,Arg8,/3-Me-Trp9,Lys10]-NH2, a cyclic a-MSH analogue with 
incorporation of a methyl group at the pro-S or pro-R position of the /3-carbon of 
tryptophan-9 limiting topography to four possible conformations. The potency order 
of these isomers was found to be 2S,3S > 2R,3R, > 2R,3S, »  2S,3R as determined 
by receptor binding and stimulation of cAMP. As the only notable difference 
between these analogues is side chain orientation, the variation in potency between 
the conformers suggests a more defined role for the indole moiety than determined in 
this work. However, as the cyclic nature of the analogue already alters peptide 
backbone conformation, extrapolation to the linear analogues investigated here may 
not be valid.
In summary, the data obtained from this investigation show that aromaticity 
appears to be the most critical property of the tryptophan-9 residue of a-MSH for 
conferring high affinity binding to the human MCI receptor. According to a model 
proposed in this laboratory for the interaction of melanocortins with the MCI 
receptor, [Trp9] would interact with Phe(45), perhaps via stacking interactions 
(chapter 6). Loss of aromaticity at position 9 would disrupt this interaction thereby 
destabilising the ligand binding pocket for the His-Phe-Arg-Trp pharmacophore. 
Hydrophobicity of tryptophan-9 is also important for high ligand affinity whereas 
there appears to be a lower requirement for a pyrrole moiety and specific 
stereochemistry.
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3.5. Quantification of Functional Activity by [3H]-cAMP Measurement
The cAMP assay employed for this work is detailed in section 2.6. Its 
applicability was determined using the murine melanoma cell line B16, which 
natively expresses the MC-1 receptor thus bypassing the time-intensive plasmid 
isolation and electroporation process. This cell line was used thereafter as a positive 
control when optimising assay conditions for the COS7 and 293 cells. The 293 cell 
line is a human epithelial kidney cell line which is commonly used for stable receptor 
expression (chapters 4 and 5).
3.5.1. Determination o f Optimum Stimulation Time
Quoted values for melanocortin peptide stimulation times for [3H]-cAMP 
production range from 10 minutes (Fathi et al., 1995) to 120 minutes (Desamaud et 
al., 1994), these differences presumably reflecting a dependence on cell type. Figure 
3.10. illustrates the dependence of [3H]-cAMP production on the time of incubation 
at 37°C with [Nle4,DPhe7]a-MSH for the cell lines used throughout this work. Both 
the B16 cell line and stably transfected 293 cells achieve maximum [3H]-cAMP 
production after an approximately 45 minute incubation with the stimulant peptide 
and exhibit a gradual decrease thereafter. However, in comparison, the transiently 
transfected COS7 cells exhibit negligible production with levels not significantly 
different from those obtained with their untransfected counterpart. This indicates an 
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Figure 3.10. Effect of incubation time at 37°C with 5 nM [Nle4,DPhe7]a-MSH on 
[3H]-cAMP production in: (■) B16 cells natively expressing the mMCl-R; (a)(#) 
COS7 cells transiently expressed with the hMCl-R; (x) untransfected COS7 cells; 
(b)(A) 293 cells stably transfected with the hMCl-R; (T) untransfected 293 cells.
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3.5.2. Determination o f  Maximum [ 3H]-Adenine Uptake Time
The time required for saturation of [3H]-adenine uptake might also be expected 
to vary between cell lines. Figure 3.11. illustrates that incubating the cells with [3H]- 
adenine at 37°C produces an approximately linear increase in uptake until saturation 
is reached. An incubation period of about 120 minutes is required for saturation of the 
three cell lines. The B16 and COS7 cells exhibit comparable uptake levels whereas 
293 cells appear to have a lower saturation threshold.
3.5.3. Possible Explanations fo r  Absence o f  Functional Activity in COS 7 Cells
Functional expression can be demonstrated and quantified by measurement of
different parameters depending on both the end-product of hormone-receptor 
stimulation and the cell type being used for expression. For example, functional 
activity in the B16 cell line which natively expresses the murine MCI receptor can be 
assessed by measurement of cAMP generation, tyrosinase stimulation or melanin 
synthesis. These different assays would be expected to give comparable relative 
activity measurements and, indeed, allowing for inter-assay variation, this has been 
shown to be the case for tyrosinase and melanin production (Sahm, 1994). 
However, artificial expression of the melanocortin receptors in the COS7 cell system 
would not be expected to result in melanin production as these cells lack the 
necessary synthetic machinery. Possible parameters for activity measurement are 
therefore more limited and functional expression in transfected cells is commonly 
determined by cAMP generation. The absence of detectable [3H]-cAMP production 
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Figure 3.11. Effect of time of incubation of [3H]-adenine at 37°C on [3H]-cAMP 
production in: (■) B16 cells natively expressing the mMCl-R; ( • )  COS7 cells 
transiently expressing the hMCl-R; (A) 293 cells stably expressing the hMCl-R.
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indicates either some procedural error or a true absence of functional receptor 
activity.
The comparatively high [3H]-adenine uptake (Figure 3.11.) achieved in COS7 
cells eliminates inadequate substrate levels as the source of the problem. Concurrent 
binding assays were performed on every batch of transfected cells used for cAMP 
studies to confirm receptor presence. The high levels of specific ligand binding 
routinely obtained confirmed the reproducibility of electroporation.
A comparison of [3H]-cAMP production in the closely related COS7 and 
COS1 cell lines was undertaken (Figure 3.12.). There appears to be no significant 
difference between them, a predictable result given the similar origin of both cell 
lines (Gluzman, 1981). A further explanation for the apparent lack of functional 
activity might be the rapid efflux of cAMP from the cells after production, and this 
possibility was investigated by comparison of intracellular and extracellular [3H]- 
cAMP levels. The latter was measured by retaining the medium after peptide 
stimulation whilst performing nucleotide extraction from the adhered cells as per 
normal (section 2.6.2.). Both samples were subsequently subjected to double-column 
chromatography. However, Figure 3.13. indicates a comparable intracellular and 
extracellular [3H]-cAMP level which is no higher than the background tritium level 
of the alumina columns.
The complex cellular processes involved in successful receptor stimulation 
raise numerous possible explanations for the absence of functional activity. Although 
COS7 cells are able to carry out some post-translational modifications they may not 
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Figure 3.12. [3H]-cAMP production as a result of incubation with various 
concentrations of [Nle4,DPhe7]a-MSH at 37°C for 45 minutes.
(■) B16 cells expressing the native mMCl-R; ( • )  COS7 cells transiently expressing 
the hMCl-R; (A) COS1 cells transiently expressing the hMCl-R.
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Figure 3.13. [3H]-cAMP production as a result of incubation with various 
concentrations of [Nle4,DPhe7]a-MSH at 37°C for 45 minutes.
(■) B16 cells natively expressing the mMCl-R, (intracellular levels); ( • )  COS7 / 
hMCl-R, (intracellular levels); (A) COS7 / hMCl-R cells, (extracellular levels).
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human MCI receptor is known to be glycosylated at residues Asn(15) and Asn(29) 
(Mountjoy et al., 1992). Given the large receptor expression achieved via 
electroporation, an overburdening of the COS7 cell glycosylation machinery might 
occur, resulting in the expression of non-functional receptors. However, this is 
unlikely to be a valid explanation as the role of glycosylation, whilst uncertain, is 
generally believed not to be associated with agonist binding. Indeed, removal of the 
two glycosylated asparagine residues of the p2-adrenoceptor has been shown to have 
little effect on agonist or antagonist binding or coupling of the receptor to adenylate 
cyclase (O’Dowd et al., 1989).
G-proteins are heterotrimeric, being composed of a , P and y subunits. Each is 
encoded by multiple distinct genes, thereby producing a diverse range of subunit 
chains. cAMP generation follows receptor-linked activation of the heterotrimeric 
protein, Gs and interaction of the free Gsa-chain with adenylate cyclase. The P and y  
chains form a tight complex anchoring Gs to the cytoplasmic face of the plasma 
membrane (Alberts et al., 1994). Six distinct mammalian adenylate cyclase 
isoenzymes with unique tissue distributions have been isolated each of which differs 
in their activation requirements. For example, G-protein py dimers are important 
regulators of some adenylate cyclase subtypes (Watson and Arkinstall, 1994). One 
isoenzyme, designated adenylate cyclase type m  is detectable in 293 kidney cells but 
is insensitive to G-protein py, (Glatt and Snyder, 1993). Transfection of other 
receptors, such as the 5-HTia receptor, into different cell lines produced a cell-type 
dependent differential signal transduction by the same receptor (Baneijee et al., 
1993). This phenomenon may be a consequence of stimulation of different Gsa
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subtypes. These data outline the diversity of the G-proteins and suggest that one of 
the many necessary components for successful expression of the human MCI 
receptor may be absent from the COS cell system.
Despite the above discussion, apparently successful quantification of cAMP 
generation via melanocortin receptor stimulation has been reported in both COS1 
(Gantz et al., 1993b; Fathi et al., 1995) and COS7 (Barrett et a l, 1994; Weber et al.,
1993) cells. None of these publications however, cite data for MCI receptor 
stimulation. Other studies suggest that expression difficulties in COS cells have been 
encountered by other groups. For example, Desamaud et al. (1994) quote binding 
data for the mMC3-R in COS7 cells but expression data in stably transfected CHO 
cells. No functional expression data are included with the COS7 results reported by 
Chhajlani and Wikberg (1992) for hMCl-R and Chhajlani et al. (1993) for the hMC5 
and mMC5 receptor binding. All of the studies cited above employed expensive, 
commercially available radioimmunoassay kits, and it is possible that the assay 
method adopted here is insufficiently sensitive to detect the relatively small 
quantities of cAMP produced in the COS7 cells. However, this does not explain the 
success of this method for the 293 cell line, which exhibits both a lower transfected 
receptor population (chapter 4) and a lower uptake of [3H]-adenine.
It is evident from the above discussion that there is no unequivocal explanation 
for the absence of functional activity in the COS7 cells. The importance of 
correlating binding and activity data for the peptides under investigation and the 
timely availability of 293 cells stably transfected with the melanocortin peptides led 
to use of the latter for all further assays.
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CHAPTER 4: RESULTS and DISCUSSION ( Part n )
Binding affinity and biological activity of a-MSH derivatives in 293/hMCl-R cells
This chapter describes binding affinity and functional activity assays 
undertaken with a-MSH derivatives in HEK 293 cells stably transfected with the 
human MCI receptor. The natural ligands a-MSH and desacetyl-a-MSH were 
compared to investigate the possibility of an endogenous role of the latter. Various 
a-MSH analogues were synthesised to investigate the importance of the C-terminal 
residues. Emphasis was placed on possible explanations for the different ligand 
binding and activation profiles obtained with the human MCI and MC4 receptors 
(chapter 5) with a view to determining the specific structural requirements in this 
region for these receptor subtypes.
4.1. Re-selection Using Geneticin
HEK 293 cells were obtained with the hMCl-R sequence ligated into the 
vector pcDNAl Neo, as described in the previous chapter. Stable transfectants were 
isolated by polyclonal selection using the antibiotic geneticin (G418), the gene for 
whose resistance is encoded by this plasmid. Despite the so-termed ‘stable’ nature of 
the expressed hMCl-R within the 293 cells, receptor expression was found to 
decrease significantly with repeated subculturing. This suggests a slower growth rate 
of the transfected cells with their subsequent loss from the cell population. The rapid 
decrease in receptor expression is probably a consequence of the polyclonal selection
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procedure which is more convenient but less discriminating than monoclonal 
isolation of transfectants.
To maximise receptor expression hence assay sensitivity, regular re-selection 
of stable transfectants was performed using geneticin. The optimum geneticin 
concentration was determined using an MTT viability assay (section 2.1.2.5.). Figure 
4.1a. shows a linear relationship between cell density and absorbance of the MTT- 
formazan-treated cells in accordance with the Beer-Lambert Law. This confirms the 
suitability of the assay over this cell density range. Figure 4.1b. illustrates that 
inclusion of geneticin to a final concentration of 0 .8  pg/ml in cell culture medium for 
five days prior to MTT-formazan treatment reduces absorbance to approximately 
background levels. This indicates an almost complete loss of cell viability. It may 
therefore be presumed that similar treatment of transfected 293 cells will result in a 
surviving population, the majority of which will express the geneticin resistance gene 
and hence the hMCl receptor.
293 / hMCl-R cells were used for a maximum of five passages after which the 
mixed population was grown in culture medium supplemented with 0 .8  pg/ml 
geneticin for a further two passages enabling re-selection of transfectants.
4.2. Optimisation of Binding Assay Conditions
4.2.1. Confirmation of an Absence of Endogenous Receptors
Figure 4.2. depicts the [Nle4,DPhe7]a-MSH binding profiles obtained from 293 
cells transfected with the human MCI receptor compared with wild-type 293 cells. 
The latter exhibited comparable levels of total and non-specific binding with specific 
binding, as determined by subtraction, being negligible. This lack of specific binding
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Figure 4.1. (a) The absorbance of 293 cells treated with MTT-formazan / DMSO as 
a function o f cell number (curves show 95% confidence interval); (b) The absorbance 










Figure 4.2. Comparison of binding at 0-4°C of [125I-Tyr2,Nle4,DPhe7]a-MSH to the 
hMCl-R stably expressed in 293 cells with binding to wild-type 293 cells.
(■) total binding of [125I-Tyr2,Nle4,DPhe7]a-MSH to wild-type 293 cells; ( • )  non­
specific binding to wild-type 293 cells, in the additional presence of lOOOx excess 
non-iodinated [Nle4,DPhe7]a-MSH; (A ) specific binding to 293 / hMCl-R cells.
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confirms the absence of endogenous melanocortin receptors in wild-type 293 cells. It 
may therefore be assumed that any specific binding achieved in transfected 293 cells 
must be a consequence of the hMCl-R gene introduced by transfection.
4.2.2. Determination o f Equilibrium Binding Time
The time required for equilibrium binding at 0-4°C of [125I-Tyr2,Nle4,DPhe7]ot- 
MSH to the human MCI receptor was determined for a fixed concentration of 
radioligand (section 2.5.1.). Additional determinations were made in the presence of 
0.5 nM, 5 nM, 50 nM and 1000-fold excess [Nle4,DPhe7]a-MSH to ensure 
equilibrium is reached over a suitable concentration range.
Figure 4.3. shows that cell-associated radioactivity reaches a plateau within 24 
hours for all studied concentrations, indicating attainment of equilibrium. This is 
longer than the equilibrium binding time required for COS7 cells and may be a 
consequence of the lower receptor concentration in the 293 cells which, according to 
the Law of Mass Action, would reduce the hormone and receptor association rate. No 
appreciable hormone-receptor dissociation, as denoted by a decrease in cell- 
associated radioactivity, is observed over the 30 hour assay incubation thus 
confirming the stability of the different assay components over this time period.
4.3. Binding Isotherm of [125I-Tyr2,NIe4,DPhe7]a-MSH to the 293 / hMCl-R
The dissociation constant, IQ, for [125I-Tyr2,Nle4,DPhe7]a-MSH binding to the 
human MCI receptor stably expressed in 293 cells was determined from four 
replicate assays (section 2.5.3.) and assigned a value of 0.67 ± 0.08 nM using 









240 4 8 12 16 20 28
time / hours
Figure 4.3. Binding at 0-4°C of 0.22 nM [l25I-Tyr2,Nle4,DPhe7]a-MSH to the 
hMCl-R stably expressed in 293 cells, as a function of peptide incubation time.
(■) 0.22 nM [125I-Tyr2,Nle4,DPhe7]a-MSH alone, and in the additional presence of: 
( • )  0.5 nM [Nle4,DPhe7]a-MSH; (A) 5 nM [Nle4,DPhe7]a-MSH; (T) 50 nM 
[Nle4,DPhe7]a-MSH; (X ) 0.22 (xM [Nle4,DPhe7]a-MSH (non-specific binding)
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by MINSQ analysis, was within the range of 3000 and 14000 per cell. Experimental 
data (Figure 4.4.) show a linear rise of non-specific binding with increasing 
radioligand concentration indicating its non-saturation over this concentration range. 
Specific binding shows an approximately linear rise with increasing radioligand 
concentration to 1 nM after which a plateau is reached representing full receptor 
occupancy.
The calculated dissociation constant is predictably very similar to the figure of 
0.56 nM obtained for the transiently expressed human MCI receptor described in the 
previous chapter. The receptor population per cell is lower than that measured in the 
transiently transfected COS7 cells; an expected observation given the more stringent 
requirements for successful stable expression. Scatchard analysis (Figure 4.5.) 
confirmed the presence of a homogeneous receptor population as would be expected 
given the proven absence of endogenous expression.
4.4. Binding and Activity of a-MSH Analogues
Dissociation constants were determined by MINSQ analysis (section 2.5.4.). 
Standard deviations between replicates were consistently less than 10% for binding 
assays and 20% for activity assays. Means and standard deviations were determined 
for each peptide from three or more experiments. Absolute values are shown in Table
4.1. and relative values as compared to a-MSH given in Table 4.2. Examples of 
experimental data are presented in Figure 4.6.,4.8.,4.9. A measure of intrinsic 
efficacy of each peptide was determined by its ratio of relative activity to relative 










Figure 4.4. Isotherm for the binding at 0-4°C of [125I-Tyr2,Nle4,DPhe7]a-MSH to 
the hMCl-R stably expressed in 293 cells.
(■) total binding of [125I-Tyr2,Nle4,DPhe7]a-MSH; ( • )  non-specific binding in the 
additional presence of lOOOx excess non-iodinated [Nle4,DPhe7]a-MSH; (A) 
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Figure 4.5. Scatchard plot for the confirmation of a homogeneous melanocortin 
receptor population in 293 cells stably transfected with the hMC 1 -R.
(Curves show 95% confidence interval)
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Peptide
K j / M  
(± standard deviation)
E C j o / M  
(± standard deviation)
[Nle4,DPhe7]a-MSH
5.74 x 10'9 
(± 1 .2 0  x 1 0 '9) 
n = 9
3.64 x Iff10 
(± 1.79 x 10'10) 
n = 5
a-MSH
3.02 x 10“ 
(± 3.49 x 10'9) 
n = 4
3.19 x 10‘9 
(± 5.29 x Iff10) 
n = 3
desacetyl-a-MSH
8.03 x 10' 9 
(± 3.38 x 10'10) 
n = 3
3.87 x 10' 9 
(±5.91 x Iff10) 
n = 3
[Asp‘°]a-MSH
7.86 x 10“ 
(± 2.35 x 10'“) 
n = 3
4.32 x 10' 9 
(± 1.03 x 10'9) 
n = 3
[Phe'°]a-MSH
2.76 x 10“ 
(± 9.54 x 10'9) 
n = 5
3.38 x 10' 9 
(± 5.80 x Iff10) 
n = 4
[Phe12]a-MSH
1.53 x 10‘7 
(±4.03 x Iff8) 
n = 4
8.76 x 10“ 
(± 9.69 x 10'9) 
n = 4
[Asp'°,Phel2]a-MSH
1.57 x Iff7 
(± 1.93 x 10'8) 
n = 3
3.34 x 10' 7 








2.81 x 10'7 
(±2.18 xlO'8) 
n = 3
7.63 x 10'8 
(± 2.38 x 10'9) 
n = 3
[Ala11, Ala13] a-MSH
3.36 x 10'8 
(± 8.02 x 10'9) 
n = 4
7.16 x 10'9 
(± 6.40 x 10'10) 
n = 3
[Alan ,Ala12,Ala13]a-MSH
4.48 x 10'7 
(± 2.03 x 10'7) 
n = 3
2.01 10'7 
(± 5.73 x 10’8) 
n = 3
Table 4.1. Dissociation constants determined by displacement binding at 0-4°C and 
EC50 values determined by [3H]-cAMP generation at 37°C (± standard deviation) for
melanocortin peptide analogue binding to the human MCI receptor expressed in 293 




Kj txMSH / Kj
Relative activity 
EC50 aMSH /EC50 E C sO re l/K i rel.
[Nle4,DPhe7]a-MSH 5.3 8.8 1.7
a-MSH 1.0 1.0 1.0
desacetyl-a-MSH 3.8 0 .8 2 0 .2 6
[Asp‘°]a-MSH 0 .3 8 0 .7 4 2.2
[Phe‘°]a-MSH 1.09 0 .9 4 0.86
[Phe12]a-MSH 0.20 0 .0 4 2 0 .1 8
[Asp'°,Phel2]a-MSH 0.20 0 .0 0 9 6 0 .0 4 8
[A la", Ala12]a-MSH 0.11 0 .051 0 .4 6
[Ala",Ala'3]a-MSH 0 .9 0 0 .4 5 0 .5
[Ala",Ala12,Alal3]a-
MSH
0 .0 6 7 0 .0 1 6 0 .2 4
Table 4.2. Relative dissociation and activity of melanocortin analogues as 
compared to a-MSH together with the relative activity (EC50 rel.) to relative
dissociation (Kj  rel.) constant ratio for each peptide on the human M C I  receptor 
stably expressed in 293 cells.
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4.4.1. Binding and Activity o f [Nle4,DPhe7] a-MSH, a-MSH & desacetyl-a-MSH
This section investigated the proposed species difference between the murine 
and human MC1-R in their response to [Nle4,DPhe7]a-MSH and a-MSH (Mountjoy,
1994), together with the possibility of desacetyl-a-MSH rather than a-MSH, being 
the predominant endogenous ligand in man.
All three peptides fully displaced [Nle4,DPhe7]a-MSH from the hMCl-R and 
showed maximum receptor stimulation (Figure 4.6.). a-MSH exhibited a 
dissociation constant of 30 nM and an EC50 value of 3.2 nM (Table 4.1.). 
[Nle4,DPhe7]a-MSH was the most potent ligand with an approximately 5-fold and 9- 
fold higher affinity and activity, respectively (Table 4.2.). Desacetyl-a-MSH 
exhibited a significantly higher binding affinity but no significant difference to 
a-MSH in the stimulation of cAMP production. The higher affinity but similar 
activity of desacetyl-a-MSH as compared to a-MSH assigns desacetyl-a-MSH a 4- 
fold lower intrinsic efficacy than a-MSH.
A significant difference was found in the dissociation constant calculated for 
[Nle4,DPhe7]a-MSH (5.74 nM) and its radioiodinated counterpart, [l25I-Tyr2,Nle4, 
DPhe7]a-MSH (0.67 nM) (section 4.3.). A similar difference for the two peptides 
was observed for the B 16 murine MCI receptor and rat MC3 receptor expressed in 
293 cells. It was proposed that the iodination process non-specifically improves 
affinity by increasing peptide hydrophobicity (Sahm, 1994). However, this affinity 
difference was not observed for interaction with the human MCI receptor in COS7 
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Figure 4.6.(a) Displacement binding at 0-4°C of 0.20 nM [125I-Tyr2,Nle4,DPhe7 ]a- 
MSH and (b) stimulation at 37°C of cAMP production by a-MSH analogues on the 
hMCl-R stably expressed in 293 cells.
(■ ) [Nle4,DPhe7 ]a-MSH; ( • )  a-MSH; (A ) desacetyl-a-MSH
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of cell surface occupied by receptors, the first cellular point of contact of a hormone 
molecule is likely to be the lipid phase. Any interactions with the lipid bilayer will 
therefore represent the initial steps of hormone-cell contact. The measured 
dissociation constant thus becomes a function of the whole cell membrane system 
rather than the receptor alone. Given the divergence in membrane lipid profiles 
between cell lines, a particular receptor might be expected to show different binding 
characteristics according to its local environment.
Affinity and activity constants quoted in the literature for the MCI receptor 
vary widely. This is probably a result of different cell lines used as discussed above, 
together with the different assay methods and conditions employed. For example, 
Chhajlani and Wikberg (1992) quote dissociation constants of 0.23 pM and 0.92 pM 
for [Nle4,DPhe7]a-MSH and a-MSH, respectively, for transient expression of the 
hMCl-R in COS7 cells. These figures were calculated after a two hour incubation of 
the peptide with the receptor at 37°C and are considerably higher than the affinities 
determined here. However, there is a 4-fold difference in the relative values between 
the peptides and this is comparable to the ratio of 5.3 determined from this work 
(Table 4.2.). Haskell-Luevano (1994) quote dissociation constants of 1.2 nM and 
6.5 nM for [Nle4,DPhe7]a-MSH and a-MSH, respectively, on the human MCI 
receptor expressed in L-cells. These figures are in agreement with both the absolute 
and relative values determined in this work. It is therefore more appropriate to use 
relative rather than absolute values when comparing data obtained from different 
laboratories.
In contrast to the murine MC1-R, which has been found to have at least a 10- 
fold difference in activity between [Nle4,DPhe7]a-MSH and a-MSH (Lunec et al.,
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1992; Mountjoy et al., 1992; Sahm, 1994), Mountjoy (1994) found the two peptides 
to have comparable activity on the human MC1-R homologue. This observation was 
supported by the finding of approximate equipotency for these peptides on 
melanogenesis in cultured human melanocytes (Hunt, 1995). The possibility of a 
species difference was therefore raised. Such a species specific role would not be 
unexpected given the 76% sequence homology between the human and murine 
homologues and the equipotency of ACTH and a-MSH on the former but not the 
latter (Chhajlani and Wikberg, 1992; Mountjoy et al., 1992; Gantz et al., 1993a). 
However, the results presented here are at variance with this hypothesis with the 
determination of an approximate 9-fold difference in activity between the analogues. 
These data are in broad agreement with the 4-fold and 10-fold difference in activity 
between [Nle4,DPhe7]a-MSH and a-MSH reported by Haskell-Luevano et al. (1994) 
and Gantz et al. (1993a), respectively for the human MCI receptor. These conflicting 
data may be explained by the different behaviour of variant hMCl-R alleles, a 
phenomenon thought to be responsible for differences in pigmentation in other 
species (Robbins et al., 1993).
N-terminal acetylations are important in determining the biological activity of 
many peptide hormones and neurotransmitters (Tsunasawa and Sakiyama, 1984). A 
modification such as the omission of an acetyl group, whilst a seemingly small 
alteration may concurrently change several features. A positive charge appears at the 
amino-terminal end, the hydrophilicity of the region is increased with the loss of the 
lipophilic methyl group together with a change in the hydrogen-bridge forming 
ability and the stereochemical relationships of nearby residues. N-terminal
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acetylations are important for high affinity binding to the human MC2 receptor 
(Garren, 1968). The human MC3-R and murine MC1-R however, do not apparently 
distinguish between acetylated and desacetylated ACTH(1-13) (Miwa et al., 1995; 
Sahm, 1994). Desacetyl-a-MSH has been located using HPLC and 
radioimmunological characterisation in both the human foetal and adult pituitary 
gland (Tilders et al. 1981; Brubaker et al., 1982; Bateman et al., 1986) and this 
peptide also predominates in the hypothalamus (Parker et al., 1981). Early work 
(section 1.5.1.) showed the effect of acetylation of the N-terminal serine residue to be 
dependent on the particular amphibian model being investigated with the general 
conclusion that desacetyl-a-MSH exhibits either equipotency or lower potency than 
its acetylated counterpart (Eberle, 1988). More recently Mountjoy (1994) and Gantz 
et al. (1993a) found no significant difference between desacetyl-a-MSH and a-MSH 
in the stimulation of cAMP via the human MCI receptor. Affinity constants reported 
for its interaction with the murine MCI receptor (Eberle, 1988; Sahm, 1994) were 
not significantly different to values obtained by these workers for a-MSH. The 
results presented in Table 4.1. assign a significantly higher affinity to desacetyl-a- 
MSH but agree with the above data in showing no significant difference in activity to 
a-MSH. The ratio of relative activity to relative affinity assigns desacetyl-a-MSH a 
lower intrinsic efficacy than a-MSH but its widespread occurrence together with its 
equipotency with a-MSH supports the possibility of desacetyl-a-MSH being an 
important natural ligand in man. However, ACTH has also been proposed as having 
a physiological pigmentary role as human melanocytes have been found to respond 
to lower concentrations of ACTH than MSH peptides (Hunt, 1995). This raises the
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interesting possibility of a combined role for ACTH and the MSH peptides in human 
skin pigmentation.
4.4.2. Binding o f C-terminally-substituted oc-MSH Analogues
The C-terminal has long been recognised to play a significant role in the 
interaction of the melanocortin peptides with their receptors (section 1.5.3.). The two 
endogenous peptides, a-MSH and y-MSH show a high degree of conservation except 
in this C-terminal region (Figure 4.7.). a-MSH has been shown repeatedly to be a 
high affinity agonist on the human MCI receptor whereas y-MSH binds only weakly. 
For example, Gantz et al. (1993a) found y^-MSH unable to induce a full cAMP 
response even at maximal concentrations whereas Chhajlani and Wikberg (1992) 
found y-MSH to have approximately ten-fold lower potency than a-MSH on the 
human MCI receptor. Mountjoy (1994) found y2-MSH to have an approximately 
four-fold lower activity than [Nle4,DPhe7]a-MSH and a-MSH on the human receptor 
but several orders of magnitude lower on the murine MC1-R.
a-M SH: Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
Yi-MSH: H-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-OH
Figure 4.7. Amino acid sequences of the endogenous ligands a-MSH and yi-MSH. 
(Major C-terminal differences highlighted.)
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Two major structural differences between these endogenous peptides occur at 
the C-terminal end and these were probed using a-MSH analogues containing the 
corresponding y-MSH residues. Aspartic acid was substituted for glycine-10 and 
phenylalanine for proline-12, numbered with respect to a-MSH. Position 11 of a- 
MSH is lysine and its equivalent in y-MSH is arginine. Both residues are basic with 
comparable size and hydrophobicity (appendix A), therefore it was supposed that the 
difference in behaviour between the two peptides was unlikely to be due to this 
conservative change. yj-MSH lacks an equivalent residue for valine-13 of a-MSH. 
The aim of this study was to obtain a clearer understanding of the structural 
requirements in this region for high affinity binding to and activation of the human 
MCI receptor. The importance of the C-terminal region was also more generally 
probed using multiple alanine-substituted peptides to increase understanding of the 
combined importance of these residues.
Each investigated peptide was able to displace fully [ 125I-Tyr2,Nle4,DPhe7] a- 
MSH from the human MCI receptor and produce maximum receptor stimulation 
(Figure 4.8., 4.9.). Neither [Asp10]a-MSH or [Phe10]a-MSH showed any significant 
difference to a-MSH in binding affinity or activity. [Phe12]a-MSH showed one-fifth 
of the affinity and only 4% of the activity of the parent peptide. Di-substitution to 
give [Asp10,Phe12]a-MSH did not significantly affect binding affinity as compared to 
[Phe12]a-MSH but further reduced cAMP production to less than 1% of a-MSH. 
Both [Phe12]a-MSH and [Asp10,Phe12]a-MSH showed lower intrinsic efficacies, 
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Figure 4.8.(a) Displacement binding at 0-4°C of 0.18 nM [125I-Tyr2,Nle4,DPhe7 ]a- 
MSH and (b) stimulation at 37°C of cAMP production by a-MSH analogues on the 
hMCl-R stably expressed in 293 cells.
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Figure 4.9.(a) Displacement binding at 0-4°C of 0.20 nM [125I-Tyr2,Nle4,DPhe7 ]a- 
MSH and (b) stimulation at 37°C of cAMP production by a-MSH analogues on the 
hMCl-R stably expressed in 293 cells.
(■ ) a-MSH; ( • )  [Alan ,Ala13]a-MSH; (A) [Alan ,Ala12]a-MSH;
(▼) [Alan ,Alal2,Ala13]a-MSH
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those calculated for a-MSH. [Alau ,Ala12]a-MSH showed no significant difference 
in either binding or activity to [Phe12]a-MSH. [Alan ,Ala13]a-MSH produced no 
significant difference in either binding or activity as compared to the parent 
compound. Substitution of the terminal tripeptide to give [Alau ,Ala12,Ala13]a-MSH 
produced 7% and 1.6% of the binding and activity of the parent peptide, respectively. 
The activity of this peptide was significantly lower than that of the di-substituted 
[Ala11,Ala12] a-MSH. Multiple alanine substitution within the C-terminal affected 
biological activity more than binding affinity producing peptides with between 2  to 
4-fold lower intrinsic efficacies than a-MSH. The relative binding affinity and 
activity of each peptide as compared to a-MSH was determined for every assay 
(Figure 4.10.) to illustrate experimental reproducibility.
The glycine residue at position 10 of a-MSH was originally described as 
having a “spacer function” (section 1.5.3.) since the presence of an amino acid rather 
than the nature of the residue itself was thought to be the critical feature 
(Medzihradsky, 1976). Introduction of residues such as cysteine in c[Cys4,Cys10]a- 
MSH (Sawyer et al., 1980; Eberle, 1988) or lysine in Ac-
c[Nle4,Glu5,DPhe7,Lysl0,Gly“ ]a-MSH(4-13)-NH2 and Ac-c[Nle4, Asp5, DPhe7,
Lysl0,Glyu ] a-MSH(4-13)-NH2 (Al-Obeidi et al., 1989a, b) appears to be possible in 
both linear and cyclic analogues without a significant effect on peptide action. The 
data determined here are in agreement with these observations. Replacement of the 
small neutral glycine molecule with the more bulky phenylalanine produced an 
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Figure 4.10. Relative affinity and activity of C-terminally substituted a-MSH  
analogues as compared to a-MSH (log scale). Each column represents a single
experiment.
(black: binding affinity; white: cAMP production)
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a-MSH. Substitution with aspartic acid produced a small decrease in affinity but no 
significant difference in activity to a-MSH. The longer side chains of the 
substituents and charged nature of aspartic acid appear therefore, to have little 
detrimental effect on the local conformation of the peptide backbone. These data 
suggest the presence of glycine at position 10 of a-MSH to be relatively unimportant 
for high affinity binding to the human MCI receptor. In agreement with the above, 
replacement of the [Gly10] residue of a-MSH with alanine produced a peptide not 
significantly different in affinity or activity from a-MSH on the murine MCI 
receptor (Sahm 1994). Given the structural similarity of glycine and alanine this 
result is not unexpected although the methyl side chain of alanine might be expected 
to limit the conformational freedom of the peptide backbone and increase 
lipophilicity. However, further work with the murine receptor produced data at 
variance with the results reported here. [Phe10]a-MSH was found to have 3% of the 
affinity and 0.7% of the activity whereas [Asp10]a-MSH retained only 1.2% of the 
affinity and activity of a-MSH (Peng et al., 1996). These data support a proposed 
species difference between the human and murine MCI receptors as discussed 
previously, in which glycine-10 of a-MSH plays a greater role in receptor 
recognition and stimulation of the murine than the human homologue.
Position 12 of a-MSH is proline whereas the equivalent residue in y-MSH is 
phenylalanine. Substitution of proline with its D-stereoisomer, norvaline or glycine 
has been found to reduce peptide activity significantly in several amphibian assays 
and in the Cloudman S91 tyrosinase assay, (Eberle, 1988). Sahm (1994) found an 
insignificant difference in biological activity between [Ala12]a-MSH and its parent
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peptide although it exhibited only 10% of the binding affinity of a-MSH. 
Substitution to give [Phe12]a-MSH had a significantly detrimental effect on both 
affinity and activity on the murine MCI receptor (Peng et al., 1996) and is in 
agreement with the data presented in this work. The significantly lower activity of 
[Asp10,Phe12]a-MSH as compared to [Phe12]a-MSH shows that di-substitution in 
these positions results in a greater loss of potency than the product of each single 
change. This may be due to an interaction of the aspartic acid and phenylalanine side 
chains unfavourably distorting peptide conformation.
The positive charge carried by the lysine residue at position 11 was originally 
thought to be critical for a-MSH activity (Eberle and Schwyzer, 1975). Its ornithine 
analogue was found to be almost fully active, whereas the norleucine derivative, with 
a neutral side chain of comparable length, had 20-fold lower activity than the original 
hormone as measured by pigment dispersion (Medzihradszky, 1982). Replacement 
by serine, glycine or glutamic acid reduced biological activity by 20 to 100-fold as 
measured by pigment dispersion and tyrosinase stimulation in Cloudman S91 cells 
suggesting the necessary presence of hydrophilicity and the basic side-chain of lysine 
for optimum effect (Eberle, 1988). Substitution of lysine-11 to arginine-11 within 
ACTH analogues had no significant effect on corticosteroidogenicity whereas 
protection of its positive charge diminished potency by 80-fold (Goverde et al.,
1993). Other studies refute the importance of this residue with substitution by glycine 
being found to have an insignificant effect on activity (Al-Obeidi et al., 1989a, b). In 
this laboratory a photoaffinity label has successfully been attached onto the lysine 
residue, (Ahmed et a l  1992) and replacement with alanine has been made (Sahm,
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1994) with neither alteration producing a significant loss of potency on the murine 
MCI receptor. Substitution of valine-13 with methionine, its 5-oxide or 5-dioxide 
produced little change in the pigment-dispersing activity of a-M SH(ll-13) (Eberle, 
1988) and Sahm (1994) found [Ala13]a-MSH to exhibit equipotency with a-MSH on 
the murine MCI receptor. These results are in agreement with data obtained in this 
study showing no significant difference between [Ala11,Ala13]a-MSH and a-MSH. 
This suggests that neither position 11 nor 13 are significant for peptide action. The 9- 
fold and 20-fold reduction in affinity and activity, respectively seen with 
[Ala11,Ala12]a-MSH as compared to a-MSH, produce similar relative values to those 
obtained for [Phe12]a-MSH and would appear to agree with the above data for the 
dispensability of lysine. This suggests that the significant decrease observed for 
[Alan ,Ala12]a-MSH is mostly attributable to alanine-12 substitution. The 15-fold 
reduction in affinity and 60-fold loss of activity for [Alau ,Ala12,Ala13]a-MSH is 
comparable to the results obtained by Sahm (1994) who found the fragment a - 
MSH(l-lO) to have an approximately hundred-fold lower binding affinity and 
activity than a-MSH in B16 murine melanoma cells. Tri-alanine substitution has a 
further detrimental effect on activity than its di-substituted counterparts probably as a 
consequence of the alteration of peptide conformation in this region. These data 
support the hypothesis of this region containing a second message sequence as 
proposed by Eberle and Schwyzer (1975).
Taken together these data confirm the importance of the C-terminal region for 
both high affinity binding to and full activation of the human MCI receptor.
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However, within this sequence proline-12 appears to be most sensitive to alteration 
and therefore the most critical amino acid for conferring these properties. The 
relative unimportance of glycine-10 for the human but not the murine receptor lends 
weight to the proposed species difference between these receptor homologues 
although the different binding profiles of [Nle4,DPhe7]a-MSH and a-MSH to the 
human and murine MCI receptors as found by Mountjoy (1994) was not 
corroborated in this work. These data also infer that the low activity exhibited by the 
y-MSH peptide on the MCI receptor is largely due to the requirement for proline at 
position 12 rather than the absence of glycine at position 10.
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CHAPTERS: RESULTS and DISCUSSION (PartIH )
Binding affinity and biological activity o f OrMSH derivatives in 293/hMC4-R cells 
Comparison of the hMCl and hMC4 receptors
Since the recent isolation and cloning of the human melanocortin-4 receptor 
(section 1.6.4.) relatively few structure-activity data have been reported. Further 
information would be of interest given the widespread neural distribution of the 
MC4-R and its possible association with some of the CNS effects attributed to the 
melanocortins (section 1.4.2.2.).
This chapter investigates a-MSH analogue interaction with the human MC4 
receptor subtype. The potency of [Nle4,DPhe7]a-MSH and the natural ligands 
a-MSH and desacetyl-a-MSH were once again compared to determine a possible 
endogenous role. Gantz et al. (1993b) reported comparable ligand binding profiles 
for ACTH, a-MSH and y-MSH on the MCI and MC4 receptors and proposed the C- 
terminal of a-MSH to be important for determining selectivity between these 
receptors. Use of the same analogues as detailed in the previous chapter enabled an 
investigation into the role of the C-terminal region for MC4-R binding and 
activation. It also allowed a direct comparison between the hMCl and hMC4 
receptors with possible delineation of the specific structural requirements of these 
receptor subtypes.
Degenerate oligonucleotides based on conserved melanocortin sequences in 
transmembrane domains II and VII were used to probe total rat brain RNA and
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resulted in the isolation of a fragment of rat MC4-R. Hybridisation of this fragment 
with a human genomic DNA library led to the successful identification of the human 
homologue (Mountjoy et al., 1994). The coding fragment was subsequently 
subcloned into pcDNAl Neo and stably transfected into 293 HEK cells as outlined 
previously for the hMCl-R.
The obtained 293-hMC4 cell line underwent re-selection with geneticin as 
necessary ( section 2.1.2.5.) as discussed in chapter 4.
5.1. Binding Isotherm of [125I-Tyr2,Nle4,DPhe7]a-MSH to the 293 / hMC4-R
The binding affinity of [125I-Tyr2,Nle4,DPhe7]a-MSH for the human MC4 
receptor stably expressed in 293 cells was determined from three replicate 
experiments. Representative data are given in Figure 5.1. and MINSQ linear least 
squares analysis gave a dissociation constant, K^, of 5.17 ± 0.54 nM. The absence of
receptor saturation at the highest working concentration (2 nM) indicates the lower 
affinity of the ligand for this receptor subtype than for the human MC1-R. The 
population was shown to be homogenous by Scatchard analysis (Figure 5.2.) with a 
range of 5000 to 12000 receptors per cell determined by MINSQ analysis.
5.2. Binding and Activity of a-MSH Analogues
Absolute and relative Kj and EC50 values were determined by MINSQ analysis
from displacement binding and cAMP assays, respectively (Tables 5.1., 5.2). 
Average means and standard deviations were determined from three or more 
experiments. Representative binding curves are given in Figure 5.3a.-5.5a. with 









Figure 5.1. Isotherm for the binding at 0-4°C of [125I-Tyr2,Nle4,DPhe7]a-MSH to 
the hMC4-R stably expressed in 293 cells.
(■) total binding of [125I-Tyr2,Nle4,DPhe7]a-MSH; ( • )  non-specific binding in the 
additional presence of lOOOx excess non-iodinated [Nle4,DPhe7]a-MSH; 
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Figure 5.2., Scatchard plot for the confirmation of a homogeneous melanocortin 
receptor population in 293 cells transiently transfected with the hMC4-R.







5.69 x 10'8 1.75 x 10'9
[Nle4,DPhe7]a-MSH (± 6.13 x 10'9) (± 8.49 x 10'10)
n = 5 n = 6
7.28 x 10'7 6.89 x 10'8
a-MSH (±5.51 x 10'8) (± 7.80 x 10'9)
n = 6 n = 3
4.62 x 10'7 2.10 x 10'8
desacetyl-a-MSH (± 3.63 x 10'8) (± 8.94 x 10'9)
n = 3 n = 3
NA 2.23 x Iff*
[Asp‘°]a-MSH (±7.73 x 10'7)
n = 3 n = 3
1.95 x 10'5 3.48 x 10'7
[Phe'°]a-MSH (± 3.52 x 10"6) (± 8.57 x 10'8)
n = 4 n = 3
2.35 x lO'6 5.03 x 10'8
[Phel2]a-MSH (± 4.56 x 10'7) (± 9.40 x 10'9)
n = 4 n = 3
NA 3.42 x lO-6
[Asp10,Phe12]a-MSH (± 5.23 x 10'7)
n = 3 n = 3
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Peptide
K |/M  
(± standard deviation)
ECS» /M  
(± standard deviation)
[Ala“ ,Ala12]a-MSH
2.34 x lO-* 
(+ 5.74 x 10‘7) 
n = 3
2.49 x 10'7 
(± 5.92 x 10'8) 
n = 3
[Alan ,Ala13]a-MSH
2.52 x 10'6 
(±4.23 x 10'7) 
n = 3
2.10 x 10'7 
(± 2.42 x 10'8) 
n = 3
[Ala11 ,Ala12,Ala13]a-MSH
4.91 x 10-6 
(± 3.97 x 10‘7) 
n = 3
9.49 x 10'7 
(± 1.16 x 10'7) 
n = 3
Table 5.1. Dissociation constants as determined by displacement binding at 0-4°C 
and EC50 values as determined by [3H]-cAMP generation at 37°C (± standard 
deviation) for melanocortin peptide analogue binding to the human MC4 receptor 
expressed in 293 cells.
(NA = ‘non-applicable’; indicating too low a peptide affinity for accurate 
calculation)




Kj aMSH / K;
Relative activity 
EC50 aMSH/ECso ECsorel/Kj rel.
[Nle4,DPhe7]a-MSH 1 2 .8 39 3.1
a-MSH 1 .0 1 .0 1 .0
desacetyl-a-MSH 1 .6 3.3 2 .1
[Asp‘°]a-MSH NA 0.031 NA
[Phe10]a-MSH 0.037 0 .2 0 5.4
[Phe12]a-MSH 0.31 1.4 4.5
[Asp10,Phe‘2]a-MSH NA 0 .0 2 0 NA
[Ala",Ala12]a-MSH 0.31 0.28 0.90




Table 5.2. Relative dissociation and activity of melanocortin analogues as 
compared to a-MSH together with the relative activity (EC50 rel.) to relative 
dissociation (Kj rel.) constant ratio for each peptide on the human MC4 receptor 







«  6 0 -
o
m
> 4 0 -
[com peting ligand] / M
(b)
100 -




I  4 0 - co 
E
sO
^  2 0 -
60-
[com peting  ligand] / M
Figure 5.3.(a) Displacement binding at 0-4°C of 0.20 nM [I25I-Tyr2,Nle4,DPhe7 ]a- 
MSH and (b) stimulation at 37°C of cAMP production by a-MSH analogues on the 
hMC4-R.
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Figure 5.4.(a) Displacement binding at 0-4°C of 0.20 nM [125I-Tyr2,Nle4,DPhe7 ]a- 
MSH and (b) stimulation at 37°C of cAMP production by a-MSH analogues on the 
hMC4-R.
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Figure 5.5.(a) Displacement binding at 0-4°C of 0.20 nM [125I-Tyr2,Nle4,DPhe7 ]a- 
MSH and (b) stimulation at 37°C of cAMP production by a-MSH analogues on the 
hMC4-R.
(■) a-MSH; ( • )  [Ala“ ,Ala13]a-MSH; (A ) [Ala",Ala'2]a-MSH; 
(▼) [Ala",Ala'2,Ala13]a-MSH
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Sigmoidal displacement curves were not obtained for [Asp10]a-MSH and 
[Aspl0,Phe12]a-MSH which failed to inhibit completely radioligand binding at 
maximal concentrations (Figure 5.4a.). Each analogue was capable of maximum 
receptor stimulation with standard deviations between replicates generally less than 
15% (Figure 5.3b.-5.5b). Table 5.2. assigns an EC50 rel./Kj rel. constant to each 
peptide as a measure of intrinsic efficacy.
5.2.1. Binding and Activity o f [Nle4,DPhe7]a-MSH, oo-MSH & desacetyl-OrMSH 
a-MSH exhibited an activity of 69 nM as measured by its E C 5 0  value with an 
approximately 11-fold higher dissociation constant of 0.73 (iM. [Nle4,DPhe7]a-MSH 
was found to exhibit both higher affinity and activity with constants of 57 nM and 
1.8 nM, respectively. Desacetyl-a-MSH exhibited a significantly higher affinity and 
activity constant than a-MSH but significantly lower values than [Nle4,DPhe7]a- 
MSH. The E C 5 0  rel./Kj rel. value for [Nle4,DPhe7]a-MSH and desacetyl-a-MSH was 
found to be approximately 3-fold and 2-fold higher than that of a-MSH, respectively.
The K j  and EC50 values reported here for [Nle4,DPhe7]a-MSH and a-MSH are 
approximately one order of magnitude higher than those detailed in the literature 
(Gantz et al., 1993b; Adan et al., 1994a; Mountjoy et aL, 1994; Miwa et al., 1995) 
for interaction with the human MC4-R. This is in agreement with results obtained 
from the MCI (chapter 4) and MC3 (Sahm, 1994) receptors when comparing our 
assay system to published data. Analysis of the relative values is once again more 
useful with the finding of Mountjoy et al. (1994) that [Nle4,DPhe7]a-MSH exhibits 
approximately two orders of magnitude higher potency than a-MSH. This is
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comparable to the value of 39 determined from this work. [Nle4,DPhe7]a-MSH 
shows an approximately 3-fold higher intrinsic efficacy than a-MSH as determined 
by the ratio of its relative activity and affinity (Table 5.2.). This is in contrast to the 
reduced efficacy noted at the rat MC3-R (Peng et al., 1996) and approximately 2-fold 
higher than that determined at the hMCl-R (chapter 4).
The significantly higher activity of desacetyl-a-MSH as compared to a-MSH 
is in direct agreement with the 3-fold higher activity determined by Mountjoy et al. 
(1994). The hMC4R therefore differs from the hMClR (chapter 4) and hMC3R 
(Miwa et al., 1995) which did not distinguish between desacetylated and acetylated 
ligands as regards potency. The higher intrinsic efficacy of the desacetylated form, its 
predominance in the human hypothalamus and the hypothalamic localisation of the 
MC4-R support a role for desacetyl-a-MSH in mediating some of the CNS effects 
attributed to the melanocortins. Indeed, correlation of potency data from the cloned 
hMC4-R with melanocortin-induced central effects in vivo led Adan et al. (1994a) to 
attribute the excessive grooming behaviour observed in melanocortin-treated rats to 
MC4 receptor activation. These data, however, contrast with the significantly lower 
activity determined by Miwa et al. (1995) for desacetyl-ACTH(l-13) as compared to 
ACTH(1-13) and who proposed the requirement for an amino-terminal acetyl group 
for maximal activity. In the absence of an amidated C-terminal, it therefore appears 
that desacetylation has a further detrimental effect on activity.
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5.2.2. Binding o f C-terminally-substituted oo-MSH Analogues
The human MC4 receptor, like the human MCI receptor, has been reported to 
respond poorly to y-MSH, being unable to stimulate a full response at maximum 
concentrations studied (Gantz et al. 1993b). As in the previous chapter, the effect of 
two significant amino acid differences between a-MSH and y-MSH within the C- 
terminal region, namely glycine-10 and proline-12 of a-MSH were probed. A more 
general investigation of the C-terminal importance was undertaken using multiple 
alanine-substituted peptides.
The relative binding and affinity of each C-terminally-substituted peptide as 
compared to a-MSH for every assay is given in Figure 5.6. This serves to illustrate 
assay reproducibility. [Asp10]a-MSH and [Asp10,Phe12]a-MSH exhibited extremely 
low affinities. Displacement of radioligand from the hMC4-R was less than 15% at 
the maximum working concentration of 0.1 mM (Figure 5.4a). This rendered an 
accurate calculation of binding affinity impossible, although extrapolation would 
suggest a value within the millimolar range. Peptide activity was also greatly reduced 
with [Asp10]a-MSH exhibiting 3% and [Asp10,Phe12]a-MSH significantly reducing 
activity even further to 2% of that determined for a-MSH. Substitution with 
phenylalanine at position 10 reduced binding affinity to approximately 4% of that 
calculated for a-MSH although its 5-fold lower activity was not significantly 
different. [Phe12]a-MSH was not significantly different in either affinity or activity 
to a-MSH. Both [Phe10]a-MSH and [Phe12]a-MSH showed approximately 5-fold 
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Figure 5.6. Relative affinity and activity of C-terminally-substituted a-MSH  
analogues as compared to a-MSH (log scale). Each column represents a single
experiment.
(black: binding affinity; white: cAMP production)
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Di-substitution with alanine in the C-terminal tripeptide to give [Ala1 Ala12]a- 
MSH and [Ala11,Ala13]a-MSH produced no significant difference in affinity or 
activity between them. Both peptides exhibited a significant decrease in affinity to 
approximately one third of that of a-MSH. A significantly reduced activity was 
found for [Ala11,Ala12]a-MSH but not [Alan ,Ala13]a-MSH as compared to the 
parent peptide. [Ala11,Ala12,Ala13]a-MSH exhibited significantly reduced binding 
and activity as compared to its di-substituted counterparts with 15% of the affinity 
and 7% of the activity of a-MSH. None of these peptides differed greatly in intrinsic 
activity as compared to a-MSH.
The data presented above assign an important role to position 10 of a-MSH for 
hMC4-R binding and stimulation. Both [Asp10]a-MSH and [Phe10]a-MSH exhibited 
low affinity although replacement with aspartic acid but not phenylalanine 
significantly affected activity. These substituents have comparable masses and are 
bulkier than the native glycine (appendix A). The reduced affinity may be explained 
by these bulky residues sterically hindering access of the ligand to the receptor 
binding pocket. The observed difference in activity between the substituted peptides 
is most likely due to the negative nature of the aspartic acid moiety which may 
disrupt the receptor conformational change necessary for G-protein interaction. It 
therefore appears that amino acid neutrality at position 10 is of greater importance 
for high potency than residue size. However, the higher intrinsic efficacy attributed 
to [Phe10]a-MSH suggests a more important role for glycine-10 of a-MSH in 
receptor recognition than receptor stimulation.
150
No significant difference in binding and activity was found for [Phe12]a-MSH 
as compared to a-MSH. This is at variance with the proposal of Gantz et al. (1993b) 
for the specific requirement of proline at position 12 for high potency. They found 
the truncated peptide ACTH(l-lO) to be a partial agonist at the MC4-R and later 
work assigned [Pro12]y-MSH a six-fold higher activity than y-MSH (Miwa et al., 
1995). However, this would not fully account for the approximate 100-fold 
difference in activity between a-MSH and y-MSH that they first reported (Gantz et 
al. 1993b) supporting a role for other residues in conferring high potency.
The same group also found tyrosine-2 to be an important determinant of 
activity at the hMC4-R although as this residue is shared by both a-MSH and 
y-MSH, it does not explain the lower affinity of the latter. The role of tyrosine-2 is in 
agreement with findings for the rat MC3-R but contrasts with findings for the mouse 
MC1-R (Sahm, 1994) and may therefore be a specific requirement for neurally 
expressed receptors.
The reduction in binding affinity observed with the alanine-substituted 
analogues emphasises the requirement for the C-terminal tripeptide for high potency. 
Amino acid substitution at positions 11 and 13 appears to have no detrimental effect 
on peptide activity indicating the relative unimportance of the nature of these 
residues. The lower activity observed with [Alan ,Ala12]a-MSH shows that 
substitution at position 12 with a less bulky residue adversely affects activity. 
Together with the results obtained for [Phe12]a-MSH this suggests that substituent 
size at position 12 may be more important than side chain structure, with the smaller 
amino acid side chain of alanine seemingly disrupting the peptide backbone induced
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by favourable receptor interaction more so than the bulkier phenyalanine. This 
importance of correct conformation within the C-terminal tripeptide is emphasised 
by the greatly adverse effect on both affinity and activity exhibited by the tri- 
substituted [Ala11 ,Ala'2,Ala13]a-MSH.
In summary, this chapter demonstrates the requirement for a neutral residue at 
position 10 of a-MSH for high affinity binding to and activation of the human MC4 
receptor. The nature of the C-terminal tripeptide also contributes to peptide activity 
and within this fragment, residue size at position 12 appears to be a determinant of 
high potency. These data further suggest that the presence of the aspartic acid residue 
of y-MSH is largely responsible for the low potency of this peptide on the hMC4-R. 
Biological activity of the C-terminally-substituted peptides was less affected in 
general, than receptor binding leading to peptides with higher intrinsic efficacies than 
a-MSH. This suggests that the C-terminal region of a-MSH plays a more significant 
role in receptor binding than stimulation of the human MC4 receptor.
5.3. A Comparison of the hM Cl and hMC4 Receptors
The human MCI and MC4 receptors show 47% amino acid identity (Mountjoy 
et a l, 1994). Although they are not the most closely related receptors, with the MC4 
showing greatest homology to the MC5-R, initial studies reported similar ligand 
binding profiles (Gantz et al., 1993b). The relatively sparse structure-activity data 
currently available are unable to account satisfactorily for selectivity between them. 
Much of this study focused on the largely non-specific knowledge of the importance 
of the melanocortin C-terminal for biological efficacy and attempted to isolate
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differences in melanocortin structure that distinguish between the binding to and 
activation of these receptor subtypes.
There is a clear difference in the response of each receptor to the tested ligands. 
Table 5.3. gives the relative affinity of each peptide as compared to the binding of 
a-MSH to the hMCl-R. Each peptide shows approximately 10 to 100-fold higher 
affinity and therefore, a higher selectivity for the hMCl-R as compared to the hMC4- 
R. Figure 5.7. compares the relative activities of each peptide on the two receptors. 
The synthetic a-MSH analogue, [Nle4,DPhe7] a-MSH exhibits “superpotency” at 
both subtypes but shows an approximately 2-fold higher intrinsic efficacy on the 
hMC4-R than the hMCl-R. The presence of an acetyl group on the N-terminal serine 
of a-MSH is not required for high potency at either receptor, and indeed, the hMC4- 
R exhibited a significantly higher activity in its absence. This supports an 
endogenous role for desacetyl-a-MSH.
Each C-terminally-substituted peptide, with the exception of [Asp10]a-MSH, 
exhibited a lower intrinsic efficacy for the hMCl-R suggesting that this region is 
more important for stimulation of the hMCl-R than the hMC4-R. However, the loss 
of both affinity and activity obtained with [Alan ,Ala12,Ala13]a-MSH on both 
subtypes emphasises the important presence of these residues and suggests that the 
spatial arrangement of the C-terminal tripeptide relative to the central core of a-MSH 
is decisive for high potency.
The presented data illustrate that although subtype specificity is not conferred 
solely by any one melanocortin amino acid, certain residues have selective
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importance at particular receptor subtypes. The human MCI and MC4 receptors 
differ markedly in their response to peptides substituted at positions 10 and 12. The 
nature of the residue at position 10 is of little consequence at the hMCl-R, but 
neutrality appears to be critical on the hMC4-R. In contrast, position 12 is the most 
sensitive amino acid within the C-terminal for human MCI receptor stimulation but 
appears to be less significant for activation of the human MC4 receptor.
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MCI MC4 M C 1/M C 4
[Nle4,DPhe7]a-MSH 5.3 0.56 9.5
a-MSH 1.0 0.042 23.8
desacetyl-a-MSH 3.8 0.067 56.7
[Asp10]a-MSH 0.38 NA NA
[Phe10] a-MSH 1.09 0.0016 68.1
[Phe12] a-MSH 0.20 0.013 15.4
[Asp10,Phe12]a-MSH 0.20 NA NA
[Ala11 ,Ala12]a-MSH 0.11 0.013 8.5




Table 5.3. Comparison of the relative binding affinities of a-MSH and its 
analogues to the human MCI and MC4 receptors.
Binding of a-MSH to the hMCl-R = 1.
















Figure 5.7. Comparison of the relative biological activity of a-MSH analogues on 
the human MCI and MC4 receptors.
(Activities expressed relative to a-MSH).
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CHAPTER 6: SITE-DIRECTED MUTAGENESIS of the hMCl-R
A thorough understanding of receptor-hormone interaction and cell signalling 
must necessarily involve knowledge of the mechanism by which ligand binding and 
receptor activation occurs. To date, very little is known about the binding domains 
for endogenous agonists of peptidergic G-protein-coupled receptors. It is likely that 
information gained by the study of one G-protein-coupled receptor family, such as 
the melanocortin receptors, may be extrapolated to other members of this 
superfamily.
Current knowledge of the melanocortins and their receptors has led to the 
proposal of a model in this laboratory for the conformational change occurring 
during functional coupling of melanocortin receptors to heterotrimeric G-protein 
complexes. This hypothesis is to be tested using site-directed mutagenesis 
techniques. The altered receptors will then undergo biological analysis enabling 
comparison of functional coupling with that of wild-type receptors.
6.1. A Model for Melanocortin Interaction with the MCI Receptor
A model of the tertiary structure of the MCI receptor was produced using a 
universal template for G-protein-coupled receptor structure (Baldwin, 1993) by 
comparison with the projection structure of bovine rhodopsin (Schertler et al., 1993) 
(Figure 6.1.). Docking of the conserved melanocortin tetrapeptide Hisa-Pheb-Argc-
Trpd into the receptor has been performed using molecular computer modelling
(Pouton et al., 1994) The determination of energy minima has led to a hypothesis for 
the conformational changes occurring on receptor activation.
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Figure 6.1. Model of the tertiary structure of the human MCI receptor fitted to the 
Baldwin template (Baldwin, 1993).
Receptor residues proposed for interaction with the melanocortin tetrapeptide 
Hisd-Pheb-Argc-Trpd are highlighted. “K” indicates the amino acid change from 
glutamic acid to lysine within the constitutively active £ So'3J murine MC1-R mutant 
(Robbins et al., 1993).
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Based on a-MSH and the human MCI receptor, this model proposes that 
[His6] interacts electrostatically with Asp(117), a residue also proposed to be critical
7
by Prusis et al. (1995) or Asp(121) within the third transmembrane helix, [Phe ] with
8 9Phe(279) within the seventh transmembrane helix, [Arg ] with Glu(94) and [Trp ] 
with Phe(45) in the first transmembrane helix (Figure 6.1.)- Glu(94) is thought to be 
a critical residue since a spontaneous point mutation at the equivalent murine residue 
Glu(92), to lysine produces a highly pigmented black phenotype which is
constitutively active in cell culture (section 1.4.2.1.2.; Robbins et a l, 1993). This 
sombre mutant may make a salt bridge in the absence of ligand by the interaction of
Lys(92) with one of the aspartic acid residues. This bridging between
transmembranes II and HI would result in the spatial rearrangement of
transmembrane El which contains a highly conserved Asp-Arg-Tyr motif thought to 
be critical for G-protein binding (Hargrave, 1991). This reorientation would allow 
the receptor to induce a conformational change in the G-protein a-subunit thereby 
activating the cellular second messenger system. Such a transformation may be 
universal to G-protein-coupled receptor function.
6.2. Oligonucleotide Design
If the above hypothesis is valid, biological testing of mutant receptors using 
melanocortin ligands would produce reduced binding and receptor stimulation. Use 
of a suitable marker for confirmation of receptor expression is therefore essential. 
One such system involves the incorporation of a short amino acid sequence to form a
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chimera with the recombinant protein. This could serve as an epitope recognised by 
available antibodies.
The recognition peptide chosen for this work was based on the FLAG sequence 
(Figure 6.2.), a commercially available octapeptide (IBI-Kodak Ltd.) against which 
antibodies have been raised. The use of secondary polyclonal antibodies conjugated 
to such moieties as FTTC would enable receptor detection by FACS. Proteins 
incorporating the FLAG peptide on the N-terminus have been found to be unaffected 
by its presence, exhibiting no significant difference in dissociation constant from the 
native receptor (Tate and Blakely, 1994) and retaining a high level of biological
activity (Hopp et al., 1988). The small size of this peptide moiety reduces possible
disruption of the native protein conformation. Its high hydrophilicity lends the 
peptide a high surface probability aiding both antibody attachment and antigenicity 
(Hopp etal., 1988; Prickett etal., 1989).
N-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-C
5 ' -GAC TAC AAG GAC GAC GAT GAC A A G -3 '
3 ' -CTG ATG TTC CTG CTG CTA CTG T T C - 5 '
Figure 6.2. Amino acid and nucleotide sequence of the FLAG recognition peptide.
A unique BamYil restriction enzyme site five amino acid residues upstream of 
the native ATG start codon of the hMCl-R gene as revealed by Genbank database 
searching (section 2.8.1.) was chosen as the point of attachment for the recognition 
peptide. Oligonucleotide design of the recognition peptide therefore incorporated a 
BamHl site for attachment to the MC1-R gene together with an EcoR\ recognition
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sequence for vector ligation. Both cleavage sites have a high end restriction 
efficiency which was further optimised by base pair additions to each terminus. 
Genbank database sequence analysis of pBluescript (SK+) and the hMCl-R gene 
confirmed the unique nature of these restriction sites. A new ATG initiation codon 
was incorporated immediately upstream of the FLAG recognition sequence. The 
synthesised 44-mer oligonucleotide sequence is given in Figure 6.2. and was 
designed to yield an in-frame peptide after annealing, restriction and ligation into 
pBluescript / hMCl-R (sections 2.8.6, 2.8.7.).
start codon
5' CGd A A T  TCC ATG GAC TAC AAG GAC GAC GAT GAC AAG TCC CG 3'
3' GCC TTA AGG TAC CTG ATG TTC CTG CTG CTA CTG TTC CCT ACG GC 5'
▼
EcoRl
FLAG recognition peptide ▼
BamHl
Figure 6.3. Sequence of the single-stranded complementary 44-mer 





The strategy involved the excision of the hMCl-R gene from pcDNAl Neo / 
hMCl-R plasmid using BamHl andXbal endonucleases. The gene was subsequently 
cloned into similarly digested pBluescript (SK+) (section 2.8.2.). Successful 
incorporation was confirmed by plasmid DNA preparation, digestion of a sample 
with BamHl andXbal and agarose gel electrophoresis (sections 2.2.4.-2.2.6.).
The modified plasmid (pBluescript / hMCl-R) was re-restricted with EcoRl 
and BamHl, ligated with the annealed and restricted recognition peptide (section 
2.8.6., 2.8.7.) and transformed into E. coli XLl-Blue (section 2.8.3.). Transformant 
selection on antibiotic-supplemented LB agar yielded few colonies. Subsequent 
restriction and fragment analysis using a high percentage non-denaturing 
poylacrylamide gel suitable for the detection of low molecular weight base pairs 
(section 2.8.8.) indicated unsuccessful transformant isolation.
6.4. Trouble-shooting and Future Work
Success of the transformation procedure itself and antibiotic integrity were 
confirmed by concurrent transformation of wildtype pBluescript and 
electrocompetent E. coli XLl-Blue alone as positive and negative controls, 
respectively. The probability of successful ligation was optimised by the use of 
various vector to insert ratios in the reaction mix. Unsuccessful isolation of 
transformants is therefore a consequence of failure of one or more of the procedures 
involved in recognition peptide formation from its component oligonucleotides. 
Isolation of the problem is hindered by an absence of suitable control procedures at
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each synthetic step. Further attempts at recognition peptide incorporation would 
necessarily look to simplify the synthetic protocol.
An alternative strategy would be ligation of the hMCl-R gene into a cloning 
vector already encoding a recognition epitope and against which antibodies have 
been raised. This would by-pass the multi-staged process outlined above. An 
example of such a vector is pSSBS.myc2 which includes unique restriction sites for 
in-frame fusions at the 3’ end of a 10 amino acid recognition epitope (Dr. M. 
Welham, University of Bath, personal communication). PCR primers specific to the 
hMCl-R sequence would incorporate appropriate restriction enzyme sites for ligation 
into the plasmid.
Site-directed mutagenesis of the hMCl-R gene will be performed using a kit 
based on the method of Deng and Nickoloff (1992). Two oligonucleotide primers 
will be simultaneously annealed to one strand of denatured double-stranded 
pBluescript / hMCl-R. One primer will introduce the desired point mutation, the 
second will mutate a unique restriction site for selection purposes. After DNA 
elongation using T4 DNA polymerase, ligation and digestion, the mutated and 
unmutated plasmid mixture will be transformed into a mutS E. coli strain defective in 
mismatch repair. Plasmid DNA prepared from the mixed bacterial population will be 
subjected to a second selective restriction enzyme digestion. The mutated DNA lacks 
the selected restriction enzyme site and will therefore be resistant to digestion. 
Parental DNA will, however, be linearised and rendered 100-fold less efficient to 
bacterial transformation (Cohen et al., 1972; Conley et al., 1984). A second 
transformation of the digested DNA should produce efficient recovery of the desired
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mutated plasmid. DNA sequencing will be performed to confirm successful 
mutagenesis.
Initial mutation experiments will investigate whether the five residues referred 
to above (section 6.1.) are indeed essential for receptor function. Each residue will be 
mutated in turn with the conservative replacement of Phe(45) and Phe(279) with 
leucine. The charged residues Glu(94), Asp(117) and Asp(121) are of particular 
interest given their postulated formation of ionic bridges during receptor activation 
and the latter will be replaced by the neutral polar serine residue. Each mutant 
receptor will undergo biological testing to determine the importance of the mutated 
residue for melanocortin binding and G-protein activation.
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CHAPTER 7 CONCLUDING DISCUSSION
7.1. Artificial Melanocortin Receptor Expression - A Valid Model?
Although numerous studies have been carried out using the mouse MCI 
receptor, published data for the human homologue have been more limited. This was 
largely due to variable MCI receptor expression on human melanoma cells (Libert et 
al., 1989) and on the strict culture conditions reported to be necessary for the 
successful growth of melanocytes (Hunt et a l, 1994). Indeed, until recently it was 
debated whether these cells did express the MCI receptor (Donatien et al., 1992; De 
Luca et al., 1993). In addition, the predominantly neural distribution of the MC3, 
MC4 and MC5 receptors and their uncertain cell-specific localisation preclude the 
study of native expression of these subtypes.
These limitations coupled with the rapid development of molecular biological 
techniques have led to the now commonplace expression of receptors in alternative 
cell systems. The MC1-R has been expressed both stably and transiently in a variety 
of mammalian cell lines including COS, 293 HEK, Hepa, L, CHO and Y1 (Chhajlani 
and Wikberg, 1992; Gantz et al., 1993a; Gantz et al., 1994a; Griffon et al., 1994; 
Roselli-Rehfus et al., 1993; Schioth et al., 1996a). Data obtained from these systems 
show reasonable correlation to those reported for the endogenously expressed human 
MCI receptor on melanocytes. In addition, functional expression in a non­
mammalian cell line has recently been demonstrated by Schioth et al. (1996b) using 
Sf 9 insect cells. Comparable binding constants and potency orders were measured to 
those obtained with transient expression of the hMCl-R in COS7 cells (Chhajlani
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and Wikberg, 1992). These data would appear to validate the use of such artificial 
expression systems.
However, as outlined in chapter 3 the precise details by which G-protein 
interaction and subsequent signalling events occur still remain elusive. G-protein 
structure is extremely diverse and each receptor selectively activates a particular G- 
protein subtype to produce its specific cellular response (Birnbaumer and 
Birnbaumer, 1995). Further work detailing the nature of melanocortin-induced cell 
signalling might therefore be most appropriately performed on receptors in a system 
as analogous to their endogenous environment as possible. For example, study of the 
MC1-R in melanocytic or melanoma cells might be expected to induce constitutive 
activation of the signalling pathway controlling melanogenesis. Indeed, Chluba-de 
Tapia et al. (1996) have transfected the human MC1-R gene into an amelanotic B16 
murine melanoma cell line, B16-G4F, previously shown to be MC1-R deficient 
(Solca et al., 1993) leading to melanogenesis on melanocortin stimulation. The 
ability to analyse the final response, in this case, melanogenesis, might be expected 
to reflect more accurately endogenous melanocortin-receptor behaviour.
7.2. [Nle4,DPhe7]a-MSH - A Valid Assay Standard?
Since the discovery of the high affinity and prolonged activity of the a-MSH 
analogue [Nle4,DPhe7]a-MSH (Sawyer et a l, 1980), its use as a standard in 
melanocortin work has become commonplace. However, it has been assumed that 
this closely related synthetic analogue exhibits a comparable binding mechanism to 
its endogenous counterpart. Some evidence has now been put forward to refute this 
and different points of attachment for [Nle4,DPhe7]a-MSH and a-MSH on the MCI
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receptor have been proposed. Substitution of alanine for Asp(117) and His(260) 
within the hMCl-R sequence produced mutant receptors which exhibited an 
approximately 100-fold reduced binding affinity for a-MSH as compared to the 
wild-type receptor whilst that of [Nle4,DPhe7]a-MSH remained unchanged 
(Frandberg et a l, 1994). This hypothesis is supported by the observation that C- 
terminally modified [Nle4,DPhe7]a-MSH analogues bound with equal affinity and 
exhibited comparable biological activities irrespective of amino acid substitution 
whereas the equivalent a-MSH analogues exhibited a distinct potency order (Peng et
n
al., 1996). The high peptide potency conferred by the [DPhe ] configuration appears 
to mask additional changes in binding affinity and biological activity exhibited by 
substituted [Nle4,DPhe7]a-MSH peptides. Taken together these data question the 
suitability of such an agonist as an assay standard and suggest that use of the lower 
affinity [Nle4]a-MSH which maintains the endogenous L-phenylalanine-7 
configuration might be more appropriate in further studies.
7.3. Future Directions
Future work with melanocortins in this laboratory is intended to focus on 
receptor mutagenesis as outlined in chapter 6. The interesting disparity between the 
murine and human MC1-R homologues in their relative importance of position 10 of 
a-MSH also warrants further investigation. The development of high-affinity 
antagonists is ongoing with emphasis being placed on neural melanocortin receptors 
and the development of highly selective agents. Only in this way can real progress be
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made as to how the melanocortins exert their important but subtle and complex 
effects in the brain.
7.4. The Broader Spectrum
Much progress in the melanocortin field has been made over the last decade, 
initiated largely by the cloning and characterisation of the majority, indeed, perhaps 
all of the melanocortin receptor subtypes. However, many mysteries remain 
unsolved. For example, it would be of interest to elucidate more fully the role of 
agouti protein in melanocortin regulation and to define the relative importance of 
ACTH and a-MSH in human pigmentation.
The melanocortin receptors respond differentially to closely related peptide 
ligands to which are attributed numerous biological responses. Delineation of the 
structural differences responsible for conferring this specificity will have therapeutic 
implications. For example, future development of selective melanocortin analogues 
is foreseeable for use in the control of fever and inflammation, as “neuro-protective” 
agents for chemotherapy, and by virtue of demonstrated memory-retention effects 
(chapter 1), for the treatment of such dementia-related disorders as Alzheimer’s 
disease.
Melanocytes and targeted gene therapy
Another interesting possibility involves exploiting current knowledge of the 
melanin biosynthetic pathway in the treatment of melanoma.
Melanin synthesis is specific to melanocytes which is partly a consequence of 
transcriptional regulation of tyrosinase and the TRPs (Jackson et al., 1991; Kluppel
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et al., 1994). Using the (3-galactosidase reporter gene it has been shown that 
comparatively small encoding fragments of the genes for these enzymes are 
sufficient to drive expression to both human and murine melanocytes and melanoma 
cells in vitro (Vile and Hart, 1993). Fusion of these promoter regions with a 
therapeutic gene, such as an immunity-enhancing gene or prodrug-activating gene, 
should initiate transcription of the latter when introduced into melanocyte-derived 
cells. When introduced into non-melanocytic cells, however, the absence of specific 
transcription factors means the promoter remains inactive and the gene is not 
transcribed. This approach relies on tissue-specific gene transcription in the 
appropriate cell-type and repression in other tissues (Yavuzer and Goding, 1994). 
The success of such a concept would represent a major goal in the therapeutic 
application of gene-mediated delivery.
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APPENDIX A: Amino Acids
Amino acid Abbrev. Code letter Mass Properties Hydropathy 
(1) Index (2)
Alanine Ala A 89.09 neutral 1.8 -1.6
Arginine Arg R 174.2 basic -4.5 12.3
Asparagine Asn N 132.1 neutral -3.5 4.8
Aspartic acid Asp D 133.1 acidic -3.5 9.2
Cysteine Cys C 121.1 neutral 2.5 -2.0
Glutamic acid Glu E 147.1 acidic -3.5 8.2
Glutamine Gin Q 146.1 neutral -3.5 4.1
Glycine Gly G 75.07 neutral -0.4 1.0
Histidine His H 155.2 basic -3.2 3.0
Isoleucine lie I 131.2 neutral 3.8 -3.1
Leucine Leu L 131.2 neutral 3.8 -2.8
Lysine Lys K 146.2 basic -3.9 8.8
Methionine Met M 149.2 neutral 1.9 -3.4
Phenyalanine Phe F 165.2 neutral 2.8 -3.7
Proline Pro P 115.1 neutral -1.6 0.2
Serine Ser S 105.1 neutral -0.8 -0.6
Threonine Thr T 119.1 neutral -0.7 -1.2
Tryptophan Trp W 204.2 neutral -0.9 -1.9
Tyrosine Tyr Y 181.2 neutral -1.3 0.7
Valine Val V 177.2 neutral 4.2 -2.6
Hydropathy index according to:
^  Kyte and Doolittle (1982) and 2^) Engelman et al. (1986).
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APPENDIX B: Media and Solutions
Where appropriate, media and solutions were sterilised by autoclaving at 15 lbs/sq. 
inch (121°C) for 15 minutes on a liquid cycle.
Buffer P I: 50 mM Tris-Cl, 10 mM EDTA, pH 8.0, 100 |Xg/ml RNAase A.
Buffer P2: 200 mM NaOH, 1% SDS.
Buffer P3: 3.0M potassium acetate, pH 5.5.
Buffer QBT: 7 50 mM NaCl, 50 mM MOPS, 15% ethanol, 0.15% Triton X-100 
Buffer QC: 1M NaCl, 50 mM MOPS, 15% ethanol.
Buffer QF: 1.25M NaCl, 50 mM MOPS, 15% ethanol.
Chloroform:isoamyl alcohol: Chloroform mixed with isoamyl alcohol 24:1 
(Amresco)
DNA loading buffer: 50 mM EDTA, 0.2% SDS, 0.05% bromophenol blue, 50% 
glycerol.
ethidium bromide: 1 mg/ml in double distilled water
Phosphate buffered saline (PBS): 137 mM NaCl, 2.7 mM KC1, 4.3 mM Na2HP0 4 , 
1.4 mM KH2P 0 4, pH 7.3.
LB medium: (Luria-Bertani medium): (per litre) lOg Bacto-tryptone (Difco), 5g 
Bacto yeast extract (Difco), lOg NaCl, adjusted to pH 7.0. with NaOH.
197
LB agar: LB medium plus 20g agar (Difco).
Phenol:chloroform: Tris-phenol: chloroform : isoamyl alcohol 25:24:1 (Amresco)
RNAase A: 10 mg/ml pancreatic ribonuclease A (Sigma) in STE.
Heated to 100°C for 5 minutes and allowed to cool to room temperature.
SOC medium: 2% Bacto-tryptone (Difco), 0.5% Bacto yeast extract (Difco),
10 mM NaCl, 2.5 mM KC1, 10 mM MgCh, 1 mM MgSCU, 20 mM glucose.
STE: 10 mM tris-Cl, 15 mM NaCl, pH 7.5.
TBE buffer (lx): 10.8g Tris base, 5.5g boric acid, 0.93g Na2EDTA.H20, pH 8.3 
TE buffer: 10 mM Tris-Cl, ImM EDTA, pH 8.0.
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APPENDIX C: Molecular Weight Markers
For agarose gel electrophoresis, markers consisted of HindJR-cut lambda DNA 
(Sigma). The digest consists of DNA fragments of the following sizes (base pairs):
1. 23130 5. 2322
2. 9416 6. 2027
3. 6557 7. 564
4. 4361 8. 125
For non-denaturing PAGE, markers consisted of HaeID-cut pBR322 (Sigma). The 
digest consists of DNA fragments of the following sizes (base pairs):
1. 587 9. 192 17. 57
2. 540 10. 184 18. 51
3. 504 11. 124 19. 21
4. 458 12. 123 20. 18
5. 434 13. 104 21. 11
6. 267 14. 89 22. 8
7. 234 15. 80
8. 213 16. 64
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APPENDIX D: FACS Data
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APPENDIX E: Statistical Analysis of Binding and cAMP Assay Data
C0S7-hMClR BINDING DATA 
















MTB > Oneway c8 c9;
SUBC> Tukey 5;
SUBC> Fisher 5.
One-Way Analysis of Variance
Analysis of Variance on C8
Source DF SS MS
C9 4 249.38 62.35
Error 10 18.27 1.83
Total 14 267.66
Level N Mean StDev
1 3 6.597 0.750
2 3 0.682 0.143
3 3 1.510 0.225
4 3 1.820 0.282
5 3 11.433 2.902
Pooled StDev = 1.352
F p
34.12 0.000
Individual 95% CIs For Mean 
Based on Pooled StDev
 +----------------+-----------------+----------------+----
( — *  )
(  * _ _ _ )
(  * _ _ _ )
(  *___)
(  * _ _ _ )
0.0 4.0 8.0 12.0
Tukey's pairwise comparisons 
Family error rate = 0.0500 
Individual error rate = 0.00819
Critical value = 4.65
Intervals for (column level mean) - (row level mean)














Family error rate = 0.245 
Individual error rate = 0.0500
Critical value = 2.228 
Intervals for (column level
1 2



























SUBC> Tukey 5; 
SUBC> Fisher 5.
One-Way Analysis of Variance
Analysis of Variance on C35
Source DF SS MS
C36 2 1.543E+09 771504832
Error 8 185237968 23154746
Total 10 1.728E+09
Level N Mean StDev
1 3 1 0
2 4 2423 1185
3 4 25925 7768
Pooled StDev = 4812
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual error rate = 0.0212
F p
33.32 0.000
Individual 95% CIs For Mean 
Based on Pooled StDev
(  *  )
(  *  )
( *— )
0 12000 24000 36000
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Critical value = 4.04







Family error rate = 0.112 
Individual error rate = 0.0500
Critical value = 2.306 
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One-Way Analysis of Variance 





















Level N Mean StDev
Individual 95% CIs For 
Based on Pooled StDev
1 4 30.175 3 .493
2 9 5.740 1.198 (-*-)
3 3 8.030 0.338
Pooled StDev = 1.928 8.0 16.0
Tukey's pairwise comparisons
24.0
Family error rate = 0.0500 
Individual error rate = 0.0205
Critical value = 3.73






1 . 1 0 0
Fisher's pairwise comparisons
Family error rate = 0.116 
Individual error rate = 0.0500
Critical value = 2.160






























MTB > Stack Cn' ) 'ASP10' 'PHE10' ('PHE121) 'ASPPHE' c25 ;
SUBC> Subscripts c26. 
MTB > Oneway c25 c26; 
SUBC> Tukey 5;
SUBC> Fisher 5.
One-Way Analysis of Variance
Analysis of Variance on C25 
Source DF SS MS
C26 4 62583 15646
Error 14 7117 508
Total 18 69699
Level N Mean StDev
1 4 30.17 3 .49
2 3 78.60 23 .50
3 5 27.62 9.54
4 4 153.00 40.27
5 3 157.00 19.31
Pooled StDev = 22 .55
Tukey's pairwise comparisons
Family error rate = 0.0500
Individual error rate = 0.00755
Critical value = 4.41 








-73 .1 -20.7 -78
-180.5 -135.8 -180
-73 .1 -21.0 -78
F p
30.78 0.000
Individual 95% CIs For Mean 
Based on Pooled StDev
( * )( * )











Family error rate = 0.256 
Individual error rate = 0.0500
Critical value = 2.145
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4 -157.0 -111.3 157.8
-88.6 -37.5 -92.9
5 -163.8 -117.9 164.7 -40.9
-89.9 -38.9 -94.1 32.9
293-hMClR BINDING DATA















MTB > Stack ('n' ) ('ALA112') ('ALA113') ('ALA123') (c27);
SUBC> Subscripts c28.
MTB > Oneway c27 c28;
SUBC> Tukey 5;
SUBC> Fisher 5.
One-Way Analysis of Variance





































Individual 95% CIs For Mean 
Based on Pooled StDev





Family error rate = 0.0500 
Individual error rate = 0.0120


















Family error rate = 0.181 
Individual error rate = 0.0500
Critical value = 2.228
Intervals for (column level mean) - (row level mean)













293-hMClR cAMP DATA 
NLDP, AMSH, desacetyl-AMSH











MTB > Stack ('nldp') ('amsh') ('des') (c4);
SUBC> Subscripts c5.
MTB > Oneway c4 c5.
One-Way Analysis of Variance
Analysis of Variance on C4
Source DF SS MS F P
C5 2 28.031 14.015 134.70 0.000
Error 8 0.832 0.104
Total 10 28.863
Individual 95% CIs For Mean 
Based on Pooled StDev
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Level N Mean StDev -----------+----------+----------+------
1 5 0.3640 0.1790 ( —  *--)
2 3 3.1900 0.0529 (--- *--)
3 3 3.8700 0.5910 ( — *--- )
Pooled StDev = 0.3226 1.2 2.4 3.6




Family error rate = 0.0500 
Individual error rate = 0.0212
Critical value = 4.04


























MTB > Stack ('amsh') ('asplO') ('phelO') ('phel2') ('aspphe') (clO);
SUBC> Subscripts ell.
MTB > Oneway clO ell;
SUBC> Tukey 5;
SUBC> Fisher 5.
One-Way Analysis of Variance
Analysis of Variance on CIO
Source DF SS MS F p
Cll 4 312227 78057 67.53 0.000
Error 13 15027 1156
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Total 17 327254
Level N Mean StDev
1 3 3 .19 0.05
2 3 4.32 1.03
3 4 3.38 0.58
4 4 87.60 9.69
5 4 334.00 70.10
Pooled StDev = 34.00
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual error rate = 0.00772
Critical value = 4.45
Intervals for (column level mean)
1 to
to - 8 8 . 5
8 6 . 2
3 - 8 1 . 9
8 1 . 5
- 8 0 . 8
8 2 . 6
4 - 1 6 6 . 1
- 2 . 7
- 1 6 5 . 0
- 1 . 6
- 1 5 9
- 8
5 - 4 1 2 . 5  
- 2 4 9  . 1
- 4 1 1 . 4
- 2 4 8 . 0
- 4 0 6
- 2 5 5
Individual 95% CIs For Mean 
Based on Pooled StDev 
 +---------------+------------- +-----
( „ * „ )
0 120 240







Family error rate = 0.254 
Individual error rate = 0.0500
Critical value = 2.160 
































MTB > Stack (cl ) (c3) (c4) (c5) (c27);
SUBC> Subscripts c28.
MTB > Oneway c27 c28;
SUBC> Tukey 5;
SUBC> Fisher 5.
One-Way Analysis of Variance
Analysis of Variance on C27
Source DF SS MS
C28 3 76538 25513
Error 8 6585 823
Total 11 83122
Level N Mean StDev
1 3 3 .19 0.05
2 3 76.30 2.38
3 3 7.16 0.64
4 3 200.67 57.33
Pooled StDev = 28.69
Tukey's pairwise comparisons
Family error rate = 0.0500
Individual error rate = 0.0126
Critical value = 4.53





Individual 95% CIs For Mean 
Based on Pooled StDev




















Family error rate = 0.176 
Individual error rate = 0.0500
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Critical value = 2.3 06























MTB > Oneway c41 c42;
SUBC> Tukey 5;
SUBC> Fisher 5.
One-Way Analysis of Variance


































6 . 2 0
P
0.014
Individual 95% CIs For Mean 




(  * .
150 300 450
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual error rate = 0.0122
Critical value = 4.42
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Intervals for (column level mean) - (row level mean) 














Family error rate = 0.178 
Individual error rate = 0.0500
Critical value = 2.262























MTB > Oneway c47 c48; 
SUBC> Tukey 5;
SUBC> Fisher 5.
One-Way Analysis of Variance 
Analysis of Variance on C47
Source DF SS MS F P
C48 3 162557 54186 25.08 0.000
Error 10 21607 2161
Total 13 184164
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Individual 95% CIs For Mean 
Based on Pooled StDev
Level N Mean StDev --------- +----- ----+----------+-------
1 4 87.60 9.69 (----*---- )
2 4 334.00 70.10 (----*-----
3 3 76.30 2.38 (-----*----- )
4 3 200.67 57.33 (-----*----- )
Pooled StDev = 46.48 100 200 300
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual error rate = 0.0120
Critical value = 4.33
Intervals for (column level mean) - (row level mean) 
1 2  3
2 -347.0
-145.8
3 -97 .4 149.0
120.0 366.4
4 -221.8 24.6 -240.6
-4.4 242.0 -8.2
Fisher's pairwise comparisons
Family error rate = 0.181 
Individual error rate = 0.0500
Critical value = 2.228































MTB > Stack ('n') ('a') ('des') (c4);
SUBC> Subscripts c5.
MTB > Oneway c4 c5;
SUBC> Tukey 5;
SUBC> Fisher 5.
One-Way Analysis of Variance
































Individual 95% CIs For Mean 
Based on Pooled StDev
(*-)
( * - )
( _ * _ _ )
2.5 5.0 7.5Pooled StDev = 0.4039
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual error rate = 0.0206
Critical value = 3.82





1 . 8 8 8 6  
3.4314
Fisher 1s pairwise comparisons
Family error rate = 0.115 
Individual error rate = 0.0500
Critical value = 2.201

























MTB > Oneway c9 clO;
SUBC> Tukey 5;
SUBC> Fisher 5.
One-Way Analysis of Variance
Analysis of Variance on C9
Source DF SS MS
CIO 2 94474 47237
Error 11 3784 344
Total 13 98258
Level N Mean StDev
1 6 7.28 0.55
2 4 195.00 35.21
3 4 23 .50 4.56
Pooled StDev = 18.55
F p
137.32 0.000
Individual 95% CIs For Mean 





Family error rate = 0.0500 
Individual error rate = 0.0206
Critical value = 3.82





Fisher's pairwise comparisons 




Individual error rate = 0.0500 
Critical value = 2.201























MTB > Stack ('a') (Cll) 
SUBC> Subscripts cl5. 




One-Way Analysis of Variance





































Individual 95% CIs For Mean 
Based on Pooled StDev
(-*-)




Family error rate = 0.0500 
Individual error rate = 0.0118
Critical value = 4.26
















Family error rate = 0.183 
Individual error rate = 0.0500
Critical value = 2.201







293-hMC4R cAMP DATA 
NLDP, AMSH, desacetyl-AMSH












MTB > Stack (C16) (C17) (C18) (cl9);
SUBC> Subscripts c20.
MTB > Oneway cl9 c20;
SUBC> Tukey 5;
SUBC> Fisher 5.
One-Way Analysis of Variance
Analysis of Variance on C19
Source DF SS MS F P
C20 2 90.395 45.197 142.63 0.000
Error 9 2 .852 0.317
Total 11 93.247
Individual 95% CIs For Mean 















2 . 1 0 0 0
Pooled StDev 0.5629 0 . 0 2.5
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual error rate = 0.0209
Critical value = 3.95






Family error rate = 0.113 
Individual error rate = 0.0500
Critical value = 2.262

























MTB > Stack (C17) (C21)
SUBC> Subscripts c26. 
MTB > Oneway c25 c26; 
SUBC> Tukey 5;
SUBC> Fisher 5.
(C22) (C23) (C24) (c25);
One-Way Analysis of Variance 
Analysis of Variance on C25
Source DF SS MS F p
C26 4 279410 69852 39.81 0.000
Error 10 17548 1755
Total 14 296958
Individual 95% CIs For 
Based on Pooled StDev
Level N Mean StDev ------ +----------------+-------------
1 3 6.89 0.78
2 3 223.00 77.25
3 3 34.80 8.57
4 3 5.03 0.94
5 3 342.00 52.26 ____ ___________ __________
Pooled StDev = 41.89 0 150
Tukey's pairwise comparisons
Family error rate = 0.0500
Individual error rate = 0.00819
Critical value = 4.65










4 -110.6 105.5 -82 .7
114.3 330.4 142 .2
5 -447.6 -231.5 -419 .7 -449.4
-222.6 -6.5 -194 .7 -224.5
300 450
Fisher's pairwise comparisons
Family error rate = 0.245 
Individual error rate = 0.0500
Critical value = 2.228


































MTB > Stack (Cl) (C2) (C3) (C4) (<
SUBC> Subscripts c6.





One-Way Analysis of Variance
Analysis of Variance on C5
Source DF SS MS
C6 3 13984.2 4661.4
Error 8 351.0 43 .9
Total 11 14335.2
Level N Mean StDev
1 3 6.89 0.78
2 3 24.90 5.92
3 3 21.00 2.42
4 3 94.90 11.58






Individual 95% CIs For Mean 
Based on Pooled StDev
0 30 60
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual error rate = 0.0126
Critical value = 4.53
















Family error rate = 0.176 
Individual error rate = 0.0500
Critical value = 2.3 06
Intervals for (column level mean) - (row level mean) 
1 2  3
-30.48
-5.54
-26.58
-1.64
-8.57
16.37
-100.48 
-75.54
■82 .47 
•57.53
-86.37
-61.43
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